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ABSTRACT 
Objective: 
The effectiveness of available treatments of Sjogren’s syndrome (SS) induced 
xerostomia remains unclear. The present thesis was aimed at determining the 
evidence of current therapies and to assess the efficacy of using an 
electrostimulation device for the treatment of xerostomia in patients with SS. Hence 
it comprises two studies to address the problem (a) a systematic review and (b) a 
clinical trial. 
 
Methods:  
For the systematic review the following databases were searched in November 2013 
and in August 2015: MEDLINE, Cochrane Central, EMBASE and AMED. 
Randomized controlled trials comparing any topical or systemic intervention for the 
treatment of SS-induced xerostomia were included. 
The clinical trial was a six-month double-blinded randomized sham-controlled 
feasibility trail of 30 patients with SS. Outcome measures were collected at baseline, 
month 1, month 3, and at end of the study. This was followed by a 6-month open 
label extension. 
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Results:  
The systematic review identified 33 randomized controlled trials. The meta-analysis 
included 9 studies. The principal measure of effect size was the mean difference for 
continuous data and the odd ratio of improvement for categorical data. Results 
suggest that oral sialogogues are more effective than placebo in ameliorating dry 
mouth symptoms.  
The clinical study found that unstimulated salivary flow increased more in 
participants receiving active devices compared to sham stimulation (1g/15min 
higher). The xerostomia inventory score reduced more in the active group by 3.3 
points. Xerostomia VAS scores did not show any significant difference. 
 
Conclusion:  
The findings of the systematic review display statistically significant evidence that 
SS-induced xerostomia may be lessened by systemic pilocarpine, cevimeline or 
electrostimulation. The clinical trial reported that the electrostimulating device was 
well tolerated, increased salivary function and reduced dry mouth symptoms of SS. 
Thus there is merit in future studies being focused upon the use of sialagogues and 
electrostimulation devices. 
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1.1 Sjögren’s Syndrome 
1.1.1 History  
The first case report describing what is now known to be Sjőgren’s syndrome (SS) 
was in 1882, when the German physician Theodor Leber described a condition of 
filamentary keratitis (mucous strands that attach to and inflame the cornea). In 1888, 
surgeon Johann Mikulicz presented to the Society of Scientific Medicine at 
Kőnigsberg the case of a 42-year-old East Prussian farmer with painless parotid, 
lacrimal and submandibular gland swelling. The term Mikulicz’s syndrome was 
commonly used to describe other conditions associated with parotid gland swelling, 
such as tuberculosis and lymphoma. Later that year, the London physician W. B. 
Hadden presented to the Clinical Society the case of a 65-year-old female with dry 
mouth and inability to tear, whose condition responded to tincture of jaborandi 
(pilocarpine). 
 
It took 30 more years for evidence of a ‘syndrome’ to emerge. In 1926, Henri 
Gougerot in Paris described three patients with salivary gland enlargement, mucous 
membrane and vulvar atrophy and dryness. In 1927, Houwer observed an 
association of connected filamentary keratitis with arthritis. Of note however in 1933, 
the Swedish ophthalmologist Henrik Sjőgren published his seminal monograph (not 
translated into English until 1943) in which he described a series of 19 patients with 
dry eyes and dry mouth, 13 of whom also had arthritis. He coined the term 
keratoconjuctivtis sicca having used rose Bengal staining to study the ocular surface 
for abnormalities due to dryness (Sjogren 1933; Wallace 2006). 
In 1953, William Morgan and Benjamin Castleman rediscovered and popularized 
Sjőgren’s work (which had received little attention) and elaborated upon its 
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histopathological features as atrophy of the acinar parenchyma and diffuse 
lymphocytes infiltration (Fox et al. 1986). Kurt Bloch and colleagues reported in 1955 
that Sjőgren’s syndrome could exist by itself or be secondary to other autoimmune 
disorders. In the 1950s and 1960s, Joseph Bunim and Norman Talal described the 
clinical presentation, natural history and laboratory features of large numbers of 
patients linked probably with Sjőgren’s syndrome, and for the first time, the 
syndrome with increased risk of lymphoma development. Although antibodies (anti-
Ro/SSA and anti-La/SSB) linked to Sjőgren’s syndrome were discovered in the late 
1960s, it took another 30 years for “autoimmune” Sjőgren’s to be differentiated from 
other causes of sicca symptoms, such as HIV infection, Hepatitis C infection and 
chronic graft-versus-host disease (CGvHD). The definition of disease, it’s 
classification and activity measures, are now permitting the development of more 
robust methodologies in designing clinical trials in Sjőgren’s syndrome (Wallace 
2006). (Table 1) 
 
Table 1. Key events in the history of the description of Sjőgren’s syndrome (Epstein and 
Stevenson-Moore 1992). 
1888       Single case reports by Hadden and Rowlands 
1892      Case report and histology described by Miculicz 
1926                         Three patients described by Gougerot 
1928       Link with arthritis reported by Houwer 
1933       Sjőgren’s thesis describing 19 patients with ‘keratoconjunctivitis sicca’ 
1946      Sjőgren’s thesis translated into English 
1953      The term ‘Sjőgren’s syndrome’ becomes established in the literature 
1965       Primary versus secondary Sjőgren’s syndrome described 
1970s      Autoantibodies Ro (SS-A) and La (SS-B) described.  
1980s and 1990s     Extraglandular manifestations described 
1990s       Trials of disease-modifying drugs 
1993       Preliminary European classification criteria detailed 
2002       Revised American–European consensus criteria detailed 
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1.1.2 Definition  
Sjőgren’s syndrome is now known to be a chronic autoimmune disease, 
histopathologically characterized by lymphocytic infiltration of exocrine glands 
(Scully 1986; von Bultzingslowen et al. 2007; Bayetto and Logan 2010). Although 
salivary and lacrimal glands represent the most common targets of SS, it can also 
affect exocrine glands in the nose, ears, skin, vulva, vagina, respiratory and 
gastrointestinal systems (Al-Hashimi 2005; Bayetto and Logan 2010). Sjőgren’s 
syndrome can also give rise to a wide range of extra-glandular manifestations 
(Carsons 2001). The term ‘sicca’ has been used to describe dryness of the eyes 
and/or mouth and indeed in the past the term ‘sicca syndrome’ has been used to 
describe what is now known as primary SS. While SS can occur as a stand-alone 
disease (primary SS) (pSS) in which the dominants are those associated with 
lacrimal and salivary gland dysfunction, it can also be associated with other 
autoimmune disorders, particularly rheumatoid arthritis and lupus erythematosis but 
also scleroderma (sometimes termed systemic sclerosis), dermatomyositis, mixed 
connective tissue disease (MCTD), primary biliary cirrhosis and autoimmune 
hepatitis (Golding et al. 1970; Pérez et al. 1995; Al-Hashimi et al. 2001; von 
Bultzingslowen et al. 2007; Patel and Shahane 2014). Primary SS is usually seen 
with Raynaud’s phenomenon, parotid gland enlargement, purpura, anti-Ro and anti-
La autoantibodies and a strong association with HLA DR3 alloantigen 
(Moutsopoulos 2014). 
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1.1.3 Epidemiology 
It is estimated that SS affects 0.2-3 % of the population (Carsons 2001; Hammi et 
al. 2005; Willeke et al. 2007; Margaix-Muñoz et al. 2009; Bayetto and Logan 2010; 
Reksten and Jonsson 2014), indeed it is considered the second most common 
autoimmune connective tissue disorder after rheumatoid arthritis (Fox, Stern, and 
Michelson 2000; Manoussakis and Moutsopoulos 2001; Porter, Scully, and Hegarty 
2004). It is a disorder of middle to late age with most affected individuals diagnosed 
between 30 to 60 years of age (Carsons 2001; Jonsson et al. 2002; Margaix-Muñoz 
et al. 2009; Bayetto and Logan 2010; Reksten and Jonsson 2014). There is a female 
predominance of approximately 9:1 with a higher prevalence in menopausal women 
than other groups (Carsons 2001; Margaix-Muñoz et al. 2009; Bayetto and Logan 
2010; Reksten and Jonsson 2014). Secondary Sjőgren’s syndrome (sSS) can affect 
up to one third of patients with other autoimmune disorders (i.e. rheumatoid arthritis, 
lupus erythematosis, scleroderma, mixed connective tissue disease and primary 
biliary cirrhosis) (Golding et al. 1970; Pérez et al. 1995; Carsons 2001; Vitali et al. 
2002; Bayetto and Logan 2010). 
 
In 2014, a review described three studies reporting the incidence of pSS (Patel and 
Shahane 2014). The first study was a retrospective study, and was undertaken in 
the USA between 1976 and 1992 (Pillemer et al. 2001). An annual incidence of pSS 
at 3.9 per 100,000 was estimated. Similarly an incidence of 3.9 per 100,000 was 
reported in the second prospective study between 2000 and 2002 in Slovenia 
(Rozman et al. 2004). While in Greece a prospective study carried out between 1982 
to 2003, reported an incidence of 5.3 per 100,000 (Alamanos et al. 2006). With 
regards to prevalence rates, pSS can vary according to the classification criteria 
used (Patel and Shahane 2014). In a Norwegian study, the prevalence percentage 
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of pSS in individuals aged 40–44 years was 0.44 using the European criteria (EC), 
and 0.22 using the revised American-European Consensus Group (AECG) criteria 
(Rozman et al. 2004). In Denmark the prevalence of pSS was 0.6%-2.1% using the 
EC and 0.2%–0.8% using the Copenhagen criteria (Bjerrum 1997). And in Sweden 
it was 2.7% using the Copenhagen criteria (Jacobsson et al. 1989). A Turkish study 
reported the prevalence of pSS at 0.35 using the EC and 0.21 using the AECG 
criteria (Birlik et al. 2009).  Furthermore, the prevalence was 1.56 using the EC and 
0.72 using the revised criteria in women aged 18-75 in a cross sectional study in 
Turkey (Kabasakal et al. 2006). In Greece, the prevalence ranged from 0.09%–
0.23% (Dafni et al. 1997; Alamanos et al. 2006; Anagnostopoulos et al. 2010) where 
the first study used the preliminary European criteria and the other two used the 
AECG criteria. And 0.60% in Slovenia applying the EC (Tomsic et al. 1999). 
According to the revised AECG criteria the prevalence was 1.6 in Manchester 
(Thomas et al. 1998) and 1.14 in Birmingham (Bowman et al. 2004). In China, 
according to the Copenhagen criteria the prevalence was 0.77% (Zhang et al. 1995), 
and 0.03% in Japan (Miyasaka 1995). 
Recently in 2014 a systematic review and meta-analysis reported a high pooled 
(included 6 studies) incidence rate as 6.92 per 100,000 person/years and an overall 
pooled (included 18 studies) prevalence rate of 60.82 cases per 100,000 
person/year. The female/male ratio was similar to previous studies with 9.15, and 
overall age of pSS patients was 56.16 years (Qin et al. 2014). 
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1.1.4 Classification and diagnostic criteria 
The increased need to drink water during the night to lessen dryness of the mouth 
and/or throat and the need to have chewing gum and lozenges handy to help 
stimulate saliva production can be the first sign of xerostomia (Reksten and Jonsson 
2014).  
Sjőgren’s syndrome, especially in its early stages, is often under-recognized by 
clinicians and therefore under-diagnosed. In some instances it can take up to 6 to 
10 years from the onset of initial symptoms to final definitive diagnosis (Talal 2000; 
Hammi et al. 2005). Such delay in diagnosis can be explained by the following: 1) 
symptoms of mouth and/or eye dryness can have many causes, particularly 
medication; 2) symptoms of cutaneous, oral and vaginal dryness/discomfort may be 
confused with those of menopause in middle-aged females; 3) the disease can 
present with initial non-specific systemic symptoms such as arthralgia and fatigue; 
4) due to the multiple organ involvement, patients are often seen by different 
specialists each of whom detects only one element of the syndrome and 5) clinicians 
do not always apply international classification/diagnostic criteria (Jonsson, Haga, 
and Gordon 2000; Bayetto and Logan 2010). Furthermore prompt identification of 
SS can be compromised by the existence of other systemic diseases that can cause 
inflammatory infiltration of exocrine glands leading to glandular swelling and 
dryness. Examples include hepatitis C infection, HIV infection and CGvHD and rarely 
sarcoidosis and IgG4 disease (Gratwohl et al. 1977; Itescu, Brancato, and 
Winchester 1989; Jorgensen et al. 1996; Carsons 2001). 
 
Since 1965, there have been 11 sets of classification criteria (Sankar, Noll, and 
Brennan 2014) for SS, suggested by different groups of specialists from different 
countries including Japan, America and Europe (Manthorpe et al. 1986; Homma et 
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al. 1986; Fox et al. 1986) although none of them were supported by robust validation 
(Vitali et al. 2002; Moutsopoulos 2014). Eventually a multicentre study was 
undertaken by a European Study Group in 1998, with the intention to: i) validate a 
simple questionnaire for sicca symptoms; ii) select the most sensitive and specific 
tests for the diagnosis of SS; iii) define a set of criteria for SS; iv) validate this criteria 
set (Vitali et al. 1993); see Table 2. The relevant European classification was initially 
accepted by the scientific community, but it was later criticized as histopathological 
evidence of disease  (focal sialadenitis) or serology (anti Ro/La antibodies) were not 
considered necessary for the diagnosis- potentially leading to misclassification bias 
(Vitali et al. 2002). 
In view of the criticism, the AECG modified this classification to include at least one 
objective finding, thereby redefining the rules of the ESGCC. They added a number 
of specifications to available criteria to make the classification accurate and 
acceptable (see Tables 3 and 4). This classification has shown a high sensitivity 
(89.5%) and specificity (95.2%) for the diagnosis of pSS (Vitali et al. 2002). 
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Table 2. The validated diagnostic/classification criteria for Sjőgren’s syndrome, as suggested by the 
European Community Concerted Action for SS (Vitali et al. 1996; Manoussakis and Moutsopoulos 2001). 
Criteria                                                                                       Definitions
1. Ocular symptoms  A positive response to at least one of the three selected questions: 
1 Have you had daily, persistent, troublesome dry eyes for more than   3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than three times a day? 
2. Oral symptoms A positive response to at least one of the three selected questions: 
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrently or persistently swollen salivary gland as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
3. Ocular Involvement  Objective evidence of ocular involvement defined as a positive result in at least one 
of the following two tests: 
1. Schirmer's I test (less than or equal to 5 mm in 5 minutes) 
2. Rose-Bengal score (greater than or equal to 4 according to van Bijsterveld's 
scoring system) 
4. Salivary gland Objective evidence of salivary gland involvement defined as a positive result  in at 
least one of the following  three tests: 
1. Salivary scintigraphy 
2. Parotid sialography 
3. Unstimulated salivary flow (less than or equal to 1.5 ml in 15 minutes) 
5. Histopathology  A focus score greater than or equal to 1 in a minor salivary gland  biopsy (a focus is 
defined as an agglomerate of at least 50 mononuclear cells;   the focus score is 
defined by the number of foci in 4 mm2 of glandular tissue) 
6. Autoantibodies  Presence in the serum of the following autoantibodies: Antibodies to Ro(SSA) or    
La(SSB) or both 
Rules for classification: In patients without any potentially associated disease the presence of any four of the six items is 
indicative of primary SS. In patients with a potentially associated disease (for instance another connective tissue disease) 
item 1 or item 2 plus any two from items 3, 4, 5 is indicative of secondary-SS. 
Exclusion criteria: pre-existing lymphoma, acquired immunodefciency disease (AIDS), sarcoidosis, graft-versus-host 
disease, sialadenosis. Use of anti-depressant and anti-hypertensive drugs, neuroleptics, parasympatholytic drugs. 
Test should be excluded from the criteria or not considered indicative of a diagnosis of SS in elderly subjects (older than 
60 years). 
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Table 3. Revised international classification AECG criteria for Sjögren’s syndrome (Vitali et al. 
2002). 
I. Ocular symptoms, a positive response to at least one of the following questions: 
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than 3 times a day? 
II. Oral symptoms, a positive response to at least one of the following questions: 
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrently or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
III. Ocular signs, objective evidence of ocular involvement defined as a positive result for at least one of the 
following tests: 
1. Schirmer I test, performed without anaesthesia (<5 mm in 5 minutes) 
2. Rose bengal score or other ocular dye score (>4 according to van Bijsterveld’s scoring system) 
IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal 
lymphocytic sialadenitis, evaluated by an expert histopathologist, with a focus score >1, defined as a 
number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 
50 lymphocytes) per 4 mm2 of glandular tissu 
V. Salivary gland involvement, objective evidence of salivary gland involvement defined by a positive result 
for at least one of the following diagnostic tests: 
1. Unstimulated whole salivary flow (<1.5 ml in 15 minutes) 
2. Parotid sialography showing the presence of diffuse sialectasis (punctate, cavitary or destructive 
pattern), without evidence of obstruction in the major ducts19 
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer 
VI. Autoantibodies, presence in the serum of the following autoantibodies: 
1. Antibodies to Ro(SSA) or La(SSB) antigens, or both 
Table 4. Revised rules for classification (AECG criteria) (Vitali et al. 2002) 
For primary SS 
In patients without any potentially associated disease, primary SS may be defined as follows: 
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV 
(Histopathology) or VI (Serology) is positive 
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI) 
c. The classification tree procedure represents a valid alternative method for classification, although it 
should be more properly used in clinical epidemiological survey 
For secondary SS 
In patients with a potentially associated disease (for instance, another well defined connective tissue 
disease), the presence of item I or item II plus any 2 from among items III, IV, and V may be considered as 
indicative of secondary SS 
Exclusion criteria: 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency disease (AIDS) 
Pre-existing lymphoma 
Sarcoidosis 
Graft-versus-host disease 
Use of anticholinergic drugs (since a time shorter than 4-fold the half life of the drug) 
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This AECG classification specified that the Schirmer I test in iteim III, which is a 
quantitative measurement of tear production over a specific period of time, should 
be performed without anaesthesia (Vitali et al. 2002). This test is considered as a 
simple and cost-effective test, but in mild cases of keratoconjunctivitis sicca it is 
difficult to reproduce accuracy (Bayetto and Logan 2010). As the severity of 
keratoconjunctivitis sicca increases, the Schirmer I test increases in reproducibility. 
The rose bengal eye stain, which stains the conjunctival surface, helps to reveal any 
breaks in the corneal epithelial surface (Lemp 2000). It may be used in conjunction 
with the Schirmer I test to increase diagnostic accuracy (Bayetto and Logan 2010). 
These tests are used to assess the function of the lacrimal glands and the integrity 
of the tear film layer (Sankar, Noll, and Brennan 2014). 
In regards to item IV (histopathology), the focal lymphocytic sialadenitis (FLS) was 
defined as “multiple, dense aggregates of 50 or more lymphocytes in perivascular or 
periductal locations” (Chisholm and Mason 1968), with only a small proportion of 
plasma cells, and located adjacent to normal-appearing acini in gland lobules without  
showing any duct dilation or fibrosis (Daniels and Whitcher 1994). The term focal 
lymphocytic sialadenitis applies to labial salivary gland biopsy specimens having this 
pattern of lymphocytic infiltration and a focus score >1 focus/4 mm² (Daniels and 
Whitcher 1994; Vitali et al. 2002). Labial salivary gland biopsy had a limitation of a 
varied range of sensitivity and specifity, 63%–93% and 61%–100%, respectively 
(Sankar, Noll, and Brennan 2014). Yet the focal lymphocytic infiltrates of the labial 
salivary gland was found not to be specific for pSS, and can be observed in healthy 
individuals in a range of 7-32% (Pedersen et al. 1999). Stewart et al. (2008) reported 
poor reproducibility of the results, with variations across pathologists and gland 
section levels.  On the other hand (Costa et al. 2015) studied the intraobserver and 
interobserver minor salivary gland biopsy (MSGB) reliability and considered it to be 
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substantial in pSS patients, with 12.6% of pathology samples resulting in a different 
diagnosis. They also noted that there was no standard process used to read the 
samples and to write the reports. 
Furthermore, salivary gland hypofunction (criteria V) is one of the most common 
symptoms of SS, but due to the fact that it can be caused by many other co-existing 
factors such as anticholinergic drugs, systemic disease and psychological or 
physiological changes it thus has low specifity for SS (Daniels 2000). In this 
classification the positivity of parotid sialography was defined by the presence of 
diffuse sialectasis. According to Rubin and Holt the scoring system and the positivity 
of salivary scintigraphy should be defined as delayed uptake, reduced concentration 
and/or delayed secretion of the tracer (Rubin and Holt 1957). Low salivary flow can 
also be detected via salivary sialometry, using a threshold of 1.5ml/15 minutes (Al-
Hashimi et al. 2001). 
The presence of serum Ro (SSA) and in particular La (SSB) autoantibodies (criteria 
VI) is highly specific for SS, although healthy individuals and patients with 
rheumatoid arthritis and systemic lupus erythematosis (SLE) are occasionally 
proven to be positive for one or both antibodies (Talal 2000; Bayetto and Logan 
2010). 
 
Considering the different imaging techniques involved in the diagnosis, SS can give 
rise to a variety of salivary gland changes that can be detected with different 
radiological methods. Sialography involves the retrograde instillation of a contrast 
medium into the excretory duct where the architecture and configuration of glandular 
ducts can be determined. In SS the characteristic feature of sialography is a 
snowstorm-like (sialectasis) or Christmas tree pattern. Sialectasia is the dilatation of 
the acinar system; it is classified to punctate, globular, cavitary, and destructive 
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sialectasia. As these changes represent the glandular damage caused by the 
chronic salivary gland inflammation, the progression of the disease process can be 
monitored using sialography imaging (Kalk et al. 2002). However the test can be 
painful and time-consuming and relies upon easy identification of the opening of 
salivary gland duct (Scully 1986; Pedersen et al. 1999). Different stages of 
sialectasis can be found in patients with SS, but 15–29% of the healthy population 
may demonstrate some elements of sialectasis and other diseases such as non-
specific chronic sialadenitis and recurrent parotitis of childhood can give rise to 
similar radiological features, hence reducing the specificity of the test (Soto-Rojas 
and Kraus 2002; Afzelius et al. 2014). 
In a recent investigation 98 patients were enrolled (38 pSS patients, 38 sSS patients, 
22 control subjects) the most common radiological finding in SS was sparsity of the 
branching pattern of the ducts. The most commonly affected ducts were the 
peripheral ducts rather than the main excretory duct. Asymmetric involvement of the 
parotid glands in pSS and the submandibular glands in sSS is commonly seen. 
Globally the parotid glands were more commonly involved than submandibular 
glands (Golder and Stiller 2014).  
Scintigraphy with sodium pertechnetate of 99m Tc evaluates the function of salivary 
glands. In addition, it can be used to examine glandular response to stimulation. The 
sensitivity of this test for the diagnosis of SS ranges from 75 to 87%, but has a low 
specificity (Vitali, Moutsopoulos and Bombardieri 1994). It has the disadvantage of 
being only performed in hospital settings and repetition is not appropriate in view of 
its invasive nature (Hermann, Vivino and Goin 1999). 
Magnetic resonance (MRI) is mainly useful in the recognition of masses and cysts 
and provide excellent views of the parenchyma.  In addition it can be useful in 
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selecting suitable places for biopsies of major salivary glands and assist in the 
diagnosis of lymphoma. Due to its high cost their cost and low sensitivity to identify 
SS, MRI is not considered to be a routine method of diagnosing SS (Soto-Rojas and 
Kraus 2002; Afzelius et al. 2014). 
Ultrasonography (US) is an increasing useful and reliable method for diagnosis of 
SS; it has good correlation (~85%) with sialography and scintigraphy.   
Ultrasonography of the major salivary glands in recent studies have showed high 
specificity (73-99%) but lower sensitivity (59-87%) for the diagnosis of pSS (Hocevar 
et al. 2005; Salaffi et al. 2008; Milic et al. 2009).  Indeed a report in 2010 showed 
that US of the salivary glands had a diagnostic sensitivity of 82% and specificity of 
73% which can allow them to be an alternative imaging modality to sialography in 
the diagnosis of pSS. Milic et al (2012) reported that US had a high diagnostic 
accuracy, comparable to scintigraphy and biopsy, therefore US can be considered 
as a reliable diagnostic method, comparable with biopsy of major salivary glands. 
Nevertheless, the US changes seen in salivary glands can occur in disorders giving 
rise to xerostomia unrelated to SS such as HIV salivary gland disease and HCV 
sialadenitis.  
 
An intra-study comparison between the preliminary EC and AECG in the same 
population, confirmed that the prevalence of pSS was lower using the AECG 
compared to the prevalence using previously the EC (Kabasakal et al. 2006; Haugen 
et al. 2008; Birlik et al. 2009). This gives an advantage in clinical trials as using the 
AECG criteria can lead to a much more homogenous group of patients, thus the 
AECG has been employed as an inclusion criteria in several randomized clinical 
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trials in pSS (Ramos-Casals et al. 2010; Baldini et al. 2011). Likewise the AECG 
criteria also has a benefit in clinical practice, Brun found that out of 203 outpatients 
with a clinical diagnosis of pSS, 116/203 (57.1%) satisfied the preliminary EC, when 
only 83/203 (40.9%) also fulfilled the AECG criteria (Brun et al. 2002). In the same 
way, Locht and co-workers reported that when using the AECG criteria on a cohort 
of 321 patients with pSS, initially diagnosed by the Copenhagen criteria1, only 
205/321 patients satisfied the criteria for pSS (Locht, Pelck and Manthorpe 2005).  
Another study showed that only 23.5% of the patients classified with pSS according 
to the European preliminary criteria met the criteria of the AECG (Langegger et al. 
2007). A study carried out in China has shown a high sensitivity and specificity to 
the criteria of the AECG (Zhao et al. 2005; Gálvez et al. 2009).  Nevertheless, there 
are patients who fulfil the Preliminary EC however not the AECG, although they have 
similar long-term disease complications. Thus giving rise to an argument on how to 
classify such patients. 
Furthermore, the Sjőgren’s International Collaborative Clinical Alliance (SICCA) has 
highlighted some weaknesses of the AECG which were considered in developing a 
new criteria (Shiboski et al. 2012; Sankar, Noll, and Brennan 2014). These 
weaknesses were as following: 
“(1 and 2) Ocular/oral symptoms2: 
• Scales for scoring subjective measures vary and are not unique. 
																																																								1 The Copenhagen criteria (Manthorpe et al. 1986) set was confirmed if two criteria for 
keratoconjunctivitis sicca (schirmer-I test, break-up time and rose-Bengal score) and two for 
xerostomia (unstimulated whole sialometry, salivary gland scintigraphy and lower lip biopsy) were 
fulfilled.	
2 One strength was that these symptoms are the usual prompts that drive patients to seek out a 
diagnosis. 
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• Subjective tests lack specificity for SS and do not correlate with objective 
measures. 
• The use of subjective tests potentially creates a heterogeneous pool of patients 
with SS, making it difficult to diagnose, assess efficacy of treatment, and 
determine the prognosis of patients with SS. 
(3) Ocular signs assessed by Schirmer I test 
• The test does not correlate with disease. 
• The test lacks specificity for SS. 
(4) Ocular signs assessed by ocular dye scores 
This is a time-consuming grading system that is difficult to apply in clinical practice. 
(5) Histopathology: none found 
(6) Salivary signs assessed by salivary flow rates 
• Types of saliva (whole vs individual gland) and collection techniques (spitting, 
drooling, suc- tion devices, absorption, use of wafers, and use of iodine starch) 
vary. Other factors such as circadian variation, patient hydration, fasting state, 
medication, and possibly age and sex affect saliva production rates. 
• Measures lack specificity for SS. 
(7) Salivary signs assessed by sialography  
• Technique is becoming obsolete. 
• Technique cannot distinguish between various causes of glandular inflammation. 
(8) Salivary signs assessed by scintigraphy 
• Test scores correlate with flow rates but not FSs. 
• The test may not provide sufficient diagnostic specificity to offset monetary 
expenses. 
• The test lacks specificity for SS. 
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• The test requires referral to a tertiary-care facility and placement of intravenous 
access for radiographic dye isotope placement. 
(9) Autoantibodies  
• Found in only 60% of patients with SS. 
• Found in other CTDs. 
• The presence of these autoantibodies correlates with earlier onset of the disease, 
longer duration of SS, and is associated with extra-glandular features (parotid 
gland enlargement, vasculitis, splenomegaly)”. 
 
A new classification criteria of the American College of Rheumatology criteria (ACR) 
was proposed in 2012 (Shiboski et al. 2012; Maślińska et al. 2014), it recommended 
that preliminary criteria for SS should be at least 2 out of 3 of the following objective 
tests:  
1. Positive serum anti-SSA and/or anti-SSB or [positive rheumatoid factor and 
ANA ≥ 1:320]  
2. Ocular staining score ≥ 3  
3. Presence of focal lymphocytic sialadenitis with focus score ≥ 1 focus/4mm2 in 
labial salivary gland biopsies. 
In trying to avoid misclassification of asymptomatic patients, the ACR classification 
criteria do not include symptomatic manifestations (Hernández-Molina and Sánchez-
Hernández 2013). Cornec considered the introduction of salivary gland US to the 
ACR as an improvement in the diagnostic value of this classification system (Cornec 
et al. 2014). 
AECG and ACR performance were compared in 646 participants. Each potential 
participant was interviewed via phone using the six standardized and validated 
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questions in the subjective criteria of the revised AECG criteria, the responses were 
used to assess the presence of ocular and oral symptoms. Of the 646 study 
participants, 279 and 268 patients were classified as SS according to AECG and 
ACR criteria, respectively. Of the 303 participants classified by either system as SS, 
244 (81%) individuals met both sets of criteria. This comparison shows that there 
are no significant differences between AECG and ACR. Participants classified as SS 
under the AECG criteria, 12.5% (35 of 279), were not considered SS when evaluated 
by the ACR criteria; conversely, 8.9% (24 of 268) met only the ACR criteria 
(Rasmussen et al. 2014). 
On the other hand, 100 patients who met the AECG at Carolinas Center for Oral 
Health were assessed using the available data from the AECG criteria, and the 
specific criteria used in the ACR classification criteria were documented. The results 
indicated that of the 100 patients with pSS based on the AECG criteria, only 5 
patients had adequate data available to meet the ACR criteria (Sankar, Noll, and 
Brennan 2014). Moreover, in comparing the AECG and ACR criteria, Tsuboi 
examined 302 patients with pSS, and reported that the sensitivity and specificity of 
the AECG criteria were slightly superior to those of the ACR criteria, 83.1 vs 79.1% 
and 90.9 vs 84.8%, respectively (Tsuboi et al. 2013). 
In a prospective study patients previously diagnosed with SS were re-evaluated 
using the following classification criteria: the Copenhagen, European, Californian  
(also known as San Diago3), and AECG or the new ACR criteria. After 7.6 years of 
follow up, from the 34 patients with complete data, 25 (73%) fulfilled the same criteria 
as initially, 6 (18%) fulfilled different criteria as initially, and 3 (9%) could no longer 																																																								
3 This criteria set diagnoses “definite SS” when patients meet all four of the following: KCS (Schirmer, 
rose Bengal or fluorescein staining), symptomatic xerostomia (resting and stimulated salivary flow), 
lymphocytic infiltration and at least one serum antibodies (rheumatoid factor, SS-A or SS-B antibody 
(Fox et al. 1986). 
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be classified as having SS by any criteria. The agreement between the initial and 
follow-up classification was the highest for the Californian and the AECG criteria 
(Plešivčnik Novljan et al. 2014). 
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1.1.5 Aetiopathogenesis mechanisms in SS 
The precise aetiology of SS is unkown. Previous studies have suggested that the 
pathogenesis consists of the following stages (Bultzingslowen et al. 2007; Margaix-
Muñoz et al. 2009): i) initiation by an exogenous factor; ii) disruption of salivary gland 
epithelial cells; iii) T-lymphocyte migration and lymphocytic infiltration of exogenous 
gland; iv) B-lymphocyte hyper-reactivity and production of rheumatoid factor and 
antibodies to Ro(SSA) and La(SSB) (Konttinen and Käsnä-Ronkainen 2002)  (Figure 
1).  
1.1.5.1 Risk factors 
A family history can be associated with an increased risk of developing SS among 
family members compared to the general population, suggesting a role of genetic 
susceptibility in the aetiopathogenesis of SS (Al-Hashimi 2001a). Indeed a link 
between HLAB8, Dw3, HLA-DRw4 and SS has been reported (Margaix-Muñoz et al. 
2009; Jonsson et al. 2002). The majority of pSS patients, regardless of racial and 
ethnic background, have the DQA1*0501 allele, suggesting that it may be a predictor 
of the susceptibility to pSS (Reveille et al. 1991; Tzioufas, Kapsogeorgou, and 
Moutsopoulos 2012).  A study confirmed the genetic association of IRF5 rs2004640 
T allele with predisposition to SS (Miceli-Richard et al. 2007). Another study found a 
correlation between IRF5 and STAT4 polymorphisms and SS development in a 
Swedish and Norwegian cohort (Nordmark et al. 2009; Vakaloglou and Mavragani 
2011). Thirty five percent of patients with SS have relatives with other autoimmune 
disease which suggested a hereditary link (Reveille et al. 1984; Reksten and 
Jonsson 2014).   
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A number of viruses have been proposed to have some sort of aetiological link with 
SS. Cytomegalovirus infection is known to cause SS-like features in animal models 
and it has been consequently suggested that this may represent a risk factor or a 
potential initiating event in SS (Al-Hashimi 2005; Delaleu, Jonsson, and Koller 2005). 
Other viruses reported to be potentially involved in SS pathogenesis are Epstein-
Barr virus (EBV), Hepatitis C virus (HCV) and Human T-cell Leukaemia virus-1 
(Mariette et al. 1991; Al-Hashimi 2005; Delaleu, Jonsson, and Koller 2005) but these 
are actually distinct disorders that have different clinical, histological and serological 
features from SS. 
Of note however Iwakiri and his colleagues reported that SSA/SSB might be 
released by EBV infection through epithelial cell apoptosis, leading to the activation 
of TLR3 and the consequent activation of innate immunity (Iwakiri et al. 2009; 
Mariette and Gottenberg 2010). Reactivation of the EBV by environmental pollutants 
and virus complex formation with La/SSB autoantigen was associated with positivity 
for anti-Ro/SS-A and anti-La/SSB antibodies. (Pasoto, Ribeiro, and Bonfa 2014) 
Moreover, it was reported that perifollicular plasma cells displaying Ro52 
immunoreactivity were often infected by EBV (Croia et al. 2014). 
With regard to HCV, there is some evidence supporting its pathogenic role in 
autoimmune diseases. Certainly HCV infection can cause sialadenitis that may 
mimic the clinical and some of the histological features of SS but there is no constant 
presence of anti-Ro or anti-La antibodies (Ramos-Casals et al. 2001; Ramos-
Casals, Muñoz, and Zerón 2008), as a consequence, HCV infection was added to 
the exclusion criteria list in the 2002 American-European revised classification 
criteria (Vitali et al. 2002). Conversely no conclusive evidence for any association 
between Hepatitis B virus (HBV) infection and autoimmune phenomena (Ramos-
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Casals, Tzioufas, and Font 2005; Ram et al. 2008; Chen, Xue, and Wang 2012).  
There is substantial evidence that HBV is not the cause of SS. In Spain, Marcos 
analysed 603 patients with pSS, only 5 (0.83%) patients were detectable with HBsAg 
(Marcos et al. 2009; Chen, Xue, and Wang 2012). Similar results were found by Lu 
and colleagues (1997) as they reported that the HBsAg-positive rate was lower in 
patients with SLE than in controls (3.5% vs. 14.7%), while Zhao et al. (2010) 
detected HBsAG in 2.33% of patients with SLE and 9.57% of controls (Lu et al. 1997; 
Zhao et al. 2010). Additionally, bacteria from human commensal microbiota have 
also been suggested as potential triggers for autoimmunity in SS by molecular 
mimicry with Ro/SS-A autoantigen (Pasoto, Ribeiro, and Bonfa 2014). 
Sex hormones have also been reported as potential risk factors (Bayetto and Logan 
2010), due to the high prevalence of SS in females (Talal 2000; Nakamura, 
Kawakami, and Eguchi 2006). The cellular immune response involved in the 
destruction of exocrine glands is known to be modulated by the ratio of androgen to 
oestrogen (Taiym, Haghighat, and Hashimi 2004). In animal models epithelial 
apoptosis was found to be influenced by oestrogen–androgen balance (Azzarolo et 
al. 1999). Oestrogen in particular, is an immune stimulator that has a role in 
lymphocyte growth, differentiation, proliferation, antigen presentation, cytokine 
production, antibody production, cell survival and apoptosis. Oestrogen can 
stimulate B-cell dependent responses leading to increased antibody production 
(Taiym, Haghighat, and Hashimi 2004). As women may be at of risk of developing 
SS during menopause it has been suggested that either the oestrogen decline or the 
difference in the oestrogen– androgen ratio is involved with disease onset (i.e. it is 
not the actual trigger but a factor that drives the destructive immune response 
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(Taiym, Haghighat, and Hashimi 2004; Bayetto and Logan 2010; Maślińska et al. 
2014).  
Valtysdottir reported that levels of dehydroepiandrosterone (DHEA) and its 
metabolite DHEA sulphate (DHEA-S) concentrations are 40–50% lower in patients 
with SS than in age and sex-matched controls (Valtysdóttir, Wide, and Hällgren 
2001). Oestrogen deficiency can induce overexpression of the transcription factor 
RbAP48 and animal models of SS have been found to over-express RbAP48 
(Ishimaru et al. 2008).  Over expression of RbAP48 is associated with epithelial cell 
apoptosis and expression of several antigens (Ishimaru et al. 2008). Furthermore it 
has been shown in some studies that oestrogen receptors (ER) can be detected in 
cultured human non-neoplastic salivary gland epithelial cells (Leimola-Virtanen et al. 
2000; Kassi et al. 2003; Maślińska et al. 2014). There is indirect evidence that 
oestrogen in fertile women may play a protective role, this comprising: (1) 
ovariectomized (estrogen-deficient) mice develop epithelial cell apoptosis and a SS-
like condition; (2) aromatase knock-out (estrogen-deficient) mice spontaneously 
develop a lymphoproliferative SS-like autoimmune disease; and (3) aromatase-
treated female breast cancer patients develop SS-like features (Konttinen et al. 
2014). 
 
Consequently it has presently been suggested that viruses (all be it unknown ones) 
may induce or promote autoimmune dysregulation, with a genetic susceptibility 
involving the type I interferon pathway causing SS (Croia et al. 2014) see (Figure 2). 
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Figure 2. Hypothetical model for the pathogenesis of Sjögren's syndrome (Venables 2004). 
 
 
1.1.5.2 Pathogenesis  
1.1.5.2.1 Autoantibodies 
A variety of autoantibodies have been found in patients with pSS. This involve 
including antibodies to both ubiquitous autoantigens (e.g. SSA/Ro, SSB/La, a-fodrin) 
and to autoantigens that are limited to the target tissues e.g. islet cell antigen 69, 
muscarinic M3 receptor (Hansen, Lipsky, and Dörner 2003; Kassan and 
Moutsopoulos 2004; Hansen, Lipsky, and Dörner 2005).  
Ro ⁄SSA and La ⁄ SSB autoantibodies are the most common and are found in the 
serum of 60–70% of patients with pSS (Bultzingslowen et al. 2007; Bayetto and 
Logan 2010). Anti-Ro/SSA can be found in isolation (50–70%) or along with the 
presence of anti-La/SSB antibodies (30–60%), whereas exclusive anti-La/SSB 
positive is rare (Elkon et al. 1984). 
The Ro/SS-A antigen is a RNP complex containing hY-RNAs and at least two 
proteins (Ro 52 kD and Ro 60 kD), while the La/SSB antigen consists of a 48kD 
protein (Ben-Chetrit 1993). The La protein is a transcription terminator factor of the 
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RNA polymerase III transcripts and lately the Ro protein has been recognized as an 
E3 ligase that regulates negatively cytokine production induced by the IFNγ pathway 
(Schulte-Pelkum, Fritzler, and Mahler 2009; Hernández-Molina, Leal-Alegre, and 
Michel-Peregrina 2011). Apoptosis of glandular cells may cause the exposure of 
nucleosomal and ribosomal particles to the immune system resulting in an 
autoantibody response- the target being these antigens (Waterman, Gordon, and 
Rischmueller 2000; Carsons 2001). 
Early onset of disease, increased disease severity, longer duration of disease, 
recurrent parotid gland enlargement and extraglandular manifestations have been 
associated with the presence of these autoantibodies (Tishler et al. 2001; Al-Hashimi 
2005b; Hammi et al. 2005; Reksten and Jonsson 2014). Thus, these autoantibodies 
may be used as a predictor of disease severity in newly diagnosed patients. The 
stability of the antibody profile of each patient is fixed at an early stage of disease 
and rarely changes (Davidson, Kelly, and Griffiths 1999). Patients with anti-La/SSB 
may have a higher lymphocytic infiltration of tissues than those with Ro/SSA alone, 
or those who are negative for both autoantibodies (Valesini et al. 1997; Hernández-
Molina, Leal-Alegre, and Michel-Peregrina 2011). Furthermore levels of anti-Ro/SSA 
and anti-La/SSB antibodies are higher in HLA-DR3 and HLA-DR2 positive patients 
(Wilson et al. 1984; Harley et al. 1986). In one study, patients with younger onset 
disease had a higher prevalence (45% vs. 12%) of anti-Ro/SSA antibody than those 
patients with later onset, although a comparison of >70 and <70 year old patients 
did not find any variation in the prevalence of antibodies (García-Carrasco et al. 
1999). Indeed younger onset SS patients can have higher serum levels of Ro ⁄ SSA 
and La ⁄ SSB antibodies and higher rheumatoid factor, which relates to more severe 
clinical symptoms (Tishler et al. 2001). Regarding the gender, some studies reported 
that male patients have a lower frequency of anti-Ro/La antibody compared with the 
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female population (Molina et al. 1986). Other studies reported that the positivity of 
these antibodies is associated with the salivary gland lymphocytic infiltration and 
abnormal oral and ocular tests (Hernández-Molina, Leal-Alegre, and Michel-
Peregrina 2011).  
Aqrawi reported a significantly higher degree of Ro52 expression in ductal epithelium 
in patients with SS compared to the non-pSS controls. Moreover, the level of 
inflammation was associated with the degree of ductal epithelial expression of Ro52. 
Yet, Ro52 protein could not be detected in serum and saliva samples of SS patients. 
The researchers concluded that the up-regulation of Ro52 in ductal epithelium could 
trigger the disease progression in SS (Aqrawi et al. 2014). 
Onset of SS in young adults may be correlated with the presence of rheumatoid 
factor (RF). In addition RF can be related to the presence of extraglandular 
symptoms such as arthritis being present in about 74% of patients with pSS (Reksten 
and Jonsson 2014). Together with RF, the prevalence of antinuclear antibodies 
(ANAs) in pSS reaches 80%. ANAs can be a predictor of internal organ involvement 
and the development of lymphoproliferative disorders (Reksten and Jonsson 2014). 
Studies on animal models of SS have found antibodies to salivary protein1 (SP1) 
(Shen et al. 2012). A further study of the sera of 123 patients with SS, 50 patients 
with RA and 75 controls ffound that 63% of the patients expressed anti-Ro or anti-
La whilst 52% expressed anti-SP1. Thirty-four percent of the pSS patients expressed 
anti-Ro, anti-La and anti-SP1 while 19% expressed only anti-SP1, 86% had anti-
Ro/anti-La antibodies while only 41% had anti-SP1 antibodies, with a focus score 
equal or greater than 2 per 4 mm2 (Shen et al. 2014). 
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1.1.5.2.2 Chronic lymphocytic infiltration and subsequent damage of the 
salivary acini 
Abnormalities in epithelial cells before the infiltration by auto reactive lymphocytes 
have been found in the salivary glands of the non-obese diabetic mouse model of 
SS. These are such as disturbed cell proliferation at birth, increased apoptosis of 
acinar tissue, breakdown of secreted proteins and increased expression of IFN-γ 
(Cha, Peck, and Humphreys-Beher 2002). A high expression of laminin messenger 
RNA and protein prior to the lymphocytic infiltration was found in biopsy samples 
from patients with SS in comparison to controls, thus it is suggested that altered 
synthesis of the basement membrane of glandular epithelial cells is an early event 
that is accompanied with salivary gland pathology in SS (McArthur et al. 1997; 
Voulgarelis and Tzioufas 2010).  
It is probable that epithelial cells in SS lesions have an active role in the initiation 
and maintenance of the inflammatory process (Xanthou et al. 2001; Voulgarelis and 
Tzioufas 2010). Although salivary gland epithelial cells are not considered to be 
antigen presenting cells, they hold all the features needed (Manoussakis et al. 1999; 
Matsumura et al. 2001; Manoussakis and Kapsogeorgou 2007). They have the 
ability to show higher expression of CD40 and adhesion molecules, additionally, they 
produces lymphoid chemokines, cytokines and B cell activating factor (BAFF) 
indicating that they could have a role in the accumulation of dendritic cells (DCs), T 
cell and B cells in the inflamed salivary glands and in the formation of lymphoid 
follicles (Xanthou et al. 2001; Tsunawaki et al. 2002; Dimitriou et al. 2002; Ohlsson 
et al. 2002; Lavie et al. 2004).  
The focal lymphocytic infiltration of the salivary glands consists of T and B 
lymphocytes (at a high T to B ratio) and plasma cells (De Souza et al. 2014). The 
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lymphocytic infiltration has been suggested to cause acinar atrophy, ductal 
hyperplasia and replacement of acinar cells with fibrosis and ⁄ or fatty infiltration 
leading to functional impairment (Jonsson et al. 2002; Al-Hashimi 2005b; Fox 2007). 
T-cells produce cytokines, tumour necrosis factors (TNF) and interferon (IFN), that 
may increase the antigen presenting nature of epithelial cells, and together with 
interleukin-1 (IL-1) may inhibit the release of acetylcholine from cholinergic efferent 
nerves (Fox and Michelson 2000; Fox and Stern 2002). Interferon type 1 can also 
induce apoptosis of the salivary gland epithelial cells.  
T helper (Th) cells are divided into two main subsets which control the polarization 
of the immune response. Th1 cells produce IFN-g, IL-2 and lymphotoxin and are 
implicated in cellular immunity. Th2 cells produce IL-4, IL-5 and IL-13, and have a 
major role in B-cell activation and humoral responses. In most autoimmune diseases 
this Th1/Th2 balance is altered. Recent evidence has shown that B cells are not 
strictly controlled by Th cells, but they may even regulate the levels of Th1 and Th2 
cells (Mitsias et al. 2002; Youinou 2007; Cornec et al. 2012). 
Th1 cells generally predominate in SS autoimmune lesions. On the other hand Th2 
cells are the major cytokines in mild lesions (Fox and Kang 1992; Boumba, Skopouli 
and Moutsopoulos 1995; Mitsias et al. 2002; Manoussakis et al. 2007) while Th17 
cell responses have been shown to correlate with lesion severity (Nguyen et al. 
2008; Espinosa et al. 2009; Katsifis et al. 2009). The expression of IL-12 has been 
negatively correlated with parotid gland enlargement, while IL-18 has been positively 
correlated with C4 hypocomplementemia, suggesting that IL-12 and IL-18 can be 
considered prognostic factors for the development of lymphoma (Tzioufas, 
Kapsogeorgou and Moutsopoulos 2012). IL-6 levels were found to be increased in 
the serum and tissues of patients with a range of autoimmune diseases, including 
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pSS (Youinou and Jamin 2009; Cornec et al. 2012). In addition, IL-6 also plays a 
major role in the development of Th17 cells, a proinflammatory T-cell subset which 
has the capacity to secrete cytokines such as IL-17, TNFa or IL-22 
(Miossec, Korn and Kuchroo 2009; Cornec et al. 2012).  
Perforin, granzyme A and Fas/Fas ligand mechanisms, could lead to glandular 
destruction (Bolstad et al. 2003). Although only partial destruction of the gland occurs 
in most cases, yet the local production of cytokines, autoantibodies, and 
metalloproteinase is thought to lead to dysfunction of the residual glandular tissue 
(Konttinen et al. 1992; Konttinen and Käsnä-Ronkainen 2002). 
B-cells are known to produce immunoglobulins with autoantibody activity and can 
participate in antigen presentation (Jonsson et al. 2002). In addition, B cell activation 
can increase the tendency for lymphoma development (Masaki and Sugai 2004). B-
cell-activating factor of the tumour necrosis factor family (BAFF) also termed (BLyS), 
supports B cell survival and antibody secretion (Mariette and Gottenberg 2010). 
BAFF-transgenic mice can develop polyarthritis, clinical features of lupus, and SS 
development. In patients with SS, serum BAFF levels correlate with levels of 
autoantibodies i.e.anti-SSA/SSB and rheumatoid factor (Mariette et al. 2003). An 
increase in serum BAFF levels correlates with a decrease in BAFF-R expression on 
B cells of patients with SS and SLE (Sellam et al. 2007), this decrease in BAFF-R is 
correlated with disease activity in both diseases (Mariette and Gottenberg 2010).  
In SS, not only monocytes and dendritic cells express BAFF, but also T cells (Lavie 
et al. 2008), B cells  (Pers et al. 2007) and salivary epithelial cells (Ittah et al. 2006; 
F. Lavie et al. 2008). IFNs are the main cytokines that stimulate BAFF secretion 
(Ittah et al. 2006; Lavie et al. 2008). 
One fifth of patients investigated with SS can have ectopic germinal centre-like 
structures that correlate with abnormal B cell proliferation (Fox 2005). The formation 
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of these germinal centres is allocated with increased glandular inflammation, 
elevated titres of rheumatoid factor, increased levels of auto antibodies and 
increased IgG levels compared with SS patients without germinal centres (Jonsson 
et al. 2007; Le Pottier et al. 2009; Voulgarelis and Tzioufas 2010). 
1.1.5.2.3 Autoantibodies to muscarinic M3 receptors 
IgG antibodies against muscarinic type-3 receptors (M3Rs) exist in the serum of 
patients with pSS and they may lead to salivary gland hypofunction (Bacman et al. 
1996; Gao et al. 2004; Li et al. 2004; Jin et al. 2012). This is of great interest as it is 
recognized that M3Rs play a key role in the production of salivary fluid and 
electrolyte secretion (Jin et al. 2012). 
The anti-muscarinic M3 acetylcholine receptor antibodies may cause synaptic 
inhibition of efferent nerve stimulation of salivary parenchyma (Fox and Stern 2002) 
and thus explain the occurrence of hyposalivation in 40-50% of patients with SS who 
do not have evidence of notable parenchymal destruction by lymphocytic infiltrate 
(Fox and Stern 2002). This is confirmed by observations that pilocarpine and other 
parasympathetic agents will induce an enhanced salivary flow via cholinergic nerve-
stimulation of salivary parenchyma (Bayetto and Logan 2010).  
Subsequent studies have confirmed the presence of anti-M3 to salivary glands in SS 
patients, and their selective inhibition of acetylcholine receptors of the bowel, bladder 
and salivary glands (Dawson et al. 2005; Kovács et al. 2008).  
1.1.5.2.4 Autonomic nervous system abnormalities 
Autonomic nervous system (ANS) abnormalities are common in SS (Andonopoulos 
et al. 1998; Kovács et al. 2003; Cai et al. 2008; Mandl et al. 2008; Nikolov and Illei 
2009) and may have a role in its pathogenesis, as sympathetic and parasympathetic 
nerves control vascularity and secretory functions of salivary and lacrimal glands. 
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Autonomic nervous system dysfunction can lead to xerostomia and xeropthalmia 
independent from inflammatory infiltrate-mediated parenchyma destruction 
(Barendregt et al. 1998; Nikolov and Illei 2009).  
 
1.1.5.3 Aetiopathogenesis Summary 
 
As previously mentioned the exact initial event is still unknown. A general hypothesis 
is that the disease process is initiated by a virus. Viral infection may induce salivary 
gland epithelial cell expression/release of antigens, particularly Ro, La, and M3R and 
a triggering of secretion of cytokines and chemokines. Inerferon may then induce 
the activation of BAFF and other cytokines, initiating the migration, and infiltration of 
T and B lymphocytes into the salivary gland cells. Further activation of these 
lymphocytes creates an autoimmune reaction and B cells start to produce anti-Ro 
and anti-La antibodies. Anti-M3R antibodies may inactivate the salivary acinar cells 
and together with the inflammatory damage of parenchyma to cause glandular 
dysfunction (Reksten and Jonsson 2014). 
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1.1.6 Manifestations 
1.1.6.1 Oral manifestations 
Patients with SS typically complain of dry mouth sensation which in turn can lead to 
difficulties with chewing and swallowing, dysesthesia, dysgeusia, burning sensation 
of the oral mucosa, pain in the salivary glands during meals and salivary gland 
swelling. Clinical signs comprise cracked, dry and desquamative lips, dry 
erythematous and fissured tongue and angular cheilitis. Rampant caries can be 
observed on atypical tooth surfaces and indeed patients with SS have higher than 
normal tooth loss (Fox 2005). Chronic erythematous candidiasis can affect up to 70–
80% of SS patients (Torres et al. 2002; Margaix-Muñoz et al. 2009).  
One of the complications affecting the salivary glands in SS is the bilateral 
enlargement, which can be found in 25% to 60%. The enlargement of the parotid 
glands can be acute or chronic. Pain is usually common with acute enlargement, 
which can be caused by obstruction of the salivary glands by mucous plugging, 
which can lead to retrograde contamination. Secondary inflammation also can cause 
swelling of the salivary glands (Turner 2014). 
The oral manifestations of SS will be discussed in greater detail in section 1.2. 
 
1.1.6.2 Ocular and lacrimal manifestations 
Patient with SS can present with several ocular symptoms including foreign body 
sensation, scratching, grittiness, photophobia, redness and ocular fatigue. However  
‘dry eyes’ is the most common complaint. An inability to tolerate contact lenses has 
been suggested to be an early manifestation of ocular involvement of SS prior to 
frank xeropthalmia. Rarely, patients present with swollen lacrimal glands (Carsons 
2001). 
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Of note, the actual tear flow seems to correlate poorly with symptoms of ocular 
discomfort, although diminished tear secretion is a well known chractaristic of SS. 
This is probably due to a reduction in mucin production (Jones et al. 1998; Fox, 
Tornwall, and Michelson 1999), as mucin provides stability to the tear film and 
decreases its viscosity. Indeed some studies have suggested that mucin production 
is reduced in the corneal epithelium of SS (Jones et al. 1998). Shimazaki suggested 
that a decreased number of functional Meibomian glands in the lower eyelid might 
contribute to the ocular symptoms of pateints with SS (Shimazaki et al. 1998) via 
reduced lipid production and increased tear evapouration (Fox, Tornwall, and 
Michelson 1999; Fox 2005). 
 
1.1.6.3 Dermatologic manifestations 
Cutaneous manifestations in SS include dryness, leukocytoclastic vasculitis and 
hypergammaglobulinemic purpura (Nakamura, Kawakami, and Eguchi 2006). 
Occasionally dryness can lead to excoriation and secondary infection. Tishler 
suggested that patients with SS have a higher prevalence of contact dermatitis 
(40%) with respect to (20%) the patients with rheumatoid arthritis (Tishler, Paran, 
and Yaron 1998). A high frequency of erythema annulare has been reported in 
Japanese patients with SS (Ruzicka et al. 1991). 
 
1.1.6.4 Respiratory and Pulmonary manifestations 
Waiffenbach reported that 30% patients with SS had below normal odour 
identification score compared to 10% of controls (Weifenbach et al. 1995). This was 
explained by the dry nasal mucosa, septal ulceration and crusting which affects the 
contact between odour molecules and olfactory receptors (Su, Poon, and Grushka 
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2014). In addition xerotrachea is reported to affect 17% of patients with pSS and 
may also present as a non-productive cough (Ienopoli and Carsons 2014).  
Dysphonia and speech clarity were typically mildly affected based on an acoustic 
analysis in a study in the USA which included 11 patients with pSS. In contrast 
individuals with pSS considered their own overall voice severity as mild to moderate 
(Heller et al. 2014). 
Pulmonary symptoms have been described to affect 9% to 75% of patients with pSS. 
Cough is the most common pulmonary manifestation. Dyspnea on exertion, chest 
pain, and wheeze also have been often reported. Dryness of the upper airway 
commonly occurs as a result of the decreased glandular function accompanying SS. 
Non-specific interstitial pneumonia has been reported in up to 61% of pSS lung 
manifestations (Ienopoli and Carsons 2014). The interstitial infiltrate of the 
lymphocytes around the bronchioles give rise to most lung lesions (Venables 2004). 
 
1.1.6.5 Cardiac and vascular manifestations 
Autonomic cardiovascular dysfunction may affect up to 50% of patients with SS 
(Andonopoulos et al. 1998), moreover Raynaud’s phenomenon appears in about 
30% of cases of SS. Purpuric vasculitis is also common, thought to be due to blood 
sludging in the small vessels due to hyperviscosity (Venables 2004). The prevalence 
of vasculitis in pSS has been reported to be between 5% and 10% (Ienopoli and 
Carsons 2014). 
The prevalence of traditional cardiovascular risk factors in pSS patients was 
investigated in several studies, which reported variable outcomes due to the different 
methodologies used. Lodde reported that pSS patients had lower high-density 
lipoprotein (HDL) and total cholesterol levels than in xerostomic controls (Lodde, 
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Sankar, et al. 2006). Cruz reported similar lipid profiles in pSS patients and controls 
(Cruz et al. 2010). Perez de Lis found that diabetes mellitus and hypertriglyceridemia 
are more prevalent in pSS than in primary care patients in Spain (Pérez-De-Lis et 
al. 2010). Another study in the UK determined the prevalence of traditional 
cardiovascular risk factors in a large well-characterized pSS patient cohort: 543 
patients with pSS (5 males, 538 females) were recruited from 30 centres, and with 
473 healthy controls. The prevalence of hypertension, hypercholesterolemia, and 
hypertriglyceridemia was found to be higher among pSS patients compared to 
healthy controls. In addition there was a higher frequency of patients with pSS taking 
antihypertensive and statin therapies than control. Twenty-one percent of patients 
had hypertriglyceridemia compared to 9.5% of controls. The prevalence of 
hypertension was more in pSS patients than in controls (Juarez et al. 2014). 
 
1.1.6.6 Gastrointestinal and renal manifestations 
Sjőgren’s syndrome has been associated with several gastrointestinal 
manifestations including oesophageal dysmotility, cholestasis, atrophic gastritis and 
gastric mucosa-associated lymphoid tissue lymphoma (Ramirez-Mata, Pena Ancira, 
and Alarcon-Segovia 1976; Tsianos et al. 1985; I al-Hashimi 2001; Carsons 2001). 
A study in 1995 assessed dysphagia in patients with pSS, patients with sSS, and 
healthy controls by comparing the difference in swallowing a dry bolus with a water 
bolus. Results reported that patients with SS experienced significant clinical 
dysphagia compared to controls (Rhodus et al. 1995). 
Glomerulonephritis can affect up to 55% of patients with SS (Skopouli et al. 2000), 
and one study found it to be associated with an increased risk of lymphoma 
development (Skopouli et al. 2000). Renal tubular acidosis and nephrocalcinosis 
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have also been reported (Rodríguez-Cuartero and González-Martínez 1998). In 
contrast, Venables reported that renal disease is rare in SS, and the majority of 
cases reported in the literature are based on single-case reports. In his study of 89 
patients with SS, showed that clinically significant renal disease, as proteinuria, 
hyperchloraemia or acidosis, was identified in only four patients (Venables 2004). A 
significant renal disease was also reported in around 5% in a study of 471 patients 
(Goules et al. 2000). 
 
1.1.6.7 Haematological manifestations and lymphoma 
Haematologic manifestations of SS can range from mild asymptomatic laboratory 
abnormalities to life-threatening manifestations, particularly the development of 
lymphoma. The most common haematologic abnormalities reported in patients with 
pSS were anaemia and hypergammaglobulinemia (Baimpa et al. 2009). 
Anaemia of chronic disease was by far the most common type of anaemia, and was 
associated with systemic involvement and circulating antibodies (i.e., ANA, SSA, 
SSB) that might reveal a state of generalized inflammation rather than disease 
limited to glandular sites. The high prevalence of hypergammaglobulinemia and its 
strong association with circulating autoantibodies (i.e., ANA, SSA, SSB) are 
harmonious with the polyclonal B-cell activation implicated in the pathogenesis of 
the disease (Baimpa et al. 2009). 
In 25–66% of patients with pSS salivary gland enlargement can affect the parotid 
gland(s) (Moutsopoulos et al. 1980). The enlargement is usually firm, diffuse, non-
tender, bilateral, recurrent or chronic (Daniels and Fox 1992). This presumably 
reflects the lymphocytic infiltrate and associated inflammation. The increased 
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production of BAFF caused by B-cell activity leads to an increased risk of lymphoma 
formation (Turner 2014). 
An increased risk of lymphoma development in the course of pSS has been shown 
in different studies. Indeed, the relative risk of non-Hodgkin lymphoma (NHL) in SS, 
compared to the general population, is the highest of all autoimmune diseases 
studied, ranging from 6.1–to 44.4 fold (Kassan et al. 1978; Valesini et al. 1997; 
Smedby et al. 2006; Theander et al. 2006; Lazarus et al. 2006; Smedby et al. 2006; 
Mellemkjaer et al. 2008). There is robust evidence showing that patients with long 
standing SS are at an increased risk of developing lymphoma particularly mucosa 
associated lymphoid tissue (MALT) lymphoma. These are low-grade B cell 
lymphomas that can be located in glandular and/or extraglandular regions that 
typically have a progressive course (Fox 2005). Lymphoma is of a low-grade in SS 
and usually extra nodal. Of these low grade, 10% can convert to high-grade. It has 
been reported that the cumulative risk of lymphoma development at 5 years from 
diagnosis is 3-4% and 9-8% at 15 years (Solans-Laqué et al. 2011). 
The most common subtype of lymphoma affecting patients with pSS was the 
extranodal marginal zone B-cell lymphoma (MZBCL) of the mucosa-associated 
lymphoid tissue (MALT), (Royer et al. 1997; Zintzaras, Voulgarelis, and 
Moutsopoulos 2005; Smedby et al. 2006). However, recent research has suggested 
an association between pSS and diffuse large B-cell lymphoma (DLBCL), (Baimpa 
et al. 2009). Three subtypes of B-cell marginal zone lymphoma (MZL) were reported 
by the World Health Organization (WHO) classification according to the sites 
involved: extranodal marginal zone of mucosa-associated lymphoid tissue (MALT) 
lymphoma, splenic MZL (SMZL) and nodal MZL (Swerdlow 2013). 
In a cohort of 536 patients with pSS, Baimpa and colleagues reported forty cases of 
lymphoma with a median age at lymphoma diagnosis of 54 years, while the mean 
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time between pSS diagnosis and the development of lymphoma was 6.8 years. Only 
1 of the 40 patients was male. Thirty-nine of the lymphomas were of the non-Hodgkin 
subtype, 38 of which were of B cell origin. They reported that the likelihood of a 
patient with pSS developing lymphoma is 4 times more likely to be MZBCL diagnosis 
than DLBCL (Baimpa et al. 2009). A systematic review reported that the risk of 
developing lymphoma was about 4% during the first 5 years, 10% at 15 years and 
18% after 20 years of diagnosing SS. Parotid enlargement was considered a 
predictive factor. While palpable purpura was significantly associated with lymphoma 
development, only one study found it statistically significant as an independent risk 
factor. Lymphopenia was reported as an independent risk factor in half of the papers. 
Particularly, there was a statistically significant association between CD4+ T 
lymphopenia and NHL (Nishishinya et al. 2014). A retrospective study in the UK 
explored the data of 152 patients diagnosed with pSS from 1986–2011. The mean 
age of diagnosis was 54.4 years. Serologically, the presence of ANAs was the most 
frequent finding (75.7%) followed by anti-Ro/SSA antibodies and rheumatoid factor 
in just under 55%. Extraglandular manifestations were 3.4-fold more common than 
glandular manifestations. Of the glandular manifestations, parotid swelling was the 
most common (Abrol et al. 2014). Another retrospective study in Hungary 
investigated 547 patients diagnosed with pSS between 1975 and 2010. The mean 
age at the time of diagnosis of the 51 deceased patients was significantly higher 
than for the 496 patients still alive at the end of the study. Raynaud’s phenomenon 
and serositis were established in the early phases of the autoimmune disease. 
Vasculitis and renal manifestations usually occur after the diagnosis of pSS. 
Thyroiditis was the most common accompanying disease with an incidence of 13.9% 
(Horvath et al. 2014). 
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Clonal expansion of B cells in salivary glands has been associated with an increased 
risk of lymphoma development and it has been suggested that patients with this 
feature should be monitored more closely. One small study reported that patients 
with paraproteins and antibodies against parietal cells can have a higher risk of 
gastric MALT lymphoma (Cain, Noble, and Matthay 1998; O’Donnell and Tung 1998; 
Jønsson et al. 1999). 
It would be advantageous to be able to identify particular features of SS, either 
clinical or laboratory, at the time of diagnosis, to accurately predict subsequent 
progression to lymphoma, hence ensuring close follow-up of such high risk patients 
(Kassan et al. 1978; Skopouli et al. 2000). Patients with one or more of the following 
features (a) parotid enlargement; (b) palpable purpura; (c) low (complement) levels; 
or (d) mixed monoclonal cryoglobulinemia at the time of SS diagnosis have been 
reported to have a nine times increased risk of developing lymphoproliferative 
disease, but only the low complement levels where considered an independent 
predictor of lymphoma (Skopouli et al. 2000; Ioannidis, Vassiliou, and Moutsopoulos 
2002). Significant increase in the size of the salivary glands, lymphadenopathy, 
splenomegaly, vasculitis, an increased sedimentation rate (ESR) and pulmonary 
infiltrates should be put into consideration as a suggestion of lymphoproliferation 
(Carsons 2001). 
Neutropenia, cryoglobulinemia, splenomegaly, lymphadenopathy, or low C4 levels 
have been considered in the past as risk factors for lymphoma in pSS, although no 
study has identified risk factors for NHL subtypes. Baimpa found that the 
development of non-MZBCLs (most of which were DLBCLs) to be predicted by the 
presence of lymphopenia at diagnosis (Baimpa et al. 2009) (Table 5). 
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Table 5. Clinical manifestations and biomarkers associated with lymphoma development in pSS 
(Maślińska et al. 2014)  
Clinical manifestations Potential biomarkers 
Vasculitis 
Salivary gland enlargement 
Salivary gland/parotid swelling 
Lymphadenopathy 
Splenomegaly 
Peripheral neuropathy 
Long duration of pSSHistopathology: germinal-like 
structures in minor salivary gland biopsy 
Cryoglobulins 
Low C4 complement component 
Anti-Ro/SSA antibodies 
Leukopenia 
Presence of RF expressing B cells 
Higher levels of BAFF/BLyS 
 
Treating lymphoma should be personalized according to disease stage. In the cases 
of low-grade lymphoma an observant strategy may be acceptable (Pollard et al. 
2011). Patients with MALT lymphoma and high disease activity may benefit from 
early treatment in order to avoid transformation into more aggressive lymphomas 
(Pollard et al. 2011). The optimal treatment regimen may be a combination of 
rituximab with either alkylating agents (cyclophosphamide/chlorambucil) fludarabine 
or bendamustine (Zucca et al. 2013). The latter combination of rituximab and 
bendamustine has shown promising efficacy in recent studies concerning MZ and 
MALT lymphomas (Nocturne and Mariette 2014). 
 
1.1.6.8 Neurological manifestations 
In a large cohort study of 1010 patients with pSS, 110 patients (11%) had peripheral 
neuropathy (Ramos-Casals et al. 2008). Peripheral neuropathy can precede the 
diagnosis of SS in as many as 93% of patients, and can occur without sicca 
symptoms (Mori et al. 2005). In a study of 20 patients with SS associated 
neuropathy, 16 (80%) presented with burning feet and 12 (60%) with non-length 
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dependent sensory symptoms. Leg and thigh skin biopsies showed either reduced 
intraepidermal nerve fibre density or abnormal nerve fibre morphology (Chai et al. 
2005). The cause of peripheral neuropathy secondary to pSS is not yet fully 
understood, vasculitis of the peripheral nerves is one of the suggested causes 
(Ienopoli and Carsons 2014). Skin biopsy was performed in 14 pSS patients with 
chronic neuropathic pain, small fiber neuropathy was detected in 13 patients 
(Fauchais et al. 2011; Carvajal Alegria et al. 2014). 
The reported prevalence of pSS with CNS involvement in the literature has ranged 
from 20% to 2% and 10% (Ienopoli and Carsons 2014). In a retrospective study of 
82 patients with neurologic manifestations of pSS, 56 patients (68%) had focal or 
multifocal CNS disorders. Twenty-nine patients had spinal cord involvement, 12 with 
acute and 16 with chronic myelopathy, 33 had brain involvement and 13 had optic 
neuropathy (Delalande et al. 2004; Chai and Logigian 2010). 
Alexander and colleagues described a central nervous system disorder similar to 
multiple sclerosis, in up to 30% of patients (Alexander et al, 1986). Another report 
suggested that the multiple sclerosis-like syndromes can occur in about 1% of 
patients with SS (Vincent et al. 2003). SS patients with trigeminal neuralgia and 
Glove and Stocking-type peripheral neuropathy (Carsons 2001) have been 
occasionally reported. 
The development of central nervous system disease in SS is rare and therefore it 
has been suggested that SS patients with demyelination, seizures, dementia, focal 
findings, or psychosis should be re-evaluated for the presence of an associated 
disease including SLE, multiple sclerosis or antiphospholipid syndrome (Carsons 
2001). 
Data of 93 patients were analysed retrospectively to assess the prevalence, clinical 
picture and outcome of CNS involvement. Twenty eight percent had neurological 
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involvement, 12.9% had only PNS involvement, 14% had only CNS disorders, and 
one had PNS and CNS involvement. The average age of CNS first manifestation 
was 47.29 ± 16 years (between 19 and 66 years). Neurological manifestations 
preceded pSS diagnosis in nine of the patients with CNS involvement (64 % of the 
14 patients with CNS involvement). Three patients had movement disorders, two 
patients had epilepsy, two patients had motor and sensory deficits and two patients 
had migraine with aura. This study displays the great heterogeneity of CNS 
involvement in pSS patients (Moreira et al. 2014).  
 
1.1.6.9 Pregnancy and foetal outcomes 
Isolated congenital complete heart block (CCHB) develops around 16–24 weeks’ 
gestation in foetuses with structurally normal hearts. CCHB is a rare disorder with 
an incidence of about one in 22,000 liveborn infants (Buyon and Clancy 2005). It has 
been linked with maternal connective tissue diseases like systemic SLE and SS, due 
to the transplacental passage of anti-SSA/Ro and anti-SSB/La antibodies from 
affected mother to fetus (Tincani et al. 2006). Almost half of the mothers with these 
antibodies do not have any manifestation of connective tissue disorders (Rivera et 
al. 2009). Anti-Ro/SSA antibodies are associated with congenital heart block (CHB) 
in utero and to other clinical manifestations in newborns, i.e. skin rash, liver 
abnormalities, and thrombocytopenia (Brucato et al. 1999). 
Available studies do not consider SS to be associated with impaired foetal outcomes, 
although pregnancy outcome in pSS has not been widely studied (Mecacci et al. 
2007). Moreover two studies described a higher rate of spontaneous abortion and 
foetal loss in pregnancies before SS diagnosis (Siamopoulou-Mavridou et al. 1988; 
Julkunen et al. 1995). In his study, Haga, applying the American-European 
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Consensus Group classification criteria for pSS, did not find significant differences 
in pregnancies in pSS before diagnosis when compared with controls (Haga et al. 
2005). 
Hussein et al confirmed in their study normal fertility and absence of excess numbers 
of foetal losses or preterm deliveries in pregnant mothers with pSS. However, 
maternal age at delivery is higher in patients with pSS, birth weight in pSS offspring 
lower and delivery by caesarean section or vacuum extraction was more frequent 
than controls. This complication (i.e. operative delivery) in delivery was caused by 
an increased risk of foetal growth restriction in the pSS pregnancies resulting in a 
higher risk of severe foetal complication (Hussein et al. 2011). 
Pregnancy complications due to the presence of anti-Ro/ SSA and anti-La/SSB 
autoantibodies in the maternal serum are known as neonatal lupus and CHB (Lee 
2005). The incidence of neonatal lupus in an offspring of a mother with anti-Ro/SSA 
antibodies is 1–2% (Brucato et al. 2001), however it may be as high as >20% if the 
mother has given birth to a child with neonatal lupus or CHB before (Buyon 1996). 
Complications of high risk of CHB, idiopathic cardiomyopathy, and neonatal lupus in 
sSS mothers have been reported in some studies to be even higher than in SLE 
patients (Gordon et al. 2004; Mecacci et al. 2007). 
Some studies reported an improvement from second-degree to a first-degree block 
applying long-term dexamethasone therapy with 4 mg/d at 20 to 23 weeks of 
pregnancy (Copel, Buyon, and Kleinman 1995; Hughes 2004). At this time there is 
no evidence that steroid prophylaxis may possibly prevent CHB in SS patients at 
high risk.  
Prolonged high-dose corticosteroid therapies in the past have been associated with 
numerous maternal–foetal complications. However, Brucato reported no association 
between high dose of dexamethasone during pregnancy and negative effects upon 
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the neuropsychological outcome of treated neonates (Brucato et al. 2006; Mecacci 
et al. 2007). 
Recently 11 pregnancies with isolated fetal congenital CHB in India were reviewed 
retrospectively between July 2008 and July 2013.  The study included positive anti-
SSA/Ro or anti-SSB/La pregnant women with CCHB identified in utero by fetal 
echocardiography.  Six mothers were asymptomatic; 2 had SS and 3 had SLE. 
Connective tissue disease was diagnosed before pregnancy. Four (36.3%) were 
anti-SSB/La-positive. There was no history of CCHB in previous pregnancies in any 
of the patients. Seven (63.6%) neonates were given a pacemaker; all were alive at 
the end of the follow-up period. Oral dexamethasone 4mg daily was given as an 
intrauterine treatment to all these patients after the diagnosis was made. None of 
the patients received prophylactic corticosteroids, beta-adrenergic agonists, 
plasmapheresis, intravenous immunoglobulin or hydroxychloroquine. The study 
concluded that the presence of underlying connective disorder in the mother does 
not worsen the prognosis of the affected neonate. Still, these results should be 
confirmed in larger prospective studies (Roy et al. 2014). 
 
1.1.6.10 Other clinical manifestations 
Subclinical musculoskeletal inflammation is seen in approximately 50% of SS 
patients (Ramos-Casals, Tzioufas, and Font 2005) leading to myalgia and arthralgia 
(Kassan and Moutsopoulos 2004). Arthritis appears in about 30% of patients with 
SS, and it may be similar to the arthritis of RA. However in comparison to RA, SS 
arthritis is usually more relapsing and remitting, and stiffness is less evident 
(Venables 2004). A study including 48 patients with pSS found that 26 (54%) had 
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symptoms or signs of arthralgia or arthritis, In 31% of these, arthralgia was reported 
as occurring before sicca symptoms developed (Pease et al. 1993).  
In addition, chronic fatigue can be a prominent symptom in pSS. Studies using multi-
dimensional assessment tools demonstrated that physical/somatic fatigue can be 
more severe and frequent than mental fatigue in patients with pSS (Tensing et al. 
2001; Godaert et al. 2002; Bowman et al. 2004; Segal et al. 2008). It was described 
that 96% of pSS patients experience substantial physical fatigue with a mean score 
of 3.5, while only 48% of patients report significant mental fatigue with a mean score 
of 2.8 (Segal et al. 2008). Fibromyalgia syndrome has been reported to be present 
in approximately 20% of patients with pSS (Ienopoli and Carsons 2014). 
Autoimmune thyroiditis has been found to be nine times higher among patients with 
SS. On the other hand the prevalence of SS is 10 times higher in patients with 
autoimmune thyroiditis than in normal individuals (Al-Hashimi et al. 2001).  
The clinical presentation of SS was assessed in a retrospective study including 1115 
patients with SS. Extraglandular pSS features were noted in 520/1115 patients 
(46.6%), while the remaining patients reported only sicca symptoms. Generally, the 
extra-glandular manifestations presented by the study sample were mild, including 
arthralgias, autoimmune cytopenia, mild to moderate  polyneuropathy and mild to 
moderate pulmonary involvement. Immunosuppressive therapy was needed to treat 
severe extraglandular manifestations (15%). They were mainly synovitis (11.0%), 
sensory-motor neuropathy (2.0%), severe neutropenia or lymphopenia (14.0%) and 
diffuse purpura or ulcers related to cutaneous vasculitis (6.0%). NHL was reported 
in 50 patients with an overall prevalence of 4.5%. The majority of NHL cases were 
mucosa-associated lymphoid tissue, followed by diffuse large B cell lymphomas and 
nodal marginal zone lymphomas (Baldini et al. 2014) (Table 6). 
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Table 6. Extra-glandular manifestations in Sjögren’s syndrome (Wu and Carsons 2014) 
Skin • Xerostosis 
• Cutaneous vasculitis  
• Other skin lesions (erythema nodosum, livedo reticulares, lichen planus, vitiligo) 
Joints/muscles 
 
• Arthralgia/arthritis 
• Myalgia/myopathy 
Pulmonary • Interstitial lung disease  
• Pulmonary fibrosis 
• Pulmonary hypertension  
• Small airway obstruction  
• Bronchiectasis 
Cardiovascular/ 
circulatory 
 
• Pericarditis 
• Arrhythmia 
• Raynaud’s phenomenon 
Nervous system 
 
• Peripheral neuropathy 
• Cranial neuropathy 
• Autonomic neuropathy 
• Central nervous system involvement 
Gastrointestinal 
 
• Dysphagia 
• Esophageal dysmotility  
• Autoimmune hepatitis  
• Pancreatitis 
Urogenital 
 
• Interstitial nephritis with renal tubular acidosis 
• Interstitial cystitis 
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1.1.7 Treatment in Sjögren’s syndrome 
Carson, in his review, divided the treatment of SS into phases. The first phase 
consists of moisture replacement. This is applied to the oral cavity, eyes, nose, skin, 
and genital tract. The second phase consists of stimulation of endogenous 
secretions that have been proven to be effective mainly for xerostomia. Finally, 
patients with systemic manifestations such as pulmonary disease, vasculitis, and 
pseudolymphoma may require corticosteroids, immunosuppressive and cytotoxic 
agents (Carsons 2001). This review of course was prior to the availability of 
biological agents such as the anti-TNF and anti-CD20 agents. 
 
1.1.7.1 Treatment of glandular manifestations 
1.1.7.1.1 Oral disease 
To lessen  the risk of dental caries (and other plaque-related oral diseases), frequent 
dental reviews are recommended (Fox 2005) together with office and home fluoride 
application in dentifrices and rinses (Selwitz, Ismail, and Pitts 2007).  Patients should 
be advised to avoid retaining sucrose-containing foods in the mouth for long periods 
of time. Patients with SS should only chew sugar-free (usually sucrose-free) 
products to help control xerostomia associated caries (Wescott, Starcke, and 
Shannon 1975; Dreizen et al. 1977; Carsons 2001). 
One of the suggested common complications secondary to dry mouth is intraoral 
candidiasis. Despite this being generally asymptomatic and unlikely to have a 
premalignant potential, many authors advocate its treatment. Therapy can be 
initiated with topical agents such as nystatin. The oral suspension (100,000 IU, qid 
for 10 days) is commonly used, although it contains significant amounts of sucrose 
and could be cariogenic. Thus, nystatin vaginal tablets (troches) dissolved orally can 
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be used instead. Cotrimazole lozenges (10-mg) dissolved in the mouth 5 times per 
day for 14 days also may be used. In addition miconazole gel can be used 4 times 
a day (Margaix-Muñoz et al. 2009). Patients wearing dentures should be advised to 
remove their dentures before sleep and store them in sodium hypochlorite solution 
or chlorhexidine. Oral candidiasis is recurrent and often requires retreatment (Walker 
et al. 1981). Acute suppurative sialadenitis is another complication of xerostomia 
induced by SS. It is an uncommon disorder characterised by painful swelling - 
usually of the parotid glands. Patients can experience purulent discharge from the 
duct of the affected gland, associated dysgeusia and cervical lymphadenopathy. 
Pyrexia, malaise and a risk of abscess formation can be present in severe cases. 
Acute suppurative sialadenitis can affect children and adults (Scully 1986; Khan, 
O’Sullivan, and McKiernan 2010; Özdemir et al. 2011). In addition acute suppurative 
sialadenitis of the parotid gland was the initial manifestation of pSS in a 7-year-old 
child (Alp et al. 2011). The causative organism of acute suppurative sialadenitis is 
often not found, however, facultative anaerobes, particularly Staphylococcus aureus 
and Streptococcus viridans have frequently been reported to be of aetiological 
significance. Effective hydration and antibiotics are the mainstays of therapy of 
uncomplicated acute suppurative sialadenitis. Typically employed antibiotics are 
anti-staphylococcal penicillins (e.g. flucloxacillin, amoxycillin or co-amoxiclav), 
cephalosporins or clindamycin (Brook 2009). Intra-ductal injection of antibiotics is 
unlikely to be of practical benefit (Troeltzsch et al. 2014). 
The management of salivary gland hypofunction is discussed in detail in section 
1.2.7.  
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1.1.7.1.2 Ocular disease 
Managing SS complications affecting the eye should start with patient education on 
lifestyle modifications such as avoiding long periods of reading or watching television 
as it reduces the blink rate and eventually increase evaporative loss and indeed 
starting these periods with artificial tears. Similarly avoiding hot, windy or high 
altitude environments is necessary.  Moreover patients with SS are advised to refrain 
smoking and avoid eye rubbing (Jackson 2009). 
Next, tear supplementation, anti-inflammatory therapy, tear retention and tear 
stimulation can be an option. The main treatment for dry eye is artificial tears. They 
act as lubricants and have a wide variety of compositions, viscosity and osmolarity 
(Fazaa et al. 2014).  
Patients should be encouraged to use tear substitutes often as a moisture 
replacement. Preservative-free tears may be used in cases of irritation (Kassan and 
Moutsopoulos 2004; Ramos-Casals, Tzioufas, and Font 2005). Artificial tears based 
on pilocarpine and cyclosporine at 0.05% concentration have been suggested 
(Kujawa and Rózycki 2005). The duration of tear retention can be increased in 
severe cases using high-viscosity agents such as sodium hyaluronate, however, this 
can cause visual blurring. Ophthalmic gels should be used during the night since 
they cause more blurring. On the other hand, low-viscosity agents such as 
methylcellulose are generally prescribed for mild-to-moderate dry eye. Tear 
evaporation can be decreased using lipid-containing artificial tears as they restore 
the lipid layer of the tear film (Lemp 2008). 
Blocking the drainage of the tears or inhibiting their evaporation can retain the 
existing tears in the eye (Fox 2000). This may be accomplished by occluding the 
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puncta by inserting collagen or silicone plugs (temporary) or by electrocautery 
(permanent). Inhibiting tear evaporation can be accomplished by wearing goggles 
or glasses with specially built side chambers. Although these devices are sometimes 
not well accepted by patients they can be helpful in certain environmental conditions 
(i.e. wind). Inflammation of the meibomian glands (blepharitis) is treated with warm 
compression, cleaning the lids and topical antibiotic (Seal et al. 1990; Huber-Spitzy 
et al. 1991; Katayama, Koyano, and Nishioka 1994; Carsons 2001). Filamentary 
keratitis can be managed with frequent eyewashes and a topical mucolytic 
(acetylcysteine). Furthermore, using scleral lenses can be beneficial in creating a 
fluid-filled pre-corneal space to rest entirely on the sclera. They are recommended 
for treating severe, refractory ocular surface diseases (Fazaa et al. 2014). 
Topical corticosteroids can improve signs and symptoms. However, these should 
not be used for long periods due to their potential adverse effects (cataract, steroid-
induced glaucoma, risk of herpetic infection). Topical non-steroidal anti-inflammatory 
drugs can be used with caution as they can lead to corneal melting in patients with 
compromised ocular surfaces. Regarding immunomodulatory drugs, topical 0.05% 
cyclosporine emulsion, and 0.03% tacrolimus eye drops have been reported to 
enhance tear stability in patients with moderate-to-severe dry eye (Fazaa et al. 
2014). 
A number of trials were conducted to examine treatment options of dry eyes. A 
controlled trial evaluating 2 NSAIDs (0.1% diclofenac vs 0.1% indomethacin) 
reported that the diclofenac group showed more reduction in corneal sensitivity 
(Aragona et al. 2005). In two controlled trials and one prospective study, different 
topical glucocorticoids were examined. The first trial (Avunduk et al. 2003) reported 
that fluorometholone showed lower dry eye symptom compared to flurbiprofen and 
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artificial tears. The second trial (Pflugfelder et al. 2004) did not find any significant 
differences between 0.5% loteprednol etabonate and placebo in combined corneal 
staining score. The prospective study (Hong et al. 2007) reported significant 
improvement in ocular test scores using topical 1% methylprednisolone. 
 Three placebo-controlled trials of 1451 patients with moderate or severe dry eye 
disease were enrolled to assess topical cyclosporine. The largest trial (Sall et al. 
2000) examined 2 doses (0.05% and 0.1%) and reported significant improvement in 
Schirmer test scores for both groups however improvement in corneal staining 
scores only in the 0.05% group. A 12-month extension of this trial using the 0.1% 
dose did not find any additional improvement in the outcomes (Barber et al. 2005). 
A controlled trial tested 4 doses of cyclosporine (0.05%, 0.1%, 0.2%, and 0.4%) 
found no linear dose/response results. However, best results were found in the 0.1% 
and 0.05% groups (Stevenson, Tauber, and Reis 2000). 
Tree controlled trials compared 0.05% cyclosporine with other therapies. In the first, 
Kim and his co-workers reported significant improvement in subjective evaluation of 
dry eye symptoms in 150 patients using either 0.05% cyclosporine or with 0.05% 
retinyl palmitate compared to artificial tears. Results showed no differences between 
cyclosporine and retinyl palmitate (Kim, Choi, and Joo 2009). Sall found an 
improvement in dry eye symptom and corneal staining scores using the combination 
of cyclosporine and glycolbased tears compared with cyclosporine and standard 
artificial tears in 60 patients (Sall et al. 2006). In another study when 0.05% 
cyclosporine, punctal occlusion and both 2 therapies combined were compared in 
30 patients, no differences was seen between the cyclosporine/punctal occlusion 
combination and cyclosporine alone in Schirmer test (3.9 vs 3.0 mm over 3 minutes) 
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and in less daily artificial tear use (3.9 vs 3.2 fewer uses per day) (Roberts, Carniglia, 
and Brazzo 2007). 
Topical 0.05% cyclosporine showed statistically significant improvements in a 6 
month prospective study (Toker and Asfuroğlu 2010). Tauber conducted a placebo-
controlled trial, he assessed 2 doses (1% and 2%) of topical ocular diquafosol, in 
527 patients and found better corneal staining score but not improved clearing of 
foreign body sensation (Tauber et al. 2004; Ramos-Casals et al. 2010). 
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1.1.7.2 Treatment of extra-glandular/systemic manifestations 
Concerning the general management of the extraglandular manifestations, no 
reliable treatment has yet been identified, but use can still be made of 
corticosteroids, nonsteroidal antiinflammatory drugs, immune regulators and 
immune suppressors (Ramos-Casals, Tzioufas, and Font 2005). However, Fox, 
Datiles and Atkinson reported that there was no improvement histologically or 
functionally in salivary and lacrimal glands from the use of prednisone (Fox et al. 
1993). It was suggested in another study that the long-term side effects associated 
with this treatment far outweighed the benefits (Fox and Stern 2002). 
Hydroxychloroquine (HCQ) at doses of 6 to 7 mg/kg/day is used to treat fatigue, 
arthralgia, and myalgia in pSS, although it has not been shown to improve dryness 
(Fox et al. 1996; Manoussakis and Moutsopoulos 1996; Tishler et al. 1999). A 
randomized multi-center placebo-controlled trial of HCQ of 120 patients found that 
this drug caused a reduction in IgG and IgM, yet no significant improvement of 
dryness, pain and fatigue seen at 12 months (Gottenberg et al. 2014). In current 
practice, hydroxychloroquine may be considered for the management of vascular 
purpura (Fazaa et al. 2014). Non-steroidal anti-inflammatory (NSAID) drug therapy 
can be used to control minor musculoskeletal symptoms. In the case of elderly 
patients or patients with peptic ulcer disease, cyclooxygenase-2 (COX-2) inhibitors 
can be considered. Infrequently, short courses of low-dose corticosteroid may be 
needed for very painful or disabling joint symptoms, Methotrexate in low doses 
weekly helps in managing arthralgia and myalgia, however it has a little effect in 
increasing the saliva flow (Skopouli et al. 1996). 
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Rituximab (anti-CD20) efficacy was assessed on several controlled trials. Seventeen 
patients with SS were included in the first trial (Dass et al. 2008). Fatigue was 
assessed using a visual analogue scale (VAS) as primary end point. Fatigue was 
significantly decreased in the rituximab group. Another study enrolled 30 patients 
and demonstrated efficacy in oral and ocular dryness and fatigue VAS (Meijer et al. 
2010). Patients with recent disease-onset and/or systemic manifestations were 
enrolled in a recent multicenter trial. Pain, fatigue, dryness and disease activity were 
assessed using VAS. The proportion of patients with improvement was significantly 
higher in the rituximab group at week 6. However, at 6 months, no significant 
improvement was observed in the rituximab group (Devauchelle-Pensec et al. 
2014a). Epratuzumab was tested in an open study included 15 patients with pSS 
(Jacobi et al. 2008). Improvement of dryness, fatigue and pain VAS were observed.  
Fifteen patients with pSS received 8 infusions of abatacept and were followed-up for 
24 weeks. The ESSPRI and the ESSDAI were significantly improved. Stimulated 
whole saliva remained stable. The tolerance of abatacept was satisfactory (Meiners 
et al. 2014). Symptoms of dry skin can be improved with 20 to 30 mg/day of 
secretagogues such as pilocarpine (Carsons 2001). Tight or elastic clothing should 
be avoided in cases of hypergammaglobulinemic purpura. Intermittent use of a mild 
corticosteroid cream can be used to control pruritis. In severe cases, such as 
necrotic or ulcerating lesions, more aggressive therapy is needed. Initial suppression 
may be attained with moderate doses of corticosteroid (0.5 to 1 mg/kg/day of 
prednisolone), then tapered as rapidly as possible with continued 
immunosuppression maintained (Carsons 2001). Humidification and secretagogues 
can help in the management of xerotrachea. Cough and dyspnea may be treated 
with moderate-dose corticosteroid but may require low-dose oral cyclophosphamide 
(Carsons 2001). 
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Gastrointestinal extraesophageal reflux disease can be treated with antacids, 
histamine-2 blockers, and proton pump inhibitors. On occasion, endoscopic 
evaluation and intervention may be necessary (Carsons 2001). 
Low-dose tricyclic antidepressants or anticonvulsants, such as gabapentin can be 
used to treat cranial and peripheral neuropathy. In resistant cases intravenous 
gammaglobulin is used (Pascual, Cid, and Berciano 1998; Carsons 2001). In cases 
of raynaud’s phenomenon calcium channel blockers or angiotensin-converting 
enzyme (ACE), inhibitors appear to be sufficient in these patients (Mavragani and 
Moutsopoulos 2007).  
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1.2 Salivary gland hypofunction 
1.2.1 Saliva: composition and physiology 
Whole saliva is composed of secretions from 3 pairs of major salivary glands 
(parotid, submandibular [SM], and sublingual [SL]) plus numerous minor glands. In 
addition, whole saliva comprises gingival crevicular fluid, microorganisms, food 
debris, and shed mucosal cells (Jensen and Vissink 2014). The amount of saliva 
secreted by an average adult is at least 500 ml over a 24-hour period. However, the 
salivary flow rates can differ greatly during any 24-hour period, according to the need 
or the current physiologic status of the patient. The unstimulated/resting flow rate is 
0.3 ml/ min, while the flow rate during sleep is 0.1 ml/min; during eating or chewing, 
it can increase to 4.0 to 5.0 ml/min (Cooper et al. 1995; Guggenheimer and Moore 
2003). Due to circadian rhythms, the flow rates were found to fluctuate by as much 
as 50 percent over a 24-hour period (Dawes 1987; Ship, Fox, and Baum 1991; 
Navazesh, Christensen, and Brightman 1992b; Ghezzi, Lange, and Ship 2000; 
Guggenheimer and Moore 2003). 
The autonomic nervous system is responsible for controlling the secretion of the 
salivary glands, in addition to the action of various hormones. Salivary secretion 
depends on several modulatory influences, which performe either through a cyclic 
adenosine monophosphate–dependent, or a calcium-dependent pathway. Saliva is 
composed of two components that are secreted by independent mechanisms. 
Primary saliva is produced by the secretory end pieces (acini), which is isotonic, its 
ionic composition is similar to that of plasma (Melvin, He, and Baum 1988; Turner 
and Sugiya 2002) see Figure. 3. The primary fluid is then adjusted in the ductal 
system by the selective reabsorption of sodium and chloride, and by secretion of 
potassium and bicarbonate. Thus the secretion rate, and therfore the volume, of the 
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endproduct saliva are determined directly by the formation rate of primary saliva 
through the acinar cells (Jensen and Vissink 2014). Excitation of either sympathetic 
or parasympathetic nerves to the salivary glands stimulates salivary secretion, yet 
the effects of the parasympathetic nerves are usually stronger and long lasting 
(Guggenheimer and Moore 2003). 
Both cholinergic and adrenergic agonists stimulate the ducts of the salivary glands 
causing an increase in the rate of secretion of potassium (Kˉ) and bicarbonate 
(HCO³ˉ). In serous acinar cells, acetylcholine, norepinephrine, substance P, and 
vasoactive intestinal polypeptide are released by specific α- nerve terminals and 
increase the secretion of salivary amylase and the flow of saliva. Acetylcholine, 
substance P, and norepinephrine acting on α-receptors that increases the 
concentration of calcium ions in the serous acinar cells, resulting in copious secretion 
with a lower concentration of amylase. In contrast, norepinephrine acting on β-
receptors and vasoactive intestinal polypeptide elevates the cyclic adenosine 
monophosphate concentration in acinar cells, eliciting a secretion that is rich in 
amylase. Accordingly, parasympathetic stimulation produces copious saliva of low 
protein concentration, whereas sympathetic stimulation produces little saliva but with 
high protein concentration, which may lead to the dry mouth sensation (Carlson 
2000; Porter, Scully, and Hegarty 2004). 
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Therefore, not only the volume but the composition of mixed saliva in the mouth can 
differ depending on the role of different glands during reflex stimulation (Proctor and 
Carpenter 2007). The parotid gland has a very low secretory rate under resting 
(unstimulated) conditions compared to during stimulation. Conversely, the 
submandibular/sublingual glands secrete relatively more saliva under resting 
conditions, see Table 7 (Shannon, Suddick, and Chauncey 1969; Proctor and 
Carpenter 2007). It has been reported that different afferent stimuli can change the 
composition of saliva secreted by a single gland. A relatively greater amount of IgA 
was present in chewing-stimulated human parotid saliva when compared to citric 
acid evoked saliva (Proctor and Carpenter 2002). Other studies showed that sweet 
stimulated human parotid saliva has higher protein concentration compared to acid 
stimulated saliva (Mackie and Pangborn 1990). The effects of different reflex stimuli 
have been studied in animal models, they showed that higher concentrations of 
salivary amylase and other proteins were secreted in a rabbit, when parotid saliva 
was evoked by carrots compared to standard pelleted chow (Gjörstrup 1980; Ikawa, 
Hector, and Proctor 1991). Additionally hormones were found to have a role in 
salivary secretion; thus women tend to have lower salivary flow rates than men. And 
these rates can differ in women according to different events as puberty, 
menstruation, pregnancy and menopause (Saluja et al. 2014).  
Table 7. Relative (%) contribution of different gland types to whole saliva under various conditions 
(Jensen and Vissink 2014). 
Salivary Gland Sleep Unstimulated Whole Saliva 
Stimulated 
(Mechanical) 
Whole Saliva 
Stimulated 
(Acid) Whole 
Saliva 
Parotid 0 21 58 45 
SM 72 70 33 45 
SL 14 2 2 2 
Minor glands 14 7 7 8 
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1.2.2 Clinical features and complications of salivary gland hypofunction 
Saliva plays a major role in oral function (Table 8). It carries food particles onto the 
taste buds in an appropriate dilution to aid in taste perception. In addition amylase 
and lipase aid initial digestion of starch and fat (Valdez and Fox 1991). Saliva eases 
the formation of the food bolus, and the salivary lubricatory glycoproteins, which 
permanently coat oral surfaces assisting in food mobility and reducing friction 
between the different oral structures (teeth, tongue, cheeks and lips) and between 
these structures and foreign elements (food, dental prostheses) (Levine et al. 1987). 
It aids in lubrication, repair, lavage, antimicrobial, and buffering properties which all 
contribute extensively to the protection of oral hard and soft tissue integrity (Mandel 
1987). The presence of saliva allows the tongue, cheeks and lips to rub against the 
teeth and reduce bacteria accumulation on the tooth surfaces and oral cavity 
(Napeñas and Rouleau 2014). 
Table 8. Main salivary function (Jensen and Vissink 2014) 
• Protecting the mineralized tissues against wear and demineralization  
• Wetting the oral mucosa, thereby forestalling oral desiccation and infection 
• Promoting speech and the digestion of food. 
 
The term xerostomia is the abnormal reduction of saliva. It can effect between one-
fifth to one-third of the adult population. It is also known to affect women more 
commonly (Sreebny 1992; Billings, Proskin, and Moss 1996; Nederfors et al. 1997). 
It is more common with increasing age, and indeed 25 percent of the elderly can 
complain of daily dryness. Occasionally it could be subjective with no evidence of 
changed salivary flow. In this condition, xerostomia is usually due to psychological 
factors (Orellana et al. 2006). 
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In cases of salivary gland hypofunction, patients will often complain of a feeling of 
dryness of all the oral mucosal surfaces, involving even the throat (Wolff and 
Kleinberg 1998; Bretz et al. 2000; Guggenheimer and Moore 2003). Additionally, 
patients may complain from difficulty in chewing, swallowing, or speaking (dysphagia 
and dysarthria). Patients may report the need to drink fluids to aid in swallowing while 
eating or difficulties in swallowing dry foods. Many patients will report carrying fluids 
at all times for comfort and to help in speaking and swallowing (Loesche et al. 1995; 
Guggenheimer and Moore 2003). The lips can sometimes stick with the oral mucosa 
or to their teeth. Pain is another common complaint as the oral mucosa may become 
sensitive to spicy or coarse foods, which can interfere with a patient’s diet and 
satisfaction at meal times. Retention of removable dentures can be negatively 
affected due to lack of lubrication (Niedermeier and Krämer 1992; Fox 2008). 
The lips may appear cracked and atrophic, the buccal mucosa can be pale and look 
corrugated, and the tongue smooth and reddish with loss of papillation 
(Guggenheimer and Moore 2003). In addition the tongue was reported to have the 
appearance of ground beef because of the presence of the deep fissures and sticky 
appearance (Napeñas and Rouleau 2014). Regarding the hard tissues, there can 
be an increase in erosion and dental cavities either at the gingival margin or cusp 
tips. Carious lesions can sometimes be progressive despite the presence of 
excellent oral hygiene, though this is unusual, it can be due to the lost buffering 
action and cleansing that saliva provides (Guggenheimer and Moore 2003). Patients 
with SS usually have an increased number and frequency of cariogenic 
microorganisms as Lactobacillus spp and Streptococcus mutans in supragingival 
plaque, and Candida albicans. In addition, the mucosal immunity is deteriorated due 
to the reduction in IgA and therefore the defense against caries is lowered (Napeñas 
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and Rouleau 2014). As a consequence, Fox and colleagues found that greater 
number of dental visits, more decayed teeth, and more dental restorations were 
reported in patients with pSS in comparison with control subjects (Fox et al. 2008). 
Erythematous candidiasis may occasionally lead to mucosal sensitivity, and give rise 
to erythema of the oral mucosa (especially the palate and tongue), while thrush can 
give rise to white, curd-like patches of the soft palate and rarely other oral sites. The 
corners of the mouth can be inflamed giving rise to angular chelitis (Rossie and 
Guggenheimer 1997; Guggenheimer and Moore 2003). Food pocketing in vestibules 
and around teeth is a common finding in patients with SS due to the lack of 
mechanical cleaning forces (Napeñas and Rouleau 2014) (Table 9). 
The salivary glands must be assessed for enlargement, changes in texture, and pain, 
and also to observe the ability for saliva to be excreted from the main excretory 
ducts.  Saliva should be expressed in a clear, watery and copious form. In cases 
where saliva appears as a cloudy exudate, that may be seen as sign of bacterial 
infection i.e. acute suppurative sialadenitis (Fox 2008). Parotid gland swelling in 
particular has been reported to occur in 30% to 40% of patients with SS (Napeñas 
and Rouleau 2014) this can be due to the inflammation of the disease process , 
acute suppurative sialadenitis and lymphoma. 
  
	 81	
 
 
 
 
A study assessed the data of 35 patients with SS in order to describe variable oral 
circumstances.   Feeling of a dry mouth and ingesting liquids to manage the dry 
mouth sensation was reported in all patients. Moreover, intraoral wounds were found 
in 71% of the subjects. Level of hyposalivation was found to be related to the duration 
of disease (Olate et al. 2014). 
  
Table 9. Effects of long-standing xerostomia 
      Increased frequency of caries (particularly cervical caries) 
Proclivity toward acute gingivitis 
Dysarthria 
Dysphagia 
Dysgeusia 
Proclivity toward candidal infection (e.g.acute pseudomembranous candidiasis, median rhomboid 
glossitis, denture-associated stomatitis, angular cheilitis) 
Burning tongue/depapillation of tongue 
Oral mucosal soreness 
Dry, sore, cracked lips 
Salivary gland enlargement (various causes) 
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1.2.3 Objective hyposalivation measuring methods 
Measuring salivary output can be easily done in an office setting by determining the 
total unstimulated output of saliva, termed the whole saliva flow rate (WSR). Salivary 
flow is classified as unstimulated, or resting, and stimulated, as it arises when an 
exogenous factor is acting on the secretory mechanisms (Dawes 1987). Whole 
saliva is basically the mixed fluid contents of the mouth. In 1992, Navazesh and 
colleagues suggested that salivary output can be measured and collected, less than 
0.12 to 0.16 mL/min (unstimulated) is considered a criteria for hypofunction 
(Navazesh, Christensen and Brightman 1992; Pesce and Spitalnik 2007; Fox 2008).  
Another study indicated that unstimulated whole saliva flow rates less than 0.1 
mL/min and stimulated whole saliva flow rates less than 0.7 mL/min are considered 
abnormally low (Jensen and Vissink 2014). 
Some different methods of assessing salivary gland function are presented in Table 
10, including sialochemistry which analyses the saliva composition (Kalk et al. 2001; 
Kalk et al. 2002), impression cytology of the buccal mucosa (Aguilar, Fonseca, and 
Croxatto 1991; Maragou et al. 1996), salivary electrophoresis (Al-Hashimi, 
Haghighat, and Fox 1998), saliva ferning  (Aguilar, Fonseca, and Croxatto 1991; 
Maragou et al. 1996; el-Miedany, el-Hady, and el-Baddin 1999), and the use of 
iodine–starch reaction to identify the number of lip salivary gland ostia (Inamura et 
al. 2001).  Salivary function assessment can also be performed using the following 
methods: the wafer test (Sánchez-Guerrero et al. 2002), the Saxon test (Kohler and 
Winter 1985), the oral Schirmer test (López-Jornet, Camacho-Alonso, and Bermejo-
Fenoll 2006), the candy weight loss test (Sreebny and Valdini 1988), the palatal 
(Márton et al. 2006), and parotid gland saliva flow (Skopouli et al. 1989), the 
capsaicin-stimulated salivary flow using filter paper (Kanehira et al. 2011) and more 
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commonly the whole saliva collection, with or without stimulus (Speight, Kaul, and 
Melsom 1992; Vitali, Moutsopoulos, and Bombardieri 1994)  see Table 10. Some of 
the most frequently used methods are explained in the next section with further 
details. 
1.2.3.1 Resting whole saliva 	
Four techniques have been described to estimate resting whole saliva flow rate: the 
draining method, the spitting method, the suction method, and the swab technique. 
In the draining method, collections should be performed after an overnight fast, 
between 8 and 11 a.m., or at least at a regular time. Patients are instructed not to 
brush, use mouthwashes, drink, chew (e.g., food, gum) or smoke at least 90 minutes 
before the collection time. The test should be carried out in a quiet area. The patient 
is then seated in a chair, in an upright position with the head tilted down, given a 
funnel and a test tube, and is asked to swallow. Following this, they are asked to sit 
quietly for a period of 5 minutes and to allow the saliva to accumulate in the mouth 
and passively drain into the funnel. The volume of saliva is measured and the rate 
of flow is recorded as mL/min. Alternatively, the saliva may be collected into a 
weighing boat. In such cases, the boat is tared (zeroed) on a precision balance, the 
saliva is allowed to drool into the boat, and the boat is then weighed again after the 
test period. Results may be expressed as g/min or as mL/min. The spitting technique 
is similar to the draining method. The difference is that the patient allows the saliva 
to accumulate in the mouth and then spits it into the collecting vessel, 1–2 times per 
minute. The saliva may be collected either into the weighing boats, into test tubes, 
or into the sialometer. The suction method involves the use of the standard, plastic, 
dental saliva ejector. The swab method is conducted by placing preweighed cotton 
rolls or gauze sponges into the mouth, leaving them for a fixed period, and then 
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reweighing them after the test. However, regardless of the method used, the 
conditions of the test should be the same for each patient each time that saliva is 
collected (Sreebny and Vissink 2010). 
1.2.3.2 Stimulated whole saliva 	
Whole saliva is generally stimulated by either chewing or tasting citric acid. Both 
methods are reliable. Flow rates using citric acid are generally greater than those 
induced by wax. When applying the masticatory method, the patient is either given 
a piece of paraffin wax, a piece of gum base, or a piece of Parafilm to chew for 5 
minutes. The accumulated saliva is then actively spat into the collecting vessel every 
minute. The gustatory method uses a 2% solution of citric acid to stimulate flow. The 
solution is applied to the lateral borders of the tongue with a cotton applicator every 
30 seconds for 5 minutes. As with the chewing method, the saliva is expectorated 
into the collecting vessel every minute (Vissink et al. 1983). 
1.2.3.3 Parotid saliva 	
The orifice of the parotid gland is accessible for cannulation, but usually a (modified) 
Lashley or Carlsson-Crittenden cup is used. The Lashley cup is a bi-chambered 
device, which measures about 2 cm in diameter. The inner chamber is placed 
directly over the orifice of the Stensen duct and connected, via plastic tubing, to a 
(graduated) test tube. The outer chamber is attached to a rubber bulb or a suction 
device via plastic tubing and is secured to the mucosa by vacuum. Parotid saliva is 
usually collected under stimulated conditions because the flow rate of unstimulated 
parotid saliva is usually very low or even absent in healthy individuals. The most 
commonly applied stimulus is a 2% to 4% citric acid solution. This stimulus is applied 
to the lateral borders of the tongue at 30-second or 60-second intervals with a cotton 
swab. It is usually collected for 10 minutes (Navazesh 1993; Burlage et al. 2005). 
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1.2.3.4 Submandibular/sublingual (SM/SL) saliva 	
About 70% of the oral secretions stem from the combined SM/SL glands. Therefore, 
most studies consider that the flow and composition of saliva obtained from the 
SM/SL glands are similar to that gained with whole saliva. The suction method is 
mostly used to collect these secretions. In this technique, the Stenson ducts are 
blocked with either Lashley cups or cotton roles. This strategy allows SM/SL saliva 
to flow from the Warthin the Bartholin ducts. Saliva which accumulates on the floor 
of the mouth, can be aspirated with a syringe, micropipette, or with gentle suction. 
The SM/SL saliva can be collected in the resting or stimulated state (Sreebny and 
Vissink 2010). 
1.2.3.5 Minor salivary gland secretions 	
The advent of the Periotron®, has allowed the development of a simple to measure 
the volume of saliva from the minor salivary glands and to calculate the thickness of 
the salivary film on the oral mucosa. In practice, a small piece of pan-shaped filter 
paper (Sialopaper TM) is placed at a selected site on the mucosa and held there for 
5 seconds. The Sialopaper TM is then removed, placed between the ‘jaws’ 
(electronic sensors) of the Periotron®, and the reading is shown on the screen. The 
Periotron® is a micro moisture meter that reads volumes up to 3 μL. The Sialopaper 
TM strips collect 0–3μL of fluid. To calculate the thickness of the mucosal film (in 
μm), one divides the volume of the collected saliva by the area of the Sialopaper TM 
test strip (31.7 mm
2
). 
Several papers have now recorded the normal values for various sites in the mouth 
(DiSabato-Mordarski and Kleinberg 1996; Wolff and Kleinberg 1998a; Won et al. 
2001; Lee et al. 2002). Of particular interest is the one that is located on the hard 
palate. It is the driest site in the oral cavity. The thickness of the salivary film at this 
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site may well be a valid sialometric indicator of the subjective feeling of oral dryness 
(Sreebny and Vissink 2010).  
Table 10. Objective salivary hypofunction tests (Hernández-Molina and Sánchez-Hernández 2013) 
Test Method Abnormal test Disadvantage 
Whole saliva 
flow collection  
 
Un-stimulated: saliva collection is 
performed during 5 min to 15 min 
by the spitting method.  
Stimulated: after chewing wax or 
gum for 1 min, the volume of saliva 
expectorated during that time is 
measured.  
Non-stimulated ≤1.5 
ml/15 min  
Stimulated 
≤0.6 ml in 1 min  
Clinical practice test. 
Affected by age, time 
of the day and drugs. 
Palatal saliva 
flow  
Dry weighed 8 mm disks are 
placed on both sites of the palate, 
at the level of the upper first 
molars. Collection is carried out for 
30 s and then the disk is weighted.  
1.35 ± 
2.5 μcm-2min-1 
Clinical practice test. 
Affected by age, time 
of the day and drugs.  
Stimulated 
parotid saliva 
flow  
Saliva is collected under a stimulus 
with a cannula or other collection 
device.  
1.5 ml/5 min  Clinical practice test.  
Special collection 
material needed. 
Wafer test After swallowing any residual 
saliva, the wafer is put on the 
centre of the subject’s tongue, and 
wafer dissolution time is measured.  
>4 min  Screening/clinical 
practice test. Affected 
by age, time of the 
day and drugs.  
Oral Shirmer 
test  
After placing a filter paper on the 
floor of the mouth, the wetted 
length after 5 min is measured. 
≤30 mm/5 min  Screening/clinical 
practice test. Affected 
by age, time of the 
day and drugs. 
Candy weight 
loss test  
 
The weight loss of a standard hard 
sugar candy after 3 min of passive 
incubation between tongue dorsum 
and palate is tested.  
<0.23 g  Screening/clinical 
practice test. Affected 
by age, time of the 
day and drugs.  
Impression 
cytology  
Cellulose acetate paper is applied 
on the internal surface of the 
inferior lip and the obtained sample 
is stained with hematoxylin and 
PAS. 
Keratinized epithelium 
is abnormal  
Research test. Light 
microscopy needed. 
Age dependent. 
Iodine–starch 
reaction 
A test tape of 1×1 cm2 containing 
iodine and starch is set on the 
labial mucosa anterior to the labial 
frenulum for 30 s. The number of 
blue spots corresponds to the 
number of salivary gland ostia.  
Controls 9.4 ±2.5 spots 
Oral dryness 
4.5 ± 3.1 spots  
Sjögren’s 2.1 ± 1.3 
spots  
Screening/clinical 
practice test.  
Age dependent.  
Capsaicin- 
stimulated 
salivary flow  
An assay system comprising 5 
spots containing starch, potassium 
iodide and a colouring reagent with 
or without capsaicin is placed in 
the mouth.  
In controls the 
capsaicin-stimulated 
salivary flow increased 
from 1.2 ± 1.4 to 2.9 ± 
1.3 coloured spots  
No change in the 
hyposalivation group  
Screening/clinical 
practice test.  
Age dependent.  
Sialochemistry  
 
Measurement of specific proteins 
(lactoferrin and lysozyme), 
carbohydrate, and electrolytes.  
 
Laboratory kits Cut-offs  
 
Research test. No 
agreement about 
significant cut-offs. 
Variation between 
resting and 
stimulated saliva. 
Moderate amount of 
saliva is required. 
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1.2.4 Subjective hyposalivation measuring methods 
Though subjective dryness does not associate well with assessable salivary gland 
dysfunction, some symptoms have been found to have a predictive value (Fox, 
Busch, and Baum 1987). It is useful to note that around a 50% reduction in saliva is 
required to take place before the xerostomia becomes evident (Dawes 1987). 
The use of a questionnaire accompanied with saliva collection has been useful in 
determining subjective measures of salivary gland dysfunction (Pai, Ghezzi, and 
Ship 2001). Since measuring xerostomia is a complex process, it is necessary to 
include the measurement of subjective symptoms and therefore, it is advised to use 
scales with different items that evaluate the range of the xerostomia (Sreebny and 
Valdini 1987; Nederfors et al. 1997; Baker, Pankhurst and Robinson 2006). 
1.2.4.1 Visual analogue scale (VAS) 
 
VAS has been widely used in the measurement of pain. One potential advantage 
over dichotomous/categorical measures of xerostomia is its ratio properties, which 
could be useful in analysing relative changes in salivation over time (Pai, Ghezzi, 
and Ship 2001), when compared to dichotomous/categorical measures which have 
a limited use in detecting change in xerostomia over time (Langley and Sheppeard 
1985). A VAS is a 100 mm horizontal straight line; the end anchors are labelled as 
the extreme boundaries of the sensation or response to be measured. The subjects 
are asked to mark their response by placing a vertical line between the two ends of 
the line (Wewers and Lowe 1990). This rating scale approach provides a continuous 
score which would allow more accurate discrimination among individuals with 
respect to the severity of their symptoms, thus reducing the potential for 
misclassification which may occur with single-item approaches (‘xerostomic’ vs. 
‘normal’) defining the condition. (Price et al. 1983; Pai et al. 2001)  
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1.2.4.2 Verbal categorical rating scale (VRS) 
 
The VRS consists of a set of word descriptors such as mild, moderate, and severe. 
Patients select a word that best represents the severity of symptoms (Langley and 
Sheppeard 1985). The VRS may correspond to different values on the VAS in the 
same patient on different occasions. Thus, a categorical scale should be used only 
as a coarse screening instrument, and more accurate intensity assessment should 
rely on a VAS, even in routine clinical assessment (Breivik et al. 2008). 
1.2.4.3 Subjective clinical evaluation 
 
Investigations have already shown that the complaint of xerostomia (the feeling of 
oral dryness) by itself is not a reliable predictor of salivary gland hypofinction (Fox 
1985; Navazesh et al. 1992; Närhi 1994; Wang et al. 1998). In fact a study by Field 
showed that only 54% of patients complaining of xerostomia actually had objective 
evidence of salivary hypofunction (Field et al. 1997). However, Fox demonstrated 
that specific questions concerning symptoms of oral dysfunction can be helpful in 
identifying patients with salivary gland hypofunction (Longman et al. 2000). In clinical 
trails patients can be asked a series of standardised questions concerning 
symptoms of dry mouth. Longman demonstrated that oral dryness, assessed by the 
clinician, was indicative of a reduced salivary flow rate and a significant predictor of 
salivary hypofunction in patients attending a Dry Mouth clinic (Longman et al. 2000). 
1.2.4.4 Xerostomia inventory (XI) 
 
XI is an 11-item summated rating scale resulting in a single continuous scale score, 
which represents the severity of chronic xerostomia. The constituent items cover 
both experiential and behavioural aspects of the condition and is used to score the 
symptoms of dryness (Hernández-Molina and Sánchez-Hernández 2013). 
Measures such as the XI can be used for a diagnostic or evaluative purpose 
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(Thomson and Williams 2000). With the former, the aim is to discriminate individuals 
with mild (or no) symptoms from those with more severe symptoms at one point in 
time; with the latter, the measure’s ability to accurately depict change in symptoms 
is the key consideration (Locker et al. 2004), particularly if they are to be used as 
outcome measures in intervention studies. A change in XI score of 6 or more points 
appears to be clinically meaningful (Thomson 2007).  
1.2.4.5 The Sicca symptoms inventory (SSI)  
This is the first disease-specific score intended to assess ocular, oral, vaginal, and 
skin dryness in patients with pSS over a period of 2 weeks (Bowman et al. 2003). 
The severity of each domain is scored by a 0–7 Likert scale, with an overall maximal 
score of 28. The oral domain is includes five facets: difficulty eating, dry throat, bad 
breath, wet mouth, and oral problems. However, the sensitivity to change of this 
questionnaire is not clear yet (Hernández-Molina and Sánchez-Hernández 2013). 
1.2.4.6 Sjőgren’s Syndrome Damage Index (SSDI) 
This index is used to assess cumulative permanent damage in pSS. It includes the 
following domains (maximal score =27): ocular, oral, neurological, renal, pulmonary, 
cardiovascular, gastrointestinal, musculoskeletal, endocrine, and malignancy (Barry 
et al. 2008). 
1.2.4.7 Sjőgren’s syndrome Disease Damage Index (SSDDI)   
This index is also used to assess cumulative permanent damage in pSS.  SSDDI 
approach was based on expert validation and includes the following domains 
(maximum score =16): oral, ocular, neurologic, pleuropulmonar, renal, and 
lymphoproliferative (Vitali et al. 2007). 
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1.2.5 Assessing treatment efficacy in SS 
In 2010 Seror and colleagues developed an international consensus Sjőgren’s 
activity score on the umbrella of European League against Rheumatism (EULAR). 
The first index was a patient administered questionnaire to assess subjective 
features, the EULAR SS Patients Reported Index (ESSPRI). It is a 0–10 numerical 
scale, one for assessment of each of the three domains: dryness, fatigue and pain 
(articular and/or muscular), the final score is the mean of the score of each domain 
(Seror et al. 2010).The second index was a systemic activity index to assess 
systemic complications, the EULAR SS Disease Activity Index (ESSDAI). It includes 
12 domains (i.e. organ systems). Each domain includes three to four levels, 
according to their degree of activity (Seror et al. 2010). Seror included data of 96 
patients retrospectively to assess the sensitivity to change of the ESSDAI, which 
showed that changes over time were detected more accurately than with other 
known indices. Meiners (2012) in a prospective study, also assessed 
responsiveness to change of ESSPRI and ESSDAI in pSS patients treated with 
rituximab. The results confirmed that ESSPRI and ESSDAI are certainly sensitive to 
measure the changes in disease activity following a treatment method, which 
indicates the usefulness of these indices for future clinical trials (Vissink et al. 2012).  
In addition assessing the effect of a treatment can be monitored using US imaging 
of the salivary glands, as US is not considered only a method to diagnose pSS. It is 
also useful to note that involvement of submandibular salivary glands is earlier in SS 
than the parotid glands (Vissink et al. 2012). 
Moreover, parotid gland biopsies can have a role in assessing the efficacy of an 
intervention. It has the advantage that parotid gland tissue can be easily harvested, 
repeated biopsies from the same parotid gland are possible, and the 
histopathological results can be compared with other diagnostic results derived from 
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the same gland, e.g. secretory function, sialographic appearance, and ultrasound 
(Vissink et al. 2012). 
 
1.2.6 Xerostomia related quality of life 
Xerostomia is known to be unpleasant, and due to its chronicity in nature it can lead 
to a reduced quality of life (QoL). As xerostomia is the perception of dry mouth, a 
number of epidemiological studies have shown that actual salivary flow rates 
correlate very poorly with this subjective complaint (McMillan et al. 2004). Earlier 
European studies have found a significant reduction of health related quality of life 
in patients with pSS (Thomas et al. 1998; Sutcliffe et al. 1998; Belenguer et al. 2005; 
Champey et al. 2006; Bowman et al. 2007). 
QoL in patients with pSS can be measured using the Medical Outcome Short Form 
(36) Health Survey questionnaire (SF-36), a health-related questionnaire that 
reflects the patient’s perception of their physical, emotional and social function and 
the disease and treatment-related symptoms. The standard version of the Health 
Questionnaire SF-36 contains eight areas: physical functioning, physical role 
limitations, bodily pain, general medical health, vitality, social functioning, role 
limitations: emotional and mental health. High scores indicate better health; hence 0 
is the worst state of health and 100 is the ideal state of health (Alonso, Prieto and 
Antó 1995; Lopez-Jornet and Camacho-Alonso 2008). The SF-36 is used to 
compare the general state of health in patients (Lopez-Jornet and Camacho-Alonso 
2008). 
The Oral Health Impact Profile (OHIP-49) was developed for a thorough 
measurement of the levels of dysfunction, discomfort and disability related to oral 
disorders (Locker 1988; Slade 1998; Locker, Jokovic, and Clarke 2004; Lopez-
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Jornet and Camacho-Alonso 2008). The OHIP-49 is focused on measuring oral 
health. Each of its items was scored: ‘never’, score 0; ‘hardly ever’, score 1; 
‘occasionally’, score 2; ‘fairly often’, score 3; ‘very often’, score 4. The OHIP-49 is 
divided into seven different domains and the possible score range for each one is: 
‘functional limitation’ (nine items) – from 0 to 36; ‘physical pain’ (nine items) – from 
0 to 36; ‘psychological discomfort’ (five items) – from 0 to 20; ‘physical disability’ 
(nine items) – from 0 to 36; ‘psychological disability’ (six items) – from 0 to 24; ‘social 
disability’ (five items) – from 0 to 20; ‘handicap’ (six items) – from 0 to 24; and finally 
‘Overall OHIP score’ (49 items) – from 0 to 196. In this model, the higher scores 
indicate a poorer state of health (Lopez-Jornet and Camacho-Alonso 2008). This 
questionnaire was intended to measure self-reported dysfunction, discomfort and 
disability concerning oral conditions. Both questionnaires (SF-36 and OHOP-49) 
have been widely used internationally and both are validated (Lopez-Jornet and 
Camacho-Alonso 2008). 
 
QoL assessments have been used in some studies to estimate the effects of 
xerostomia in patients with pSS, (Strömbeck et al. 2000; Hay, Morton, and Wall 
2001; Rostron et al. 2002). In his study, Sutcliffe showed that, with the exception of 
oral damage, end organ damage was uncommon in pSS, still the amount of 
functional disability was as great in patients with pSS (Sutcliffe et al. 1998). 
In a study of 42 Swedish women with pSS investigating health related quality of life, 
all 8 scales of the SF-36 were significantly reduced and the percentage of patients 
not employed due to disability was similar among patient with pSS, RA and 
fibromyalgia. Patients with pSS scored worse on the psychological scales and had 
better physical function than the RA patients, while the fibromyalgia patients had 
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lower levels of health quality on all 8 SF-36 scales in comparasion to both patients 
with RA and pSS (Strömbeck et al. 2000). 
Another study on a Chinese population of patients with SS, the SF-36 scores in 
physical function, role-physical and general health domains were lower in SS 
patients, indicating the direct influence of the condition on health related quality of 
life (McMillan et al. 2004). In the same study when applying the dry mouth measure, 
it showed that most patients with SS had problems related to a subjective feeling of 
dry mouth particularly when eating and speaking. Moreover sticky saliva and 
coughing were also features in more than half of the primary cases (McMillan et al. 
2004). Champey emphasised, in his study of 111 patients with pSS, the role of the 
psychological dimension on results of the SF-36. Fatigue and pain, but not dryness, 
were associated with quality of life and psychological distress (Champey et al. 2006). 
In 2009 Murukutla and colleagues reported reduced function in patients with pSS in 
each domain of the SF-36, and a higher utilization of health care services in 
comparison to controls, in addition they reported a greater work disability. For 
emotional well being, the main unique predictor of quality of life was depression, 
counting on its own for 25% of the variance in the index amongst patients with pSS. 
Murukutla demonstrated that morbidity associated to sicca symptoms was high. 
Additionally on both the SF-36 and in the impact questions, patients with higher sicca 
severity reported poorer functioning (Segal et al. 2009). Segal and colleagues 
pointed out that one of the causes that can give rise to psychological distress is the 
delay in the diagnosis of SS. Therefore earlier diagnosis could possibly decrease 
morbidity related to sicca complications such as corneal scarring and tooth loss 
(Segal et al. 2009). 
In a Dutch population, Meijer and colleagues reported that patients with SS had a 
large impact on HRQOL and employment, which was suggested by lower SF-36 
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scores and employment rates, and higher disability rates when in comparison to the 
general Dutch population. These striking results allow us to apply them in different 
populations due to the huge difference between the SS patients group and the 
control group. Fatigue was reported as a main explanation for reduced physical and 
mental HRQOL (Meijer et al. 2009). In his study, Hackett reported that functional 
capacity in a wide spectrum of daily activities significantly reduced in pSS patients 
(Hackett et al. 2012). 
Patients with pSS in Korea were found to have low HRQOL and significantly higher 
ESSPRI scores in a prospective study compared to 42 non-SS sicca patients. 
Furthermore, ESSPRI scores had a significant association with all SF-36 scales 
(Cho et al. 2013). Lendrem showed that higher scores on the ESSDAI, EULAR sicca 
score and ESSPRI happen to be associated with poorer health states (Lendrem et 
al. 2014). 
Furthermore, the impaired chemosensory perception was found to influence health-
related QoL in a clinical situation other than SS itself (Epstein et al. 2002). In 2009, 
a study confirmed that impaired QoL in patients with SS can also be due to the 
abnormal chemosensory perception that leads to impaired smell and taste. Kamel 
reported in this study a high degree of impairment, particularly for smell, as 50% of 
the patients with SS demonstrated clinical hyposmia. They pointed out some factors 
that could lead to such impairment, such as decreased mucin (an odorant carrier) 
and recurrent rhinosinusitis. The recurrent epistaxis, due to dryness, leads to scab 
formation and nasal blockage that also gives rise to a reduced smell sensation 
(Kamel, Maddison, and Whitaker 2009). Within the SS group, the threshold for sweet 
taste was the least reduced due to the fact that sweet taste is independent of saliva, 
unlike the other tastes (Kaneda et al. 2000). There was a significant reduction in the 
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composite physical and mental components of SF-12 in SS patients compared with 
controls and appeared to be influenced by chemosensory impairment, particularly 
loss of taste (Doty et al. 1991; Kamel, Maddison, and Whitaker 2009). 
All these findings increasingly recognise QoL assessments as a valid, appropriate 
and significant indicator of treatment need and intervention outcomes (Locker 1988; 
Slade 1998; Locker, Jokovic, and Clarke 2004). 
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1.2.7 Salivary gland hypofunction treatment methods 
The management of long-standing xerostomia is chiefly directed towards the 
avoiding factors that may exacerbate dry mouth, applying salivary substitutes, the 
use of sialogogues and the prevention of the accompanying oral complications 
(Walls and Murray 1993; Jonsson, Haga and Gordon 2000; Porter, Scully and 
Hegarty 2004). 
 
1.2.7.1 Salivary substitutes 
It is essential to note that because these substances are removed from the mouth 
during swallowing, it leaves them with a short effect (Al-Hashimi and Taylor 2001). 
Regardless of the duration of saliva substitutes, they have a function in hydrating 
and lubricating the oral cavity tissues (Porter, Scully, and Hegarty 2004). 
1.2.7.1.1 Water 
Patients with xerostomia usually sip water on a regular basis. Olsson & Axell 
compared the efficacy of water with that of artificial saliva in patients with xerostomia 
of different etiologies in a double-blind study. Patients were asked to rinse 15ml of 
the solutions. Both subjective and objective, i.e. mucosal friction measurements, 
effects were noted. It was found that water lead to a mean duration of subjective 
improvement of 12 minutes, while the mean duration of objective improvement was 
5.5 minutes. These values were about half the values seen with artificial saliva 
(Olsson and Axéll 1991). 
1.2.7.1.2 Topical artificial saliva 
Artificial salivas are the most commonly prescribed salivary substitutes. They are 
normally based on either mucin or carboxymethylcellulose (Levine et al. 1987). 
Mucin is found in saliva, and the mucin-based artificial salivas show more 
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effectiveness and better tolerance than the carboxymethylcellulose- based ones (’S-
Gravenmade, Roukema, and Panders 1974; Vissink et al. 1983; Visch et al. 1986). 
Yet, even the mucin based artificial salivas are not considered good saliva 
substitutes (Levine et al. 1987). One study reported that the mean duration of 
subjective improvement in xerostomia with a mucin-based artificial saliva was 18 
minutes, while the mean duration of objective improvement in mucosal friction was 
11.5 minutes (Olsson and Axéll 1991). This short duration of action has also been 
reported by other investigators ( Vissink et al. 1983). However, the mucin-based 
artificial saliva is considered to have a longer duration when compared with 
carboxymethylcellulose-based agents (Vissink et al. 1983). 
Mucin-based artificial saliva was compared to flavoured water, and its non-mucin 
base in a double-blind study, it was found that the mucin-based saliva is more 
effective in reducing xerostomia (Duxbury, Thakker, and Wastell 1989). 
Nevertheless, water was considered the best treatment more often than the mucin-
based artificial saliva (Vissink et al. 1983; Visch et al. 1986). 
Patients using Carboxymethylcellulose-based artificial salivas can complain of sticky 
accumulations in the mouth, which can lead to irritation of the underlying mucosa ( 
’S-Gravenmade, Roukema, and Panders 1974; Vissink et al. 1983), whereas this is 
not apparent with mucin-based ones. In general all types of artificial salivas are not 
typically associated with systemic side effects. 
Lubricating agents in the form of gels, mouthwashes, lozenges (Senahayake, 
Piggott, and Hamilton-Miller 1998), and toothpastes (Warde et al. 2000), have been 
used with different results to lessen the symptoms of xerostomia (Epstein et al. 
1999). The qualities of a lubricating agent that increase patient acceptance and 
compliance are: lubrication, taste, duration of action, the delivery system, severity of 
xerostomia, and cost (Epstein and Stevenson-Moore 1992). Some available 
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proprietary preparations include Luborant (Antigen, UK), Saliva Orthana (AS 
Pharma, Sweden), Salivace, and Oral Balance (Anglian, UK), all have been 
approved for dry mouth related to radiation or SS (Samarawickrama 2002). 
1.2.7.1.3 Glycerine 
Greenspan has recommended the use of glycerine in combination with lemon to be 
used as a salivary substitute (Greenspan 1990). Still, glycerine was reported to be 
subjectively less effective than artificial saliva in comparative studies (Klestov et al. 
1981; Poland et al. 1987). 
1.2.7.1.4 Others 
The use of a standard bedside humidifier and supersaturated humidification have 
been of slight benefit (Criswell and Sinha 2001). An intraoral device containing saliva 
substitute, which slowly releases the lubricant into the mouth, has been reported 
more acceptable to patients with xerostomia than the use of the lubricant on its own 
(Frost et al. 2002) although there is a little supportive data. 
 
1.2.7.2 Topical saliva stimulants 
Stimulation of taste, touch, pressure and proprioceptive receptors in and around, the 
oral cavity can generate a number of stimuli that can lead to an increase in salivary 
flow. Saliva stimulants include two categories: those that stimulate the 
aforementioned receptors (afferent pathways), e.g. organic acids and chewing gum, 
and those that act directly on the parasympathetic nerves (efferent pathways), e.g. 
pilocarpine (Davies 1997). 
Although the theory is that only subjects with residual salivary gland function can 
benefit from agents that stimulate salivary glands, it is unfeasible to determine if the 
cellular infiltrate in SS has destroyed the entire salivary gland parenchyma. It is 
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possibile that residual function may exist in minor salivary glands, which can be 
undetectable by the clinicians. Therefore, stimulating agents may be of benefit in 
excreting even a small amount of saliva that may lessen the symptoms of oral 
dryness (Sreebny and Valdini 1987; Wolff et al. 2012). 
1.2.7.2.1 Ascorbic acid (vitamin C) 
Although there is little evidence to support the use of ascorbic acid tablets 
treatmenting xerostomia (Davies and Singer 1994), a study in Sweden compared 
the efficacy of ascorbic acid with artificial saliva and a number of other saliva 
stimulants in patients with xerostomia of varying aetiology (Björnström, Axéll, and 
Birkhed 1990). Ascorbic acid was subjectively more effective than artificial saliva, 
but less effective than the other saliva stimulants (Davies and Singer 1994). 
Furthermore, long term use of ascorbic acid may cause dental demineralization 
(Anneroth, Nordenram, and Bengtsson 1980). 
1.2.7.2.2 Citric acid 
Citric acid is found in some hard-boiled sweets (Twycross and Lack 1986).  Patients 
with non-radiation-induced xerostomia in an uncontrolled study, reported that a 
mouthwash containing 1% citric acid was effective (Spielman et al. 1981). Although 
patients with radiation-induced xerostomia did not report improvement using the 
mouthwash. Interestingly, subjective improvement in the sense of dryness of the 
mouth was related to an objective increase in salivary flow in only 55% of cases. 
Only three out of 34 patients discontinued this preparation due to burning sensation. 
Citric acid, similarly to ascorbic acid, can have a detrimental effect upon the teeth 
causing erosion and caries (Newbrun 1981). 
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1.2.7.2.3 Malic acid 
Malic acid is a naturally developed acid which can be found in apples, pears and 
certain other fruit. At the end of Bjornstrom’s study, 44% of the patients preferred to 
continue with the malic acid pastilles (Björnström, Axéll, and Birkhed 1990). Local 
irritation was not a major problem. However, yet again, malic acid does cause 
demineralization of the teeth (Anneroth, Nordenram, and Bengtsson 1980) and 
therefore it should not be used for long durations in dentate patients. 
1.2.7.2.4 Sugar-free confectionary 
Confectionaries containing citric and malic acid are frequently used to treat 
xerostomia (Davies 1997). Mints were reported to improve salivary flow in patients 
with xerostomia. But, subjective improvement in the sensation of dryness of the 
mouth, duration of the effect, and acceptability of the treatment, were not recorded 
(Abelson, Barton, and Mandel 1990). Additionally, patients often do not wish to use 
such confectionary on a long-term basis (Al-Hashimi and Taylor 2001). 
1.2.7.2.5 Chewing gum 
Chewing can result in an increase in saliva output, and this is usually according to 
taste, especially sour and bitter (Fox 2004). Chewing gum includes a gustatory 
action (i.e. via taste) although the physical action of chewing may also be beneficial 
to increase salivary outflow from the major salivary glands (Abelson, Barton, and 
Mandel 1990). However, these actions are probably short-lived and full dentures 
users may be unable to use it (Itthagarun and Wei 1997). Several studies have 
shown that chewing gum can increase salivary flow in patients with xerostomia of 
varying aetiology (Markovic, Abelson and Mandel 1988; Abelson, Barton and Mandel 
1990; Olsson and Axéll 1991; Aagaard et al. 1992; Risheim and Arneberg 1993)  but 
the duration of the effect was still not recorded. This objective improvement in 
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salivary flow was linked with subjective improvement in xerostomia, 56±79% of 
patients preferred to continue using the chewing gum at the end of the study (Olsson 
and Axéll 1991; Aagaard et al. 1992). Definitely, in the Bjornstrom study, chewing 
gum was the mostly preferred treatment (Davies 1997). Chewing gum, in addition, 
did not give rise to any notable adverse side effects (Aagaard et al. 1992). 
 
1.2.7.3 Systemic saliva stimulants 
Muscarinic receptors are the receptor sites for acetylcholine, the neurotransmitter of 
the parasympathetic autonomic nervous system. These receptors are located at the 
ends of parasympathetic nerve pathways on the postsynaptic cell membranes of 
various tissues, principally muscles and glands (Broadley and Kelly 2001). There are 
two types of acetylcholine receptors, nicotinic and muscarinic. Two types of drugs 
act as agonists of muscarinic cholinergic receptors: choline esters (acetylcholine) 
and cholinomimetic alkaloids (muscarine and pilocarpine). The alkaloid muscarine 
was isolated from the mushroom Amanita Muscaria by Schmiedeberg in 1869 
(Broadley and Kelly 2001). Five subtypes of muscarinic acetylcholine receptors have 
been identified (M1–M5), with M1 and M3 predominating in the salivary glands, and 
M3 in the lachrymal glands (Zoukhri and Kublin 2001). Two muscarinic agonists 
(pilocarpine and cevimeline) are licensed for the treatment of sicca symptoms in SS 
due to their ability to stimulate muscarinic acetylcholine receptors, stimulating watery 
secretions (Fox, Konttinen, and Fisher 2001; Brito-Zerón et al. 2013). 
1.2.7.3.1 Pilocarpine 
Pilocarpine is an alkaloid found in the leaves of two of the Jaborandi plants 
Maranham Jaborandi and Pernambuco Jaborandi, also referred to as Pilocarpus 
Microphyllus and Pilocarpus Jaborandi, respectively (Broadley and Kelly 2001). 
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Pilocarpine was first extracted and named in 1875 by Gerrard of University College 
Hospital in London (Berk 2008). The same year, Langley described the effects of 
Jaborandi extract on the heart (Langley 1875). The prime effect was the slowing and 
ultimately stopping of the heart. In his discussion of Jaborandi, he mentions that the 
effect of the extract, that is pilocarpine, includes ‘producing a copious flow of saliva’. 
Marshall (1904) published on the physiologic actions of pilocarpine, he found that 5 
mg of pilocarpine injected intraperitoneally into a rat rapidly produced dyspnea, 
depression and salivation lasting nearly 2 hours. He described the effects of self-
administration: ‘At first hypodermic injections were used, but later the substances 
were taken by mouth. The symptoms were salivation and sweating and with larger 
doses, a curious feeling about the eyes and fullness of the head, increased pulse-
rate and slight nausea’. The smallest dose causing this effect was 5 mg (Berk 2008). 
Pilocarpine is a non-specific muscarinic acetylcholine receptor agonist (Berk 2008). 
There are five muscarinic receptors (M1–M5). Of these, pilocarpine chiefly acts to 
increase salivary flow throughout the M3 receptors. These are expressed on smooth 
muscle and glandular tissues (Ishii and Kurachi 2006). Stimulation of central 
muscarinic receptors can lead to confusion, agitation and seizures. Moreover, 
stimulation of central M4 receptors can lead to a Parkinsonian-like resting tremor 
(Mayorga et al. 1999). Stimulation of peripheral muscarinic receptors produces 
salivation, lacrimation, rhinorrhea, bronchospasm, bronchorrhea, urinary frequency, 
defecation, increased peristalsis, vomiting, sweating, miosis and bradycardia. Unlike 
acetylcholine and acetylcholinesterase compounds, pilocarpine does not stimulate 
nicotinic receptors (Hendrickson, Morocco, and Greenberg 2004a). 
Aromdee and colleagues reported that pilocarpine absorption is from the 
gastrointestinal tract, and the peak plasma concentrations are reached within around 
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1 hour. It is metabolised in the liver and excreted principally by the kidneys, with an 
elimination half-life of around 1 hour (Aromdee et al. 1999). 
It was predicted that patients with SS might satisfactory respond to treatment of 
xerostomia with pilocarpine, due to the greater residual functional salivary 
components when compared to xerostomia due to irradiation (Nusair and Rubinow 
1999). In an early trial, Fox and colleagues tested pilocarpine on a heterogeneous 
population of patients with salivary hypofunction (Fox et al. 1991). Thirty-one 
patients were randomly assigned over the course of 5–6 months of pilocarpine and 
1 month of placebo. Salivary function, as measured by stimulated flow and 
scintography, increased during pilocarpine use in 21 of the patients and there was 
subjective improvement in 27 of the patients. 
Oral pilocarpine has been evaluated in several placebo-controlled trials. The first trial 
assessed 2 doses (2.5 and 5 mg every 6 hours) and found a higher frequency of 
improvement in dry mouth and dry eye in the 5-mg group but not in the 2.5-mg group 
(Vivino et al. 1999b). In the second trial Papas evaluated the use of 5 mg and 7.5 
mg during 6 weeks with placebo (Papas et al. 2004). Salivary flow rates were 
significantly increased in the pilocarpine groups. In 2006, a dose-escalating trial was 
performed (from 5 to 7.5 mg every 6 hours) and similarly reported a higher frequency 
of improvement in dry mouth and dry eye in the 5 mg group (Wu et al. 2006a). Vivino 
found a higher frequency of sweating was reported and increased urinary frequency 
compared with placebo (Vivino et al. 1999b). In a dose-escalating trial (Wu et al. 
2006a) 23% of patients switched from a regimen of 7.5 mg every 6 hours to 5 mg 
because of adverse effects.  
In a placebo-controlled double-blind randomized clinical trial on healthy volunteers, 
the effect of pilocarpine mouthwash on the salivary flow was tested using 0.5 mg, 1 
or 2% pilocarpine or 0.9% saline. Before the trial the patients completed an analogue 
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scale to record the intensity of anxiety, tremors, sudoresis, facial flushing, abdominal 
and/or thoracic distress, lacrimation, salivation, palpitation, nausea, visual 
disturbance and hunger. Blood pressure and heart rate were monitored and the 
salivary flow was quantified by weighing a piece of cotton that was kept under the 
tongue for 1 minute. Patients were instructed to keep the solutions in their mouth for 
1 minute without swallowing and after 75 minutes pre-trial examinations were 
repeated. It was found that mouth rinsing with 1 and 2% pilocarpine solution was 
able to induce a significant and dose-dependent elevation in salivary flow perceived 
subjectively and objectively without giving rise to any adverse effect (Bernardi et al. 
2002). 
Another study reported that juvenile SS patients could respond better using 
pilocarpine, than adult patients, which could be due to the more severely salivary 
gland damage in adult patients (Tomiita et al. 2010). 
The results of most clinical trials imply that pilocarpine is safe and well tolerated, with 
no serious adverse effects (Scully and Epstein 1996), but it is sensible to avoid 
pilocarpine in patients with respiratory disease (e.g., asthma, chronic bronchitis, 
chronic obstructive pulmonary disease) and those on antihypertensive drugs, since 
interactions with β-blockers would seem possible (Porter, Scully, and Hegarty 2004). 
Yet it is noted, that in controlled trials of oral pilocarpine, no serious reactions or 
toxicities have been reported. Rather, only mild muscarinic symptoms seem to be 
common in therapeutic use and are dose related. On the other hand, clinical toxicity 
has infrequently occurred from excessive application or ingestion of ophthalmic 
preparations of pilocarpine (Hendrickson, Morocco, and Greenberg 2004a). Topical 
ophthalmic pilocarpine caused bradycardia and muscarinic toxicity (Epstein and 
Kaufman 1965). Likewise, Littman reported a similar case that resulted in 
atrioventricular dissociation and bradycardia (Littmann et al. 1987). Another study 
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reported the accidental subcutaneous injection of 80 mg of pilocarpine ophthalmic 
solution, which lead to muscarinic symptoms (Lum and Kastl 1987). 
Hendrickson reported a case of muscarinic toxicity secondary to an accidental 
pilocarpine overdose due to patient-doctor miscommunication. Within one half-hour 
after ingestion, the patient reported sweating, and crampy, intermittent, and diffuse 
abdominal pain. Six hours later, the patient developed excessive salivation, 
lacrimation, vomiting, anxiety, tremor and profuse watery diarrhoea (Hendrickson, 
Morocco, and Greenberg 2004). 
1.2.7.3.2 Cevimeline 
Cevimeline is a cholinergic agent specific for the M1 and M3 receptors, and since 
the majority of muscarinic receptors on salivary glands are M3 (Fox, Konttinen, and 
Fisher 2001), it is suggested that it would have more efficacy and fewer cardiac side 
effects (associated with the M2 receptor) and tremor (associated with M4 receptor) 
than pilocarpine (Fox 2004; Atkinson and Baum 2001; Hendrickson, Morocco, and 
Greenberg 2004). 
It was found that doses of 30 mg of cevimeline 3 times daily significantly improved 
symptoms of dry mouth and increased the salivary output in patients with SS 
(Petrone et al. 2002a). Cevimeline has a similar pharmacological profile to 
pilocarpine, however the onset of increased salivation may be later and the duration 
of action longer than the latter agent. The safety and adverse event profiles are 
similar to those of pilocarpine, patients can complain of sweating and nausea 
secondary to cevimeline use.  
The efficacy of cevimeline has been examined in large, well-controlled trials. A trial 
assessed 2 doses (15 and 30 mg every 8 hours) and reported a higher frequency of 
improvement in dry mouth in the 30 mg group (Petrone et al. 2002a). Another trial 
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assessed 2 doses (30 and 60 mg every 8 hours) and found a higher frequency of 
improvement in dry mouth in the 30 mg group (Fife et al. 2002a). However, a third 
trial there was a significant difference in subjective sicca symptoms in the 20-mg 
group yet not in the 30-mg group (Ono et al. 2004), whereas the fourth trial, which 
tested 30 mg of cevimeline every 8 hours using a crossover design, and found no 
significant results (Leung et al. 2008). A higher frequency of nausea and sweating 
in the 30-mg group compared with placebo (Petrone et al. 2002a) and a higher 
frequency of nausea sweating and rigors in the 60-mg group in comparison with 
placebo (Fife et al. 2002a).  
 
1.2.7.4 Systemic immunologically active agents 
In SS, cases with severe systemic involvement or when improvement has failed with 
conventional therapies, the use of immunological therapies can be justified. 
However, because the role of biologic therapies in pSS patients with sicca syndrome 
and/or fatigue alone is not yet clear, it is not justifiable to use these agents for 
patients without systemic involvement. Additionally it is critical to note the cost to the 
patient and health care service (Bowman and Barone 2012). On this point, the 
literature has provided three disappointing messages concerning the use of 
immunological agents: 1) limited benefit for sicca features, 2) the lack of a specific 
analysis of extraglandular features and 3) the high rate of adverse events (ranging 
between 41% and 100%) (Ramos-Casals et al. 2010; Brito-Zerón et al. 2013). 
Several studies were conducted to assess some immunomodulatory and 
immunosuppressive drug available.  
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1.2.7.4.1 Immunomodulatory or immunosuppressive agents 
No difference was reported between groups in salivary flow rate (SFR), Schirmer 
test, rose bengal staining score, or histopathological focus score in a controlled trial 
comparing oral prednisone (30 mg per day) with piroxicam (20 mg per day) and 
placebo (8 patients in each group) (Fox et al. 1993). A prospective study reported 
that glucocorticoids did not have an effect in improving SFR, as it was worse in 60 
patients with pSS (Meijer et al. 2007). Conversely, another prospective study of 20 
patients found that oral prednisolone improved SFR (Miyawaki, Nishiyama, and 
Matoba 1999).  
A 2-year crossover trial using 400 mg of HCQ per day in 19 patients reported no 
significant differences in HCQ vs placebo for sicca symptoms, parotid enlargement, 
fatigue, myalgia, and arthralgia, and no significant difference in ocular tests (Kruize 
et al. 1993). Similar results were found in a prospective study of HCQ in 14 patients, 
as no effects on sicca symptoms and fatigue were found (Tishler et al. 1999). The 
efficacy of HCQ was examined in a recent double-blinded placebo controlled trial in 
France. The results did not show efficacy in the main disabling symptoms (dryness, 
pain, and fatigue) of pSS compared to placebo (Gottenberg et al. 2014). 
Azathioprine (Price et al. 1998) and oral cyclosporine (Drosos, Skopouli, 
Galanopoulou, et al. 1986) in 13 and 20 patients, respectively, were compared in 
two placebo-controlled trials. The first trial reported no significant differences in of 
the outcomes. The second trial found a higher rate of improvement of xerostomia in 
patients treated with cyclosporine, without significant differences in the Schirmer test 
score and SFR. 
Three prospective studies evaluated the use of methotrexate (Skopouli et al. 1996), 
leflunomide (van Woerkom et al. 2007), and mycophenolic acid (Willeke et al. 2007) 
and all showed inadequate improvements in sicca symptoms. However all these 
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studies reported a high rate of adverse events (41% for methotrexate, 63% for 
mycophenolic acid, and 100% for leflunomide). Severe adverse events lead to the 
early termination of a controlled trial of thalidomide (Pillemer et al. 2004). 
Three controlled studies assessed oral interferon-alfa (IFN-α) (150 IU daily). The first 
trial (12 patients) suggested a favourable effect on unstimulated SFR and ocular or 
oral dryness. The SG biopsies were evaluated in nine patients after treatment with 
IFN-α, they showed significant histopathological improvement, including reduced 
mononuclear infiltration. These patients in particular experienced a two-fold or 
greater increase in saliva output in response to treatment (Shiozawa and Tanaka 
1998). A single-blinded, sucralfate-controlled trial (Khurshudian 2003) reported a 
significant time-dependent improvement in the production of whole saliva at 3 
months but not at 6 months. Conversely, a large placebo controlled trial including 
497 patients reported significant improvement in only 1 of 28 outcomes evaluated 
(unstimulated whole saliva) and a higher percentage of adverse events (40% vs. 
25% in the placebo group) (Cummins et al. 2003). Two other trials reported an 
increase in stimulated whole saliva flow in a proportion of patients treated with IFN-
α 150 IU t.i.d (Gf et al. 1995; Ship et al. 1999). 
1.2.7.4.2 Biological agents 
Infiximab was evaluated in a placebo controlled trial (Mariette et al. 2004) in 103 
patients, the study did not find any significant differences in the primary outcome. 
Although a previous prospective study on 16 patients found significant 
improvements in subjective and objective sicca measures (Steinfeld et al. 2001). 
Thus the Mariette trial failed to support the favourable results reported in Steinfelds 
study (Tobón et al. 2010). 
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A placebo-controlled trial assessed etanercept in 28 patients with SS and found no 
significant differences in the primary outcome, with only 20% improvement in the 
values on 2 of 3 domains: oral, ocular, and laboratory. In addition, no significant 
differences were found for the secondary outcomes (Sankar et al. 2004). Parallel 
negative results were found in a prospective study in 15 patients with SS (Zandbelt 
et al. 2004). 
A placebo-controlled trial assessed the use of rituximab (RTX) as two 1000-mg 
doses 15 days apart (Meijer et al. 2010). It included 30 patients and has reached the 
primary outcome (improvement of stimulated SFR) at 12 weeks but not at the end of 
the study. Only the VAS score for dry eye significantly improved at 48 weeks while 
other secondary outcomes improved at different study time points but not at 48 
weeks. Another study (Dass et al. 2008) included 17 patients but did not achieve the 
primary outcome. 
Two prospective studies found significant improvement in sicca and general 
symptoms compared with baseline values (Pijpe et al. 2005; Devauchelle-Pensec et 
al. 2007). Several retrospective surveys have studied RTX effect. One study on 6 
patients with pSS treated with RTX for associated lymphoma (n=2) or systemic 
manifestations (n=4), reported significant improvement in subjective feeling of 
dryness in 3 patients. In addition, 1 of the 2 patients with lymphoma achieved full 
remission (Gottenberg et al. 2005). Another retrospective study described 5 patients 
with pSS treated with RTX for NHL and 11 for systemic manifestations. Only a small 
number of patients experienced relief from dryness. However, the extraglandular 
manifestations improved in 9 of 11 patients (Seror et al. 2007). Guzman Moreno 
evaluated the efficacy and tolerance of RTX in 31 patients with pSS in a retrospective 
study. A total of 22 benefited from improvement in arthritis and myalgias, 16 of them 
had subjective improvement in sicca symptoms (Guzman Moreno 2009). 
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Fifteen patients with pSS were enrolled in a study where biopsies were taken. The 
patients were then treated with two cycles of i.v. infusions of 1000 mg RTX on days 
1 and 15 (at time 0 and then after 6 months). After 48 weeks, another biopsy was 
taken. RTX was shown to be effective in improving whole saliva flow rate (Ciccia et 
al. 2014). Yet, a randomized placebo-controlled multi center study was conducted 
between March 2008 and January 2011. Patients received 1 g of RTX (at weeks 0 
and 2), or placebo. In this trial, RTX did not significantly increase the proportion of 
patients achieving the primary end point. However, RTX did show clinically 
significant improvements at week 6, suggesting transient efficacy that was not 
maintained throughout the 24-week period. The authors concluded by not supporting 
the use RTX with recent onset systemic pSS (Devauchelle-Pensec et al. 2014a). 
Epratuzumab (EPZ) was evaluated in a study of 14 women and 2 men with pSS. 
Patients received four 360mg/m2 EPZ infusions at 2-week intervals. 14 individuals 
received all four infusions without significant adverse side effects. After 6 months 
20% showed improvement in Schirmer test, unstimulated whole salivary flow, 
fatigue, ESR and IgG levels (Steinfeld et al. 2006).  
Belimumab has been tested in patients with RA or SLE (Dall’Era et al. 2007; Furie 
et al. 2008). Both studies established the safety and tolerability of Belimumab. 
Patients with SS enrolled in an open label study where they received Belimumab 
infusion, as an improvement in VAS dryness score was reached in 11 (37%); VAS 
fatigue score in 7 (23%); VAS pain score in 7 (23%) (Mariette et al. 2013). An open 
label trial in Japan reported that abatacept IV significantly decreased patients’ VAS 
for dry mouth and dry eye at 24 weeks (Tsuboi et al. 2014).   
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1.2.7.5 Gene transfer 
 
Re-engineering the function of the surviving non-fluid secreting ductal cells in 
damaged glands to a secretory phenotype was considered to be a conventional 
therapy for damaged salivary glands (Atkinson and Baum 2001). In salivary glands, 
due to their anatomy, gene transfer can be accessible orally using conventional 
cannulation techniques to introduce viral or non-viral vectors into the gland. 
In 1994, the first peer-reviewed paper on gene transfer to salivary glands was 
published (Mastrangeli et al. 1994). Several laboratories have transferred different 
genes successfully to salivary glands since then (Baum and O’Connell 1999). Most 
of these studies have utilised viral vectors, specifically adenoviral vectors, to mediate 
gene transfer. Viral vectors are considered very effective at transferring genes, but 
can give rise to a safety risk by stimulating a potent immune response (Atkinson and 
Baum 2001). 
Several target genes are considered in gene therapy for hyposalivation caused by 
SS, they include inflammatory mediators, cytokine inhibitors, apoptotic molecules, 
cell–cell interaction, and intracellular molecules. Kok demonstrated the effect of a 
recombinant AAVhIL10 vector administered to the salivary glands of non-obese 
diabetic (NOD) mice on the stimulated salivary flow rate. He reported that animals 
receiving the rAAVhIL10 demonstrated noticeably higher salivary flow rates than 
those in the sham group of animals (Kok et al. 2003). 
In another study, the ability to slow down the progression of SS dysfunction in NOD 
mice was explored by administering a recombinant serotype 2 adeno-associated 
virus encoding the human vasoactive intestinal peptide (VIP) transgene 
(rAAV2hVIP) into the submandibular gland. Higher salivary flow rates were shown 
but without any difference in focus scores or apoptotic rates. There was an increase 
of the expression of VIP in the submandibular gland and serum and a decrease in 
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IL2, IL10, IL12 and TNF-α in the experiential group compared to the control, 
therefore the study suggests that local delivery of rAAV2hVIP can demonstrate a 
disease-modifying and immunosuppressive action in the submandibular gland of the 
NOD (Lodde et al. 2006). 
The effect of Adenoviral vector encoding hAQP1 gene has been assessed in a small 
group of patients with radiation induced parotid gland hypofunction. This trial 
demonstrated the safety and efficacy of this strategy with a persistent expression of 
hAQP1. This method could possibly be used in the future for the long-term treatment 
of salivary gland hypofunction induced by irradiation. Additionally, this strategy might 
also be applicable to the treatment of SG hypofunction caused by SS (Lodde et al. 
2006). 
Using gene transfer for the repair of damaged glands can be an option in cases 
where epithelial tissue survives either the irradiation or autoimmune damage. 
However, when the entire parenchymal cells are destroyed, in cases where a gland 
has been fully replaced by fibrotic tissue, gene transfer cannot cause an 
improvement of saliva production given that no system exists to produce and 
transport fluid into the mouth (Atkinson and Baum 2001). Adeno-associated virus 
vectors encoding human IL-10, or vasointestinal peptide may also prove to be of 
benefit as indicated from the results of salivary flow in NOD mice (Fazaa et al. 2014). 
 
1.2.7.6 Acupuncture 
Acupuncture has long been a well known treatment for xerostomia in Chinese 
medicine (Hansen 1975). However, it is quite recent that it has been embraced by 
western medicine. The mechanism by which acupuncture increases salivary flow 
has yet to be determined, although it is known to cause an increase in blood flow 
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within the mouth (Blom et al. 1993). One group has recognised at least two 
neuropeptides (vasoactive intestinal peptide and calcitonin gene-related peptide) 
which increases in saliva following acupuncture treatment (Dawidson et al. 1998; 
Dawidson et al. 1999). Since these can stimulate salivary function, it is possible that 
generation of increased amounts of neuropeptides could be responsible for any 
increase in salivation found (Fox 2004).  
It has been reported that acupuncture is effective treating in patients with xerostomia 
of varying aetiology. In a Swedish controlled study, the active group received 
traditional Chinese acupuncture utilising local, distant and auricular points, whilst the 
control group received `placebo acupuncture', i.e. superficial needling of non 
acupuncture points. Each group received a 6-week course of twice weekly 
treatments, which was repeated after a gap of 7±10 days. The interesting finding 
was that there was an increase in salivary flow in both groups, though it was more 
marked and longer lasting in the active group. Without a doubt, the increase in 
salivary flow continued for at least a year in the active group, while it only lived for 
the period of the study in the placebo group (Blom, Dawidson, and Angmar-Månsson 
1992). One of the difficulties with these trials is the small sample size in the studies, 
a lack of double-blinding and the subjective nature of the reporting (Fox 2004). It is 
also important to consider the significant placebo effect (Blom, Dawidson, and 
Angmar-Månsson 1992). 
In another controlled study by List, 20 patients with pSS where included in a study 
where they received manual acupuncture and no treatment for the control group. 
Outcome measurements included salivary flow rate, subjective symptoms of burning 
sensation in the mouth, dry mouth, and dry eyes obtained using a VAS, but there 
was no significant difference between groups (List et al. 1998a; Jedel 2005). In a 
pilot randomized placebo-controlled trial, Cafaro used laser acupuncture and 
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showed that true laser acupuncture significantly improved saliva production in 
patients with SS (Cafaro et al. 2014). 
 
1.2.7.7 Acupressure 
 
Acupuncture is known to be an invasive procedure that must be delivered by 
licensed practitioners. In contrast, acupressure is a massage technique of Chinese 
origin. It differs from acupuncture in that pressure is put on acupoints on the surface 
of the body to relieve obstruction and to balance the energy flow; its effects are 
thought to be comparable to those achieved by acupuncture. Acupressure uses the 
hands as a tool to press acupoints on the skin (Maa 2005; Ma, Chang, and Lin 2007). 
Pressure is usually applied for a minimum of 15 s, but it can last for between 30 
seconds and 5 minutes (Matsumura 1993). The amount of pressure applied depends 
on patient tolerance, as it can be applied until the patient experiences numbness, 
pressure, heaviness, soreness or a feeling of distention (Maa 2005). 
The effectiveness of acupressure in managing the symptom of dry mouth and 
improving salivary flow for patients with SS has however, not been tested. One 
single-blinded study evaluated acupressure in stimulating salivary flow rates and 
improving hemodialysis (HD) patients with dry mouth symptoms (Yang et al. 2010). 
There is some evidence that acupressure on the acupoints CV23 and TE17 
increased the salivary flow rates in HD population and are similar to the results 
obtained in studies using actual acupuncture techniques in improving symptoms 
related to radiation-induced xerostomia. 
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1.2.7.8 Dietary supplementation 
Simple dietary advice can have an influence in aiding xerostomia patients. That 
could include types of food to avoid and increase fluid intake (Davies 1997). 
A placebo-controlled study suggested that a herbal based agent with vitamin 
supplements (LongoVital, LV, Denmark) led to a extended increase in unstimulated 
salivary flow and a reduction in rose bengal dye scores in a group of patients with 
SS (Pedersen et al. 1999). It was also suggested that evening primrose oil, rich in 
fatty acids and important in inhibiting 2-series prostaglandins, may possibly improve 
salivary flow in some individuals with SS (Horrobin 1986; Oxholm et al. 1986; Belch 
and Hill 2000). Moreover, the use of linseed extract Salinum with or without 
chlorhexidine led to improvement in symptoms in patients with SS (Johansson. et al. 
2001). 
 
1.2.7.9 Electrostimulation 
In patients with SS, electrostimulation has been reported to increase the salivary 
flow (Erlichman 1990). In 1850 Ludwig discovered that electrical stimulation of the 
chorda tympanilingual nerve in the dog caused a copious secretion of submandibular 
saliva (Ami and Wolff 2010). In 1992 a study demonstrated an improvement in 
xerostomia symptoms in a group of patients with SS who were treated with 
electrostimulation (Talal, Quinn, and Daniels 1992b). 
This will be discussed in further detail in the next section.  
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1.3 Electrostimulation in the treatment of salivary gland 
hypofunction in Sjőgren’s syndrome 
Electrostimulation of neural and muscular structures has a therapeutic significance 
in several areas of medicine (e.g. pacemakers and phrenic nerve stimulators) and 
as the autonomic control of salivary secretion is known, a similar approach could 
potentially be applied to the management of salivary gland hypofunction (Fedele et 
al. 2008). Physiologically, xerostomia can be due to an interruption of the reflex that 
induces salivation. It can be at the receptor site, the neural pathway of the afferent 
limb, the efferent pathway, the peripheral ganglion or the effector site (Fedele et al. 
2008). 
 
The salivary reflex engages a response from both divisions of the autonomic nervous 
system (i.e. sympathetic and parasympathetic). Myoepithelial cells are usually 
contracted by both parasympathetic and sympathetic nerves (Emmelin 1987; Garrett 
1987). In addition, blood vessels receive a dual innervation: the parasympathetic 
stimulus causes vasodilation as part of secretion, whereas sympathetic 
vasoconstriction is part of a general response and not a direct part of the salivary 
reflex. Parasympathetic impulses provide the main stimulus for fluid formation and 
secretion by the secretary cells; sympathetic impulses act in collaboration with the 
parasympathetic drive and increase the output of pre-formed elements from certain 
cells (Emmelin 1987; Garrett 1987; Steller, Chou, and Daniels 1988a).  
Electrical stimulation of the sympathetic nerve supply to salivary glands in 
anaesthetized animals experiments leads to a vasoconstriction of glandular blood 
vessels and the activation of parenchymal cells. In contrast, under reflex conditions 
only sympathetic secretomotor nerve fibres and not vasoactive nerve fibres to 
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salivary glands are activated. Hence vasoconstriction is not part of the salivary reflex 
(Proctor and Carpenter 2007) see Table 11. 
 In view of the presence of autoimmune SS muscarinic receptor-blocking 
autoantibodies, the sicca component of SS may not be solely caused by an 
irreversible structural damage of the secretory acinar cells, thus it can be considered 
potentially reversible and treatable (Jonsson, Gordon, and Konttinen 2003). 
Table 11. Effects of autonomic nerves on salivary gland function (modified from Garrett, 1987) 
Parasympathetic stimulation: 
1) Is mediated mainly by acetylcholine in combination with NANC peptides (e.g. VIP) 
2) Evokes most of the salivary fluid secreted. Mainly acts through M3 and to a lesser extent M1 muscarinic 
cholinergic receptors 
3) Causes variable degrees of exocytosis from salivary cells but is responsible for most mucin secretion 
by mucous glands 
4) Induces contraction of myoepithelial cells 
5) Increases glandular blood flow as part of the salivary reflex. 
Sympathetic stimulation: 
1) Is mediated mainly by noradrenaline and acts essentially on cells receiving parasympathetic impulses, 
which tends to produce synergistic effects, but exerts little effect on mucous gland secretion 
2) Often does not cause much mobilization of fluid but does not inhibit salivary secretion 
3) Tends to modulate the composition of saliva by increasing exocytosis from salivary cells 
4) Induces contraction of myoepithelial cells 
5) Exerts control on glandular blood flow but not as part of the salivary reflex. 
 
Through the application of electric impulses to one or more of the three components 
of the salivary reflex arch there is an, at least theoretical, possibility of improving 
salivary secretion and consequently to lessen the different long-term effects of 
hyposalivation.  
Animal studies have reported that the application of electrical current on this reflex 
arch can increase salivary production and relieve symptoms of xerostomia (Izumi 
and Karita 1995). In one study it was shown that electric neurostimulation in the rat 
is more effective than pilocarpine to induce salivary secretion via reflex stimulation 
(Schneyer and Hall 1965).  Likewise, the application of an electrical current via the 
	 118	
oral mucosa on afferent neuronal receptors and pathways increased the salivary 
production and lessened xerostomia in patients with salivary gland hypofunction 
(Weiss et al. 1986; Steller, Chou, and Daniels 1988a; Talal, Quinn, and Daniels 
1992b). 
It has been suggested that the stimulation of the autonomic nervous system may 
increase the release of specific neuropeptides that have trophic effects to salivary 
gland parenchyma, causing regeneration of functional tissue and thereby causing 
the effect of electrostimulation to be sustained (Schneyer et al. 1993). 
In order to electrically stimulate sympathetic salivation, it is required to use impulses 
of higher frequency and longer duration to generate sparse viscous saliva (Beal 
1989). In contrast, electric stimulation of parasympathetic nerves of the salivary 
glands produces copious amounts of watery saliva at lower frequencies, which is 
clinically most useful for managing xerostomia (Erlichman 1990). Within this dual 
autonomic system it is clear that salivation is primarily under parasympathetic control 
(Shiba et al. 2002). 
 
1.3.1 Intraoral electrostimulation devices 
1.3.1.1 First-generation and novel electrostimulating devices 
The electronic stimulation device (Biosonics Salitron System, SAL Il model, 
Biosonics, Inc., Mt. Laurel, NJ) is powered by a 9-volt battery. It consists of a small 
hand-held probe tipped with stainless steel electrodes, and a console. The console 
houses the battery, wave-form generator and associated electronics, switches, an 
intensity control dial, automatic 3-minute timer control, a counter to record the 
number of uses, and status-indicator lights. The device induces an electrical stimulus 
that is delivered to the oral cavity through the electrodes, which are placed on the 
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dorsum of the tongue and pressed against the hard palate. An intensity control knob 
with intervals from 0-10 sets peak stimulus output between 0 and 6 volts. The 
maximum average current output is 9 microamperes and corresponds to a maximum 
average power dissipation of 0.2 microwatts (Steller, Chou, and Daniels 1988b). 
 
Figure 4. First-generation electrostimulation device (Salitron) (Fedele et al. 2008). 
 
 
 
 
 
 
 
 
An effort to utilize neuro-electrostimulation to increase salivary secretion gave rise 
to the production of a device that was marketed in the USA (Salitron; Biosonics, Fort 
Washington, PA, USA) (Figure 4). The probe of the device was applied to the 
intraoral mucosal surfaces by the user (between the dorsum of the tongue and 
palate) for a few minutes each day, and delivered a stimulating signal (Weiss et al. 
1986; Steller, Chou, and Daniels 1988b; Talal, Quinn, and Daniels 1992b). It was 
found that this device when used repeatedly, led to both an immediate (direct) 
response (increase of salivation as a result of the stimulation) and a cumulative long-
term (indirect) response (sustained increase of basal salivary flow rate) as well as 
subjective improvement in symptomatic xerostomia, regardless of the fact that it was 
a fairly clumsy device (Weiss et al. 1986; Steller, Chou, and Daniels 1988b; Talal, 
Quinn, and Daniels 1992b).  
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In 1986 Weiss demonstrated the efficacy of a first generation device in a group of 
patients with dry mouth due to different causes, including Sjőgren’s syndrome (n=9) 
and radiotherapy to the head and neck (n=13) (Weiss et al, 1986). This open-label 
uncontrolled study showed an improvement in oral wetness in 50% of patients as 
measured by visual inspection. Looking in more detail at the subgroup of individuals 
with SS-related dry mouth, all treated patients showed objective improvement 
(increased moisture on visual examination) and reported slight-to-substantial 
symptomatic improvement. 
A more robust study design and reliable outcome measures were employed by 
Steller and collaborators, who designed a placebo-controlled clinical trial and 
assessed device efficacy through sialometry in 29 SS patients (Steller et al. 1988). 
Objective improvement (sialometry) was observed in 13 subjects on active device, 
and subjective improvement (patients’ complaints and non- validated questionnaire) 
in 5 patients allocated on active device. 
The same device was investigated by Talal in a multicentre, double blind study 
including 77 Sjögren’s patients (Talal et al. 1992). The electrostimulation patient 
group showed a difference of 116% greater than the placebo group between the pre- 
and post-stimulation salivary production. The duration of experimental treatment was 
3 visits in a total of 4 weeks, the same as the other two previous trials. These initial 
studies demonstrated that salivary electrostimulation could lead to an objective 
increase in salivation and a subjective improvement of dry mouth sensation.  
As the device gave promising results in proof-of-principle clinical studies (Table 12) 
and did not give rise to any associated local or systemic adverse effects, it was 
approved by the US Food and Drug Administration in 1988 (PMA No. P860067). 
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However its wider use was hindered by its large size, high price, and lack of user-
friendliness (Fedele et al. 2008). 
 
Table 12. Human trial using  generation I electrostimulating device in the treatment of xerostomia 
Authors Number of 
patients 
Diagnosis Methods and Design Results 
Weiss 
1986 
24 
 
SS (9) 
RT (13) 
Other (2) 
Short duration stimuli (1-3 
minutes) for 3 weeks. Open 
label non-randomised trial 
Objective improvement 
(assessment of oral wetness via 
visual examination). Subjective 
improvement (patients’ 
complaints). 
Steller 
1988 
29 SS (29) Short duration stimuli (3 
minutes)/day per 4 weeks. 
Double blind placebo-
controlled randomised trial 
Objective improvement (uWSF 
sialometry) in 13 subjects on 
active device. Subjective 
improvement (patients’ complaints 
and non-validated questionnaire) 
in 5 patients on active device 
Talal 
1992 
77 SS (77) Short duration stimuli (3 
minutes)/day for 4 weeks. 
Double blind placebo-
controlled  multi-centre trial 
Objective improvement (uWSF 
sialometry) in subjects on active 
device. Subjective improvement 
(patients’ complaints and non-
validated questionnaire) in 
patients on active device 
* SS: Sjögren’s syndrome; RT: radiotherapy; uWSF: unstimulated whole salivary flow 
 
1.3.1.2 Second-generation electrostimulating device 
To overcome the limitations of the first-generation device, an EU-funded Consortium 
developed and tested a second-generation electrostimulating device. The novel 
device is a removable intraoral thermoplastic polyurethane-made appliance (Figure 
5) similar to mouth-guards (splints) used by individuals with temporomandibular 
disorder or bruxism. It is custom made on the individual patient by using their teeth 
pattern moulds and its size is much smaller than the Salitron.  
The electrical circuit and the battery have been miniaturized and are embedded 
within the device to avoid saliva contamination. Two electrodes protrude through the 
appliance to deliver the electrical impulses to the trigeminal and lingual nerves via 
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the oral mucosa. An external remote control regulates device function by means of 
infrared light transmission at a wavelength of 940nm–950nm.  
	
	
	
	
	
	
	
	
	
	
	
 
 
The efficacy of the novel device was initially tested in a small feasibility study on 23 
patients with dry mouth associated with SS (n=10), medications (n=7), and in 
individuals with idiopathic xerostomia (n=6). This was a double-blind crossover, 
sham-controlled randomised multicentre feasibility trial aimed at investigating safety 
and short-term effectiveness (Strietzel et al. 2007) see Table 13. The investigated 
device was equipped with a wetness sensor, embedded within the appliance, to 
record real-time changes of wetness during stimulation. The experiment consisted 
of each patient having one stimulation test for 10 minutes, followed by 35 minutes 
wash-out and another 10-minute test. The allocation of active vs. sham test was 
cross-over randomised at stage one. Each experiment was repeated on average 6 
times in each patient. After the performance of 158 experiments, a significant 
reduction of oral dryness for the active mode was objectively registered by the 
wetness sensor, as well as subjectively by patients’ judgement. The device was well 
tolerated by all patients and did not give rise to adverse side effects. The second 
generation device was granted CE mark on the basis of the results of this initial 
feasibility short-term study. 
Figure 5. Second-generation electrostimulation device (GenNarino) (Fedele et al. 2008). 
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In order to clarify whether prolonged use of electrostimulation can provide long-term 
benefits, a multicentre longer-term clinical trial was performed in 2011. Strietzel 
designed a randomised, multicentre crossover sham-controlled double-blind trial 
with primary endpoint being defined as a subjective improvement in the severity of 
xerostomia, as assessed by VAS (Strietzel et al. 2011). Unstimulated and stimulated 
salivary flow rates as assessed by sialometry as well as QoL questionnaire were the 
second outcome measure of this study. The randomised controlled trial had a 2-
month duration and was followed by a subsequent uncontrolled phase aimed at 
investigating long-term effectiveness. In the initial randomised double-blind phase, 
the electrostimulating device was used for 10 minutes at a time, each for 1 month, 
on average 4 times per day, in either sham mode or active mode. 66 patients with 
SS, 14 with radiation-induced dry mouth and 64 with xerostomia of other causes 
were enrolled (Total 144). Analysis of results of the randomised controlled phase 
showed a better performance in terms of dryness severity (subjective symptoms) for 
the active intervention vs. the sham experiments. No statistical difference, however, 
was found with respect to unstimulated and stimulated flow rates and oral discomfort. 
The subsequent second open-label phase consisted of a 3-month investigation of 
active devices in a subset of patients (n=79). Approximately 70% of treated 
individuals reported improvement in dryness severity and 63% of them showed 
increased unstimulated salivary flow rates at the end of the 3-month treatment 
period. No changes were detected regarding stimulated salivary flow and quality of 
life scores. Alajbeg subsequently reported the outcomes of extended long-term 
follow up (after additional 6 months of device usage) confirming previous positive 
outcomes. (Alajbeg et al., 2012). 
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Table 13. Human trial using II generation electrostimulating device in the treatment of xerostomia 
Authors Number 
of 
patients 
Diagnosis Methods and Design Results 
Strietzel 
2007 
23 
 
SS (10) 
Drug-induced 
(7) 
Other causes (6) 
Two 10-minute stimuli 
with an interval of 35 
minutes(158 
experiments).  Cross-
over, randomised, sham-
controlled, double blind, 
multi-centre trial  
Objective improvement 
(assessed via an electronic 
wetness sensor) during active 
experiments. Subjective 
improvement (patients’ 
complaints and non-validated 
questionnaires) in 60% of the 
experiments patients 
Strietzel 
2011 
114 SS (66) 
RT (14) 
Other causes 
(64) 
Application of the device 
for 10 minutes at a time 
for 1 month. Stage I was 
a double blind cross-over 
randomised trial. Stage II 
was a 3-month open-
label study 
Objective improvement (uWSF 
sialometry) in 63% of the 
participants. Subjective 
improvement (assessed via a 
validated questionnaire) in 70% 
of participants  
Alajbeg 
2012 
94 SS (56) 
RT(9) 
Other causes 
(29) 
Application of the device 
for either 1, 5, 10 minutes 
at a time, not more than 
once every hour. Open-
label uncontrolled 9-
month study 
Objective improvement (uWSF) 
and subjective improvement (a 
validated questionnaire) in study 
participants 
* SS: Sjögren’s syndrome; RT= Radiotherapy; uWSF: unstimulated whole salivary flow 
 
1.3.1.3 Third- generation electrostimulation device 
Electrostimulation with implanted devices is not a new concept, and has been used 
in the treatment of pain, deafness, bone healing, micturition (urination) disorders, 
cardiac arrhythmia (pacemakers), muscle weakness, respiratory malfunction, 
seizures, and essential or parkinsonian tremors (Ami and Wolff 2010). 
The third-generation is a dental implant-based, intra-oral device designed for 
patients that may require frequent and/or constant stimulation of salivary glands. 
Thus, a miniature neuro-electrostimulating device to be permanently implanted into 
the oral cavity was developed (the Saliwell Crown) (Figures 6 and 7).  It is designed 
to be placed in close proximity (1-5 mm) to the lingual and long buccal nerves 
(Kiesselbach and Chamberlain 1984; Alling 1986).
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This generation was introduced to overcome the inconvenience related to the 
repeated application and removal of a splint-based stimulator. The same 
components of the second-generation device were miniaturized and packaged 
into a device that has the dimensions and shape of a molar tooth. The device 
can be mounted on to a commercially available osteointegrated implant. A 
wetness sensor has been embedded into the device to detect changes in 
wetness/dryness (Fedele et al. 2008). To ensure close proximity to the lingual 
nerve that carries both afferent and efferent salivary impulses, and to avoid 
interference with normal oral function, the osteointegrated implant is situated in 
the region of the lower third molar. The posterior location of the device ensures 
that there are no aesthetic concerns (Fedele et al. 2008). This technique has 
the advantage that patients can make use of saliva production while eating, as 
it is an intra-oral device (Ami and Wolff 2010). 
The aim of this device was 1) to generate a continues stimuli, 2) to be applied 
in the oral cavity without interfering with normal oral function, 3) to sense the 
wetness/dryness status of the oral cavity and according automatically increase 
or decrease the stimulus and 4) to include a remote control (Fedele et al. 2008). 
The use of a Saliwell Crown in an 81 year old female resulted in notable 
improvement of subjective parameters and increase in salivary secretion. In this 
case not only oral dryness symptoms as quality of life, and oral functional 
parameters (speech and swallowing) improved, but the oral burning sensation 
has also improved (Ami and Wolff 2010). This could be explained by the 
findings of Eliav and colleagues that 82% of patients with burning mouth 
syndrome were found to have chorda tympani dysfunction (Eliav et al. 2007). 
This is because the Saliwell Crown is designed to stimulate the chorda tympani 
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through the lingual nerve stimulation. Although a placebo effect cannot be ruled 
out, due to the well-recognized psychogenic component of burning mouth 
syndrome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Saliwell Crown location to the different  nerves responsible for stimulation of salivation 
(Ami and Wolff 2010). 
 
 
 
  
Figure 6. Third-generation electrostimulation device (Saliwell Crown) (Fedele et al. 2008). 	
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1.3.2 Extraoral electrostimulation devices 
1.3.2.1 Transcutaneous electrical nerve stimulation 
Transcutaneous electric nerve stimulation (TENS) is widely used in pain 
management; it is a safe and widely accepted means of treatment. An electrical 
current passes using surface electrodes. The mechanism of extraoral 
neurostimulation is not fully understood. It has been postulated that 
transcutaneous electric nerve stimulation (TENS) could directly stimulate the 
auriculotemporal nerve, which supplies the parotid gland, whereas it remains 
unclear whether there is also an indirect action (via afferent pathways) onto the 
salivary reflex arch (Figure 8). 
Improvement in salivary function by 0.045-0.02 ml/min was achieved using 
TENS in a study including 50 patients with xerostomia (Mittal, Keluskar, and 
Kapoor 2014).  
Figure 8. Transcutaneous electric-nerve stimulation (TENS)  
. 
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The use of TENS unit has been studied by Hargitai and colleagues in 2005 as 
a means of stimulating salivary production in a pilot study (Hargitai, Sherman, 
and Strother 2005). Fifteen of the 22 subjects experienced an increased parotid 
salivary flow when stimulated via the TENS unit. The mean unstimulated 
salivary flow rate was 0.02418 mL/min (SD 0.03432) and mean stimulated 
salivary flow rate was 0.04946 mL/min (SD 0.04328). The subjects that had the 
greater change in salivary flow were those who had an initial saliva flow prior to 
entry to the study. TENS was unable to stimulate saliva where the salivary flow 
was 0 at baseline. Therefore, it can be appreciated that TENS may act more 
efficiently as an accelerator of salivary flow rather than an initiator, and may be 
more effective in cases with decreased salivary gland function rather than 
absolute absence of function. 
TENS was assessed with 30 oral cavity and oropharyngeal cancer patients who 
received post-adjuvant (n=26) or definitive radiotherapy (n=4). The electrode 
pads were placed overlying the parotid glands. Unstimulated whole saliva was 
collected for 5 min using the spitting method. Then TENS was activated and 
stimulated saliva was collected for an additional 5 min. A statistically significant 
increase in saliva flow during stimulation was seen in 29 of 30 patients. The 
mean unstimulated saliva flow was 0.056 ml/min and the mean stimulated 
saliva flow was 0.12 ml/min with a median increase of 0.06 ml/min (Vijayan et 
al. 2014). 
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Chapter Two:  
Systematic Review and Meta-Analysis of Treatments of 
Xerostomia Due To Sjőgren’s Syndrome 
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2.1 Knowledge gap 
Sjőgren’s syndrome is a chronic autoimmune disease, histopathologically 
characterized by lymphocytic infiltration to exocrine glands (al-Hashimi 2001b; 
Devauchelle-Pensec et al. 2007; Margaix-Muñoz et al. 2009; Bayetto and Logan 
2010), clinically characterized by dry mouth and dry eyes. Sjogren’s syndrome 
can also cause a wide range of extra-glandular manifestations. It is considered 
the second most common autoimmune connective tissue disorder after 
rheumatoid arthritis (Fox, Stern and Michelson 2000; Porter, Scully and Hegarty 
2004). 
Saliva has the important function of lubrication and protection of the oral cavity 
and upper pharynx, modulating the microbial population and providing 
stabilisation and remineralisation of teeth. In healthy adults up to one and a half 
litres of saliva are produced daily, mostly by paired parotid, sublingual and 
submandibular glands (Porter, Scully and Hegarty 2004). As a consequence of 
the salivary gland dysfunction, patients with SS typically experience a dry mouth 
sensation possibly accompanied by dysarthria, dysphagia, dysaesthesia and 
dysgeusia (Fox 2005). Perhaps unsurprisingly there can be a significant reduction 
in health related quality of life (QoL) of patients with SS (Sutcliffe et al. 1998; 
Strombeck et al. 2000; Tensing et al. 2001; Rostron et al. 2002; Belenguer et al. 
2005; Champey et al. 2006; Bowman et al. 2007). 
Although a wide range of systemic and local therapeutic strategies to ameliorate 
the symptoms of SS associated xerostomia and related symptoms, the majority 
of the patients rely on drinking frequent sips of water (Cassolato and Turnbull 
2003; Ramos-Casals and Font 2007) which only provide transient relief of 
symptoms and do not prevent the complications of hyposalivation. 
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Salivary stimulation techniques with topical and systemic sialogogues may be 
appropriate for use by patients with some degree of salivary gland function. 
Topical sialogogues, such as sugar-free chewing may reduce the sensation of 
mouth dryness and facilitate speech and swallowing. Systemic saliva 
stimulation with parasympathomimetic drugs (the most widely used being 
pilocarpine hydrochloride), enhances salivary secretion by stimulating the 
parasympathetic nervous system. Where salivary glands have been irreversibly 
damaged or there are contraindications to pharmacological therapies, topical 
application of salivary substitutes can offer some benefit by providing a 
moisture coating over the oral mucosa.  Non-pharmacological interventions, 
such as acupuncture, have also been used to increase saliva production, by 
enhancing peripheral blood flow. 
The effectiveness of available treatments for SS-induced xerostomia remains 
unclear; the reason being that the systematic reviews in literature included 
participants with dry mouth due to different causes. Therefore, current 
therapeutic decisions are likely to be based upon a mix of personal experience, 
expert opinion, and reported studies. Hence we have therefore undertaken this 
systematic review and meta-analysis to summarize and estimate the 
effectiveness of available treatment options for xerostomia caused by SS. 
2.2 Methods 
2.2.1 Literature search  
For the identification of studies included for this review, we developed detailed 
search strategies (Appendix 1) for each database (Medline, Embase, The 
Cochrane Central Register of Controlled Trials).  
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We searched reference lists of retrieved reports and textbooks for additional 
references. Citations were screened and full reports of potentially relevant 
studies obtained.  
2.2.2 Study inclusion criteria  
Study inclusion criteria were (i) design: randomized controlled trials; (ii) 
population: adults with diagnosis of SS induced salivary gland hypofunction (iii) 
intervention: techniques designed to stimulate saliva production (sialogogues, 
acupuncture and electrostimulation) or to mimic the presence of saliva (saliva 
substitutes); (iv) control group: placebo, another active intervention or a 
combination of the aforementioned. The interventions could be given by any 
route, formulation, or dose. Studies had to contain sufficient, clear information 
on the effect of the experimental treatment on clinical outcome to be included. 
No language restrictions were imposed. 
2.2.3 Outcome measure 
The primary subjective outcome measure of this review was the mean overall 
change in xerostomia symptoms, which was assessed by change in a visual 
analogue scale (VAS) or be subjectively assessed as a dichotomous outcome 
either improved, or not compared to baseline. Dry mouth symptoms may also be 
measured using a validated questionnaire such as xerostomia inventory 
questionnaire (XI) or similar.  
Secondary objective outcome measure were the QoL and the saliva flow rate 
of SS patients. Finally we considered incidence of adverse effects. 
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2.2.4 Selection process and quality assessment  
Titles and abstracts of the references were reviewed to exclude articles out of 
scope. Full-text articles of potentially relevant records were assessed for 
eligibility by two independent reviewers (AH, VM). Any disagreements between 
reviewers were resolved by discussion until consensus was reached.  
The risk of bias assessment of the selected trials was performed according to 
the Cochrane Collaboration tool for assessing risk of bias, documenting the 
method of sequence generation, allocation concealment, blinding of 
participants, personnel and outcome assessors, incomplete outcome data, 
selective outcome reporting, and other sources of bias. 
2.2.5 Data extraction  
The following data were extracted by AH and MV: (i) study population; (ii) type, 
dosage, frequency and duration of intervention, (iii) control group; (iv) 
xerostomia outcome measures; and (v) effects on psychosocial outcomes 
(QoL).  
2.2.6 Meta-analysis 
We summarized effect size for continuous data as xerostomia intensity 
assessed using a 100 mm visual analogue scale, with the mean differences 
with 95% confidence intervals (95% CI). For categorical data, reported 
xerostomia relief was dichotomised into two categories (improvement or no 
improvement), and we calculated odd ratio (OR) of improvement, with 95% CI.  
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2.3 Results 
The search strategy yielded 694 articles and 12 more through other sources. Of 
these, 33 articles met the inclusion criteria and read in full. Data were extracted 
according to the pre-established protocol. These studies were included in the 
qualitative analysis with a total of 3170 participants. Nine studies out of the 33 
provided sufficient data to allow a meta-analysis (Figure 9).  
The majority were parallel (two arms) studies (30 studies). In the crossover 
studies, washout period ranged from 1-3 weeks. Ten trials were conducted in the 
United States, five in The Netherlands, three in Japan, two in Sweden, France, 
China and the UK, one in Australia, Portugal and Taiwan. Fourteen trials were 
funded by the pharmaceutical industry. Five trials received government funding, 
one study received university funding and 3 received non-governmental support. 
Studies recruited between 12 and 497 participants and lasted 3 weeks to 24 
months. Tables 14 to 19 show study populations, interventions, and extracted 
outcome measures for eligible trials. 
Participants enrolled in these clinical studies had SS diagnosed according to the 
following diagnostic criteria: Fox et al (Fox et al. 1986) (2 studies), Copenhagen 
(Manthorpe et al. 1986) (2 studies), Daniels and Talal (Daniels and Talal 1987) 
(1 study), Preliminary criteria (Vitali et al. 1993) (7 studies) and the American- 
European Consensus group (Revised European Community Study Group) (Vitali 
et al. 2002) (15 studies). In 6 studies the classification criteria were not reported. 
Topical salivary substitutes were assessed in three studies (Reijden et al. 1996; 
Klestov et al. 1981; Johansson et al. 2001). Topical saliva stimulants were tested 
in two studies (Gravenmade and Vissink 1993a; da Silva Marques et al. 2011) 
Interferon-α used in four studies (Shiozawa et al. 1998; Ship et al. 1999; 
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Khurshudian 2003; Cummins et al. 2003). Electrostimulation was tested in two 
trials (Steller et al. 1988; Talal et al. 1992). Salivary sialogogues were included in 
seven trials (Papas et al. 1998; Vivino et al. 1999; Fife et al. 2002a; Petrone et 
al. 2002a; Wu et al. 2006; Leung et al. 2008; Sugai et al. 2009). Biological agents 
were tested in four studies (Sankar et al. 2004b; Mariette et al. 2004; Meijer et al. 
2010; Devauchelle-Pensec et al. 2014). Immunomodulatory agents were tested 
in four studies (Drosos, Skopouli, Costopoulos, et al. 1986b; Kruize et al. 1993; 
Price et al. 1998; Gottenberg et al. 2014). One trial tested acupuncture (List et al. 
1998b). One study tested Gammmalinolenic acid (Theander et al. 2002). Two 
trial tested Dehydroepiandrosterone (Pillemer, Brennan, et al. 2004; Hartkamp et 
al. 2008). Nizatidine tested in one trial (Kasama et al. 2008a). One study included 
Omerga-3 supplements (Singh et al. 2010) and one trial tested a traditional 
Chinese medicine (Hu et al. 2014). 
Most of studies tested the efficacy of a treatment option against placebo; only 11 
trials compared a treatment with another agent or another dose of the test agent 
(Klestov et al. 1981; van der Reijden et al. 1996; Papas et al. 1998; Shiozawa et 
al 1998; Vivino et al. 1999; Ship et al. 1999; Johansson et al. 2001; Petrone et al. 
2002; Fife et al. 2002; Theander et al. 2002; da Silva Marques et al. 2011). 
The majority of the studies used whole unstimulated saliva flow (WUSF) and 
whole stimulated saliva flow (WSSF) as the objective outcome measures, 
whereas stimulated parotid saliva was used in two studies only. One study 
considered the findings of the investigator’s examination as an objective clinical 
evaluation (Sugai et al. 2009). On the other hand the most common subjective 
assessments used was the visual analogue scale of dryness (VAS), in addition a 
numerical analogue scale (NAS), numerical rating scale (NRS), and a categorical 
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subjective response collected either in the form of a degree scale (i.e. 0=absence 
of complaints to 4=severe complaints) or a response percentage (i.e. Excellent, 
moderate, slight, no difference, worse). One study used the xerostomia inventory 
(XI) as a subjective assessment method. 
Dry mouth symptoms at endpoint were assessed immediately after intervention 
administration in one trial (Steller, Chou, and Daniels 1988). And one hour after 
administration of the intervention in three studies (Fife et al. 2002; Petrone et 
al. 2002; Wu et al. 2006) and therefore results here were relevant to acutely 
improved dry mouth symptoms.  
Salivary function was assessed shortly after the intervention in three studies 
(Steller, Chou, and Daniels 1988b; Talal, Quinn, and Daniels 1992a; da Silva 
Marques et al. 2011). Some studies repeated salivary function assessment 
after 30, 45 minutes (Vivino et al. 1999; Papas et al. 2004), after 60 minutes in 
four studies (Vivino et al. 1999; Fife et al. 2002; Papas et al. 2004; Wu et al. 
2006) and after 90 minutes in two studies (Vivino et al. 1999; Petrone et al. 
2002).  
2.3.1 Risk of bias results: 
Eleven (27%) out of thirty-three studies were considered with low overall risk of 
bias (Figure 10). Adequate sequence generation and concealment was reported 
in 45% and 42% of studies respectively, which were therefore considered to be 
at moderate risk of selection bias. Blinding of participants to the allocated 
treatment by use of a placebo was done in 25 of the included studies (75%) and 
these trials were assessed at low risk of performance bias. Outcome assessors 
were blinded to allocated treatment in 24 trials (72%), which were considered to 
be at low risk of detection bias. Over (90%) of the included studies reported 
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complete outcome data, and (85%) of studies without selective reporting, which 
led to low attrition and reporting bias. Figure 11 reveals each bias item for studies 
individually.  
 
2.3.2 Results: Qualitative analysis of individual studies 
2.3.2.1 Saliva substitutes vs. other saliva substitutes or placebo 
Three trials evaluated different salivary substitutes, with a total of 173 participants 
enrolled (Table 14), all were considered of an unclear risk of bias. Klestov et al in 
1981 tested a newly formulated salivary substitute against a glycerine mouthwash 
as a placebo. Participants were instructed to swill 5ml of the salivary substitute 
or the placebo for one minute as frequently as desired. In the participant’s 
response to the two forms of therapy: 21.1% of test group reported excellent 
benefit and 5.3% of placebo group reported excellent benefit (P<0.01), this can 
represent minimal clinical significance. When assessing the symptoms they 
benefited completing a questionnaire; dry mouth at night time had the only 
statistical significant between test and control group (46% vs. 21% respectively) 
P<0.02.  And in the same time 30.7% of the test group and 37.5% of placebo 
group reported lack of benefit in any of the symptoms assessed; yet it didn't reach 
statistical significance. In this study the timing of outcome measurement was not 
clear and only the percentage of responders were reported with out reporting the 
magnitude of improvement. Furthermore it is unclear whether these endpoints 
were assessed at resting salivary function or with acutely enhanced salivary 
function.  Another study evaluated different polymer-based substitutes (poly 
acrylic acid (PAA), high and low xanthan gum (XG), porcine gastric mucin (SO)) 
and placebo (van der Reijden et al. 1996). This study consisted two parts, in the 
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first part 43 participants were included, each substitute was used for one week 
with a one-week washout period, with a total of 7 weeks test period. Unstimulated 
salivary flow and paraffin-stimulated whole saliva were collected on day 1 (first 
day of week 1) and day 56 (last day of week 7). The efficacy of the different 
substitutes were assessed using 3 self-administered questionnaires, 
questionnaire 1 was completed at the beginning of each test week, questionnaire 
2 completed at the end of each test week and questionnaire 3 completed at the 
end of the 7 week period. Author reported that there was no carry over effect of 
each substitute as a one-week wash-out period was adequate. PAA, high 
viscosity XG and SO were equally preferred, were as placebo was preferred in 
only 2 of the 43 participants. There was no significant difference in the reduction 
of patient’s symptoms using the substitutes; and the magnitude of reduction was 
not clear. Patients that preferred PAA had lower stimulated salivary flow than 
patients who preferred SO (P<0.05). Effect size of participant’s preference and 
salivary flow in the first part of the study was only displayed in figures. High 
(HVXG) versus low (LVXG) viscosity xanthan gum were tested in the second part 
of the trial were 33 of the participants were included. The efficacy of HVXG and 
LVXG was not significant. Unstimulated salivary flow rates did not show any 
significance, yet patients that had a reduction in symptoms using LVXG had 
significant lower stimulated flow rate than patients with symptoms reduced using 
HVXG or reduced by both, these were significant for decreasing dry mouth in 
general (P<0.05) and at day time (P<0.01). Yet it was not reported if these results 
had any clinical significance. And it was not clear when measurements were 
taken; therefor it is not possible to consider these results short or long-lived. In 
the third study Salinum (SAL) without/ with chlorhexidine (CHX) was assessed 
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(Johansson et al. 2001), for 9 weeks (3 test weeks, 3 week washout period 
between agents). This study included 22 patients; they were instructed to rinse 
10ml of intervention preparation for one minute each morning and evening. 
Unstimulated saliva flow was collected (values varied between 0-4.6 ml/15 
minutes), but without any significant changes during the trial. A mucosal mirror 
friction test using a 3-degree scale was employed. Friction was reduced to normal 
in all nine patients in the SAL group (which are patients with elevated initial 
values) (P<0.01). In the SAL/CHX group mirror friction was also reduced in 8 out 
of 10 participants (P<0.05). 11 patients reported reduced oral dryness symptoms 
in the SAL group and 15 patients in the SAL/CHX group. The reduction in 
symptoms using Sal and Sal/Chx was significant (P<0.05 and P<0.001 
respectively) yet meaningfulness to participants was not reported. Timing of 
clinical recording was not reported, likewise magnitude of improvement was not 
reported; author only presented number of participants with improvement. 
2.3.2.2 Topical saliva stimulants vs. placebo 
Two studies tested salivary stimulants with a total of 122 participants (Table 
14). Mucin lozenges and placebo were tested each for two weeks each, with a 
two week wash out period, participants were instructed to be use intervention 
and placebo as required (Gravenmade and Vissink 1993), this study had a high-
risk selection bias due to the fact that all participants were members of the 
national association of SS. Four self-administered questionnaires were used: 
questionnaire(I) was about dryness related symptoms and was completed 
before dispensing the preparations; questionnaire(II) was on the efficacy of the 
lozenges after two weeks of using the preparation; questionnaire(III) was 
similar to the initial one, and completed before the second preparation was 
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dispensed; questionnaire(IV), was similar to the second one and was 
completed by the end of the 6 weeks. Twenty-eight (67%) participants in the 
active group reported that their general complaints were diminished, 13(31%) 
reported no change and 1 (2%) reported more complaints. Oral dryness during 
the day was largely relieved in 8 (19%), moderately relieved in 26 (62%) and 
not changed in 7 (17%). Using the placebo lozenges did not reduce the 
sensation of oral dryness during the day or night. Thirty-two patients (76%) 
(P<0.001) preferred the mucin lozenges, 4 patients (14%) preferred placebo, 
which gives the investigation a good clinical significance. Mucin lozenges 
resulted in a larger reduction in complaints (P<0.001) and a reduction in the 
sensation of dry mouth (P<0.01). This study reported the magnitude of 
improvement clearly but timing of outcome measurement collection was not 
clear. Another trail compared a new malic acid gustatory stimulant with a 
placebo citric acid gustatory stimulant with 80 participants (da Silva Marques et 
al. 2011). This study is considered of high quality as it has an overall low risk of 
bias. Stimulated salivary flow was collected as a secondary outcome 
immediately after administration of intervention; therefore the study results 
represent an acute enhancement (short-lived). Both groups elicited a significant 
increase in salivary flow (P<0.05) followed by a decrease, and reaching the 
basal levels after 20 min. Yet the difference in salivary flow between groups 
was not significant. Of note the magnitude of improvement was not reported 
neither the clinical significance. 
2.3.2.3 Systemic saliva sialogogues vs. placebo 
A total of 7 studies were analysed, 3 tested cevimeline, 3 trials tested pilocarpine, 
1 tested rebamipide, with a total of 1099 patients enrolled (Table 15). Petrone et 
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al. enrolled 197 patients in a 12 week study (Petrone et al. 2002a), testing 30 mg 
of cevimeline vs. placebo. The primary endpoint was the patient’s global 
evaluation of dry mouth (worse, no change or better) which was assessed 60 
minutes after cevimeline administration. At the end of the study 66% of the 
cevimeline group, reported their mouth to feel better compared to 37% in the 
placebo group (P=0.0004). We consider these results to indicate the effects of 
long-term therapy, which are likely to be short-lived as assessment was taken 60 
minutes after medication administration. However the effect size was not 
reported. The secondary endpoint of dry mouth VAS was collected each visit 
before and 1 hour after medication administration, and therefore represents the 
short-lived effects of 1 single tablet of cevimeline. There was statistical 
significance difference (P=0.038) between the long-term use of 30mg (-
27.0±30.4) and control group (-15.0±33.4). The unstimulated salivary flow, which 
was collected 90 minutes after medication administration showed a statistical 
significant difference between placebo and 30mg groups in the baseline to 90 
minutes post dose values, likewise salivary flow represented acute salivary 
enhancement (short-lived). Of note the magnitude of salivary flow enhancement 
was not reported nor the clinical meaningfulness. Thirty mg of cevimeline vs. 
placebo was tested in another trial for 6 weeks (Fife et al. 2002), recruiting 75 
patients. Primary endpoints were the global patient evaluation of dry mouth 
(better, no change or worse) and the VAS, which were collected 1 hour after 
administration of medication. At endpoint 76% percent of the 30mg group and 
35% placebo group had a response of better long-term results in the global dry 
mouth evaluation, without reporting the magnitude of improvement. At endpoint 
the change in predose to postdose in the dry mouth VAS was -16.59±22.54 in the 
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30mg group and -8.27±14.24 in the placebo group but without statistical 
significance. The mean change predose to postdose (short –term use) in salivary 
flow was 0.194±0.179 in the 30mg group and 0.015±0.064 in the placebo group 
(P<0.01), yet it was not clear when was the postdose measurements exactly 
taken and the meaningfulness to participants was not reported. Leung et al. 
tested the 30 mg cevimeline with placebo in a 24 week crossover trial (Leung et 
al. 2008).  This trial was considered at overall low risk of bias. Assessment was 
performed (1)before treatment, (2)at the end of first period, (3)before second trial 
and (4)at the end of second trial. Subjective assessment included the xerostomia 
inventory questionnaire (XI), the general oral health assessment index (GOHAI), 
the medical outcomes short form (SF-36), patient satisfaction and preference. 
Objective assessment involved stimulated salivary flow and parotid saliva. 
Participants in the cevimeline group had significant (long-term) improvement in 
the XI. Mean XI change in active group was -2.6 (5.9) and -0.9 (5.9) in the placebo 
group (P=0.198). Mean GOHAI change in active group1.4 (4.2) and -1.1 (3.4) in 
the placebo group (P=0.057). No statistical significance difference seen in the 
SF-36 scores. Furthermore, salivary flow rates did not show statistical 
significance between the (long-term use) cevimeline and placebo groups. No 
significant differences were seen in patient’s satisfaction scores between 
cevimeline and placebo. The results of this trial are unclear if represents long or 
short term effects. However the magnitude of outcomes were correctly reported 
except for the SF-36. In the previous studies more adverse events were seen in 
the cevimeline groups than placebo. 
Pilocarpine was tested in three studies (Table 15), Papas et al. evaluated the 
use of 5mg for 6 weeks then 7.5mg for the next 6 weeks vs. placebo (Papas et 
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al. 1998). Efficacy was assessed at week 6 and week 12, pre and post drug 
administration. Patients completed a VAS (response was >25mm) and a 3-point 
categorical questionnaire evaluating dry mouth improvement. Results showed 
a high significance in subjective global improvement in dry mouth at both 6 and 
12 week, responders 61%in the pilocarpine group and 31% in the placebo 
group at week 12, yet meaningfulness to participants was unknown. Salivary 
flow was collected predose and 30,45 and 60 minutes postdose. Predose 
salivary flow rates were not changed throughout the study. However 30,45 and 
60 minutes post dose salivary flow values showed statistical significance 
(P≤0.0001) in the pilocarpine group. These represent the short- term use results 
and are considered as short-lived effects. Authors did not display the magnitude 
of improvement. Vivino et al tested pilocarpine with 2.5mg or 5mg dose vs. 
placebo (Vivino et al. 1999). Subjective assessment was using a VAS 
(response was >25mm) and a 3-point categorical questionnaire completed at 
week 6 and week 12, post drug administration. The 5mg group had a greater 
improvement compared to placebo in the global assessment of dry mouth 
(61.3% and 31.1% respectively), without presenting the magnitude of 
improvement and with unknown clinical significance. The salivary flow rate 60 
minutes post dosing demonstrated a statistically significant increase in salivary 
flow compared with the placebo group at endpoint (0.37±0.46) and (0.17±0.19) 
respectively. Again the results represent acute effect of investigation (short-
lived effect). The third study testing pilocarpine was a 12 week trial using 5 mg 
(Wu et al. 2006), it demonstrated high level of evidence as it showed overall 
low risk of bias. There were a significant proportion of patients with an 
improvement in global postdose assessment in dry mouth using a VAS 
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(response was >25mm). In the pilocarpine group it was (69.6%) compared to 
placebo (23.8%). The clinical significance was not reported nor the magnitude 
of improvement. At the end of the study 65.2% percent of the pilocarpine group 
had a higher response in the 60-minute post-dose saliva production compared 
to placebo (28.6%). The median increase was 0.05g/minutes vs. -0.02g/minute 
in the pilocarpine and placebo group respectively (P=0.0014), results were 
short-lived. Salivary function results display short-term effects. Adverse events 
were seen more in pilocarpine groups. 
Rebamipide 100mg 3 times/day vs placebo was tested in one study by Sugai 
et al. in which 104 participants were included in this 8-week study (Sugai et al. 
2009) (Table 15). Dry mouth at week 2, 4 and 8 improved by 26.0%, 44.0% and 
46.9% respectively in the rebamipide group compared to 20.0%, 27.1% and 
39.1% in the placebo group, yet no significance was found between groups. 
Rebamipide’s clinical significance was not clear. On the other hand the mean 
increase in salivary secretion was 0.14±0.40, 0.24±0.46 and 0.35±0.54 g/2 
minutes. Timing of assessment was not clear.  Higher adverse events were 
seen in the test group. 
2.3.2.4 Electrostimulation vs. placebo 
Two studies examined the use of an electrically stimulating device in a total of 
106 patients (Table 16). In the first study 29 participants were instructed to use 
the device (active, sham) for three minutes, three times a day for 4 weeks 
(Steller et al. 1988). Subjective and objective assessment was performed 
before and immediately after the use of the device. The pre stimulation salivary 
flow rates (long-lived) during the 4 weeks were as follow in the active group: at 
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week 0 (0.05±0.06) and at week 4 (0.09±0.15), and in the placebo group it was: 
(0.08±0.16) and (0.07±0.19), yet these were not significant. In addition the net 
increase between pre and post stimulation values of each visit did not reach 
statistical significance. However the post stimulation salivary flow values were 
in the active group at week 0 (0.08±0.08) and week 4 (0.24±0.33), and in the 
placebo group (0.11±0.15) and (0.08±0.18), the difference between the active 
and placebo group was statistically significant and these values represent the 
acute enhancement in salivary function (short-lived). Only five patients using 
the active device reported subjective slight increase in salivary flow, yet clinical 
importance was unclear. The second study included 77 patients (Talal et al. 
1992). The electrostimulation device was again used for three minutes, three 
times a day for 4 weeks. Salivary function was assessed before and right after 
using the device.  Mean pre stimulation salivary flow rates in the active group 
were at week 0 (0.060) and at week 4 (0.102), and in the placebo group it was 
(0.071) and (0.094), these values represented the resting condition of salivary 
flow (long-lived effects). However the mean post stimulation salivary flow 
values were in the active group at week 0 (0.330) and week 4 (0.385), and in 
the placebo group (0.209) and (0.196), these values on the other hand 
represent the acute enhancement in salivary function (short-lived). This study 
displayed high level of evidence as it had an overall low risk of bias. Of note the 
magnitude of improvement in salivary function in these trials were clearly 
reported however not the subjective outcomes. 
2.3.2.5 Acupuncture vs. placebo 
One randomised controlled study assessed the effects of acupuncture on dry 
mouth of SS (List et al. 1998) (Table 16). This included 21 participants, 
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randomized in two groups, group 1 received treatment twice/week for 10 weeks. 
Group 2 acted as a control for 10 weeks as they did not receive any kind of 
treatment, later group 2 received treatment twice/week for 10 weeks. In group 1 
there was a significant increase in the stimulated saliva ml/5min, before and after 
treatment 0.6(0.0-1.2) and 1.2 (0.05-2.6) respectively P≤0.05.  However no 
statistically significant was found between groups in before and after salivary 
flows.  Subjective assessment showed a significant reduction in mouth dryness 
before and after treatment in group 1 7.2(4.5-10.0) and 5.5 (3.2-10.0) 
respectively. Still no significance was found between groups in subjective 
assessments. Timing of outcome measurements was not clear in this study. We 
considered this study to be at high risk bias, due to the unblinded nature of the 
study, the incomplete outcome data and the selective reporting. 
2.3.2.6 Biological agents vs placebo 
Four studies on the effectiveness of biological agents (infliximab, etanercept and 
rituximab) have been reported (Table 17). A total of 281 patients have been 
examined in these studies. The first study had the largest number of patients as 
it included 103 participants and tested infliximab IV infusion (5mg/kg) vs. placebo, 
infusions were given on week 0, 2 and 6. Outcome measurements were collected 
on week 10 and week 22. (Mariette et al. 2004).  This study was considered at 
low risk of bias and therefore high level of evidence. The primary endpoint was 
the overall response (≥ 30% improvement as measured on 2 of 3 factors (fatigue 
VAS, joint pain VAS and most disturbing dryness VAS). Secondary endpoints 
were the values of each VAS, salivary flow, labial salivary gland biopsy (taken 
before treatment and at week 10), schirmer test and the SF-36. At week 10, 
27.8% of patients in the infliximab group and 26.5% in the placebo group had a 
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favorable response (P=0.89), fulfilling the definition of a primary response. At 
week 22 it was 16.7% in the active group and 20.4% in the placebo group 
(P=0.62). The Effect size of outcomes was clearly reported. Yet, none of the 
endpoints differed between the active and placebo group. Assessment was not 
performed immediately after infusions; therefore we can consider the results 
representing resting condition. The test group was accompanied with more side 
effects compared to placebo. The second study enrolled 28 participants to assess 
the efficacy of etanercept 25mg subcutaneous injections twice/week for 12 week 
vs. placebo (Sankar et al. 2004). Five patients in the active group and 3 in the 
placebo group had improvement in primary outcomes (20% improvement in 2 of 
the 3 SS disease domains: oral, ocular and laboratory tests), but no statistical 
significance was found between test and placebo groups in the primary 
outcomes. Magnitude of improvement was not clear for primary endpoints; rather 
only number of responders was reported. On the other hand secondary end point 
effect size were reported. No statistical significant changes were found in any of 
the secondary end points except for ESR. This study assessed the long-term 
effect of investigated intervention. More adverse events were seen in the 
Etanercept group. Rituximab IV infusion was tested in two studies, first study 
tested long-term use of 1000mg vs. placebo given on day 1 and day 15 assessed 
in 30 participants (Meijer et al. 2010). The follow up was performed on week 5, 
12, 24, 36 and 48. This study provided an overall low level of bias. With the 
primary endpoint (significant improvement in stimulated whole salivary flow in the 
test group compared to placebo), there was a significant improvement in the 
rituximab group at week 5 (P=0.018) and at week 12 (P=0.004), there was also 
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active and placebo groups in the stimulated salivary flow (P=0.038), outcome 
measurements were not taken immediately after intervention, thus they represent 
resting salivary function. In addition (SF-36) showed higher improvement in the 
rituximab group. VAS for oral symptoms improved in the active group and there 
was a significant difference in the mean change in VAS scores from baseline 
between groups. Magnitude of improvement was reported clearly in this trial, 
however the clinical importance was not addressed here. Rituximab group 
experienced more adverse events compared to placebo. The second study 
tested 1g IV infusion of rituximab given at week 0 and week 2 in 120 participants 
(Devauchelle-Pensec et al. 2014b). Efficacy was evaluated at week 6,16 and 24. 
The primary outcome was ≥ 30mm improvement at week 24 in at least 2 of the 4 
VAS. Secondary outcome was the change from baseline in ESSDAI, individual 
VAS, basal flow rate at week 6 and 16. Primary endpoints results were displayed 
as percentage of responders and secondary endpoints were displayed as 
magnitude of improvement. The percentage of patients with at least 30mm 
decrease in at least 2 of the 4 VAS was larger in the rituximab group only at week 
6 (difference 13.3 percentage points  (P=0.036)), however for the primary 
outcome, at week 24 the difference was not significant. In the secondary 
outcomes, the 30mm decrease in VAS fatigue was more in the rituximab group 
(absolute difference 26.6 percentage points (P<0.001) at week 6 and 18.3 
percentage points (P=0.012) at week 16). VAS dryness was not significant at 
week 6,16 and 24. In addition pain VAS was not improved by rituximab at any 
time point neither there was a decrease in ESSDAI in the test group. There was 
no improvement in the mean salivary flow rate in the test group. Results of this 
trial represent intervention long-term effect. VAS effect size was not reported, 
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rather results were displayed as percentages, and however secondary outcomes 
effect size was reported in this study. Still the clinical meaningfulness was not 
reported. Adverse events were reported more in patients in the rituximab group. 
2.3.2.7 Immunomodulatory or immunosuppressive agents vs. placebo 
The systemic agents tested were cyclosporine A, hydroxychloroquine and 
azathioprine (Table 18).  Interferon-α was tested in four trials. Drosos et al. 
assessed cyclosporine A 5 mg/kg for 6 months with 20 patients (Drosos et al. 
1986). Patients only improved in subjective measurement of xerostomia as 8 out 
of the 10 patients in the active group reported an improvement in dry mouth 
symptoms, without reporting the magnitude of the improvement. There was no 
change in parotid flow between test and placebo groups. It is unclear whether 
results refer to resting salivation or enhanced salivary flow. Adverse events were 
nearly similar between groups except for hirsutism, which was seen in 6 of the 10 
participants in the test group compared to none in the control group. In a 2 year 
study, 19 patients received hydroxychloroquine 400 mg daily vs placebo in a 
crossover design (Kruize et al. 1993). Assessment measurements were collected 
every 3 months (more likely results represent resting salivary function); patients 
were asked in a questionnaire to rate the severity of symptoms compared to the 
previous visit. There was no clear preference between hydroxychloroquine and 
placebo in improving clinical symptoms as dry mouth and parotid swelling, the 
study did not report magnitude of improvement in these subjective parameters 
nor the it found clinical significance (as there was no preference to either test or 
control). Another study evaluated the efficacy of 400mg daily of 
hydroxychloroquine vs. placebo for 24 weeks (Gottenberg et al. 2014). Primary 
endpoints were evaluated at week 24: proportion of patients with ≥ 30% reduction 
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from baseline in 2 of 3 (dryness, fatigue and pain) on a 0-10 numerical analogue 
scale (NAS). Secondary endpoints were each of the three NAS, ESSPRI, 
ESSDAI, SF-36, salivary flow rate and schirmer test. At Week 24, the proportion 
of responders in the active group was 17.9% and in the placebo group 17.2% (P 
=0.96). There was no difference in the change from week 0 between the active 
and control groups in the dry mouth subjective and objective assessments. This 
study most likely represents resting salivary gland assessment. It did not find any 
significant clinical importance. Azathioprine 1mg/kg for 6 months was assessed 
vs. placebo in 25 patients (Price et al. 1998).  Participants completed pre and 
post treatment xerostomia VAS questionnaire, and unstimulated salivary flow 
also was performed pre and post treatment. This study did not find any significant 
changes between test and placebo group in any of the outcome measurements. 
Outcomes of this study are more likely to represent salivary gland function at rest. 
A total of 679 participants were enrolled in 4 studies of interferon-α (Table 18). In 
the first trail 150 IU interferon-α vs sucralfate 250mg three times a day for 6 
months was assessed (Shiozawa et al. 1998). The mean change from baseline 
to month 6 in the test group was 0.50 and in the control group it was -0.10. Fifty 
percent of patients who received 150 IU interferon-α orally had at least a 100% 
increases in baseline whole saliva flow level at month 6. However this study 
displayed a high-risk performance, detection and reporting bias, in addition the 
timing of collecting the measurements was not clear. A second trial of 119 
patients (Ship et al. 1999) compared different doses of interferon-α orally in 
lozenges (150 IU once, 150 IU three times, 450 IU once and 450 three times) vs. 
placebp. A complete response was defined as at least a 25-mm increase in VAS 
for oral dryness and an increase of unstimulated salivary flow of at least 0.05 
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g/min, yet the analysis of the primary efficacy endpoints did not show any 
significant treatment effect based on the complete response definition. The 
secondary outcome (stimulated salivary flow) was significantly increased in the 
150 IU 3 times daily group compared to placebo at week 12. However other 
subjective measurements (oral comfort VAS, difficulty in swallowing VAS, 
difficulty in speaking VAS and eye dryness VAS) only showed a suggestion of 
benefit in the interferon-α 150 IU 3 times daily group. Furthermore timing of 
outcome measurements was unclear. In a third study twelve patient were enrolled 
in a 24 week study receiving either 150 IU interferon-α or placebo orally three 
times daily (Khurshudian 2003), participants were assessed every 6 weeks. At 
week 12 there were no significant changes in mouth comfort, burning sensation, 
furthermore there were no significant changes in the stimulated or unstimulated 
salivary flow. However, in week 24 there was a statistical significant increase in 
unstimulated whole salivary flow in the test group [median in test group: baseline 
(0.081), week 24 (0.192) and median in control group: baseline (0.069), week 24 
(0.181)] and a statistical significance improvement in oral dryness VAS in the test 
group [median in test group: baseline (26), week 24 (41), median in control group: 
baseline (16), week 24 (29.5)]. Meaningfulness of treatment to participants was 
not addressed in the study. The last study included 497 patients which received 
150 IU interferon-α or placebo three times/ day for 24 weeks via oromucosal rout 
(Cummins et al. 2003). This trial displayed high level of evidence with overall low 
risk of bias. The efficacy primary endpoints were oral dryness VAS and the 
stimulated salivary flow.  At week 24, patients in the test group had a significant 
P=0.01 increase in unstimulated salivary flow rates compared to placebo, 
although the primary endpoints (stimulated whole salivary flow and oral dryness 
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VAS) did not significantly improve. Magnitude of effect was not clearly described 
in this study and the clinical significance cannot be obtained. 
2.3.3.8 Others interventions vs. placebo 
Ninety participants were assessed in one study using gammalinolenic acid (800 
mg or 1600 mg) vs corn oil as placebo for 6 months.  Gammalinolenic acid did 
not improve dry mouth VAS or increase unstimulated salivary flow rates 
(Theander et al. 2002). A total of 88 participants were enrolled in two studies to 
assess the efficacy of oral Dehydroepiandrosterone (DHEA) 200 mg. In the first 
study Pillemer et al with 28 participants assessed the efficacy of DHEA 
200mg/daily for 24 weeks. The primary outcome was the improvement of 2 out 
of 3 of SS domains; oral, ocular, laboratory. Oral improvement was defined as 
≥20% improvement in dry mouth VAS or 20% improvement in stimulated salivary 
flow. The study did not find significant improvement in the DHEA group compared 
to placebo in the stimulated whole salivary flow. However dry mouth VAS was 
statistically significantly improved (change of measurement at final visit compared 
to baseline; active (9), placebo (-10) P=0.02, though author reported that this 
improvement was not clinically meaningful. Timing of measurements was unclear 
(Pillemer et al. 2004).  The second study enrolled 60 participants assessing 
DHEA 200mg/daily or placebo for 12 months. Secondary outcomes included dry 
mouth VAS, which was significantly changed in both groups (Hartkamp et al. 
2008). The timing of assessment in the DHEA studies was not clear, nor clinical 
importance. Nizatidine (H2 receptor antagonist) 300mg/twice a day and 
famotidine 20mg/twice a day as a control for 8 weeks was assessed for twenty-
seven participants.  Primary outcomes assessed were the salivary flow (saxon’s 
test) and global xerostomia improvement VAS. Nizatidine significantly improved 
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stimulated salivary flow rates compared to famotidine, and more participants in 
the test group did achieve a 20% improvement in the sensation of dry moth VAS 
compared to famotidine. Additionally, more frequent patients in the test group did 
reach a prominent relief in xerostomia symptoms which was indicated by a 50% 
improvement in VAS dry mouth (Kasama et al. 2008), however this study was 
presented an overall non clear risk of bias, in addition timing of assessment was 
not clearly reported.  Omega-3 and Vitamin E supplements vs. germ oil as control 
was tested in one study which included 61 participants (Singh et al. 2010).  The 
difference in unstimulated, stimulated salivary flow and dry mouth VAS between 
active and control group did not show statistical significance (P=0.38, P=0.346, 
P=0.817 respectively). A traditional Chinese medicine (ShengJinRunZao 
YangXue) once a day was tested in a 6 week trial compared to placebo (Hu et al. 
2014). The primary endpoint was schemer I test, sugar test and salivary flow (15 
min). The secondary endpoint was dry mouth and dry eyes evaluated on an 11-
point numerical rating scale (NRS). The magnitude of improvement was reported 
in this study. In regards to the primary endpoint the difference between the active 
and control groups were not significant at week 6. Yet in the secondary endpoint, 
the improvement in the NRS dry mouth was significant between the two arms of 
the study. Clinical meaningfulness was not reported. 
These treatment modalities are displayed in table 19. 
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Table 14. Qualitative analysis: Saliva substitutes and topical saliva stimulants (NR= not reported, NS=not significant). 
 
Study Country 
(Funding 
source) 
Number of 
participants 
(Males) 
Study 
duration 
Intervention/ dose Control/dose Outcome measure Results Adverse 
events 
Sa
liv
a 
su
bs
tit
ut
es
 
(Klestov et 
al. 1981)  
Australia 
(Non-
governmental) 
108 
(10) 
Not clear Salivary substitute 
(SS) 5ml/ use for one 
minute/as frequently as 
desired. 
Glycerine 
mouthwash 
As Placebo  
5ml/ use for one 
minute/as frequently 
as desired. 
Subjective: 
-Response to form of 
therapy 
 
-Assessment of benefited 
Symptoms 
Active: 21.1% reported excellent benefit. 
Placebo: 5.3% reported excellent benefit. 
P<0.01. 
 
Active: 30.7% reported lack of benefit 
Placebo: 37.5% reported lack of benefit 
P <0.02 
None. 
(van der 
Reijden et 
al. 1996) 
Part 1. 
Not clear 
(Industry) 
43 
(3) 
7 weeks 
(Each agent 
tested for one 
week) one week 
wash out 
period) 
Poly acrylic acid 
(PAA),  
Xanthan gum (XG) 
 and Porcine gastric 
mucin (PM) 
Placebo Subjective: 
-3 self-administered 
questionnaires 
 
Objective: 
WUSF, WSSF 
PAA, XG and PM were equally preferred. 
 
 
 
Patients preferred PAA had lower stimulated salivary flow 
than patients who preferred SO (P<0.05) 
None 
Part 2. Not clear 
(Industry) 
33 
(3) 
3 weeks High Xanthan gum Low Xanthan gum Subjective: 
-2 self-administered 
questionnaires 
 
Objective: 
-uWSF 
-sWSF 
Patients that had a reduction in symptoms using LVXG had 
significant lower stimulated flow rate than patients with 
symptoms reduced using HVXG or reduced by both. 
(P<0.05) LVXG vs. HVXG 
 
uWSF: NS 
sWSF: Low viscosity: 0.093±0.107 (general xerostomia) 
                                     0.069±0.089 (daytime xerostomia) 
None 
(Johansson 
et al. 2001)  
Sweden 
(Academic) 
22 
(2) 
9 weeks (3 test 
weeks, 3 wash 
out period) 
Salinum without 
chlorhexidine (SAL) 
Salinum with 
chlorhexidine 
(SAL/CHX) 
Objective: 
-Mirror friction test 
 
 
 
 
 
 
-Unstimulated salivary flow 
SAL group, friction was reduced to normal in 9 of patients 
with initial elevated values   P <0.01. 
SAL/CHX group also was reduced in 8 out of 10  P <0.05. 
11 patients reported reduced oral dryness symptoms in the 
SAL group and 15 patients in the SAL/CHX group. 
Speaking problems and burning mouth symptoms improved 
after SAL but not SAL/CHX. 
 
NS 
NR 
To
pi
ca
l s
al
iv
a 
st
im
ul
an
ts
 (Gravenma
de and 
Vissink 
1993)  
Netherlands 
(not clear) 
42 
(1) 
6 weeks: 
2 test week 
2 week wash 
out 
Mucin lozenges used 
as required  
Placebo lozenges 
Used as required 
Subjective: 
-3 self-administered 
questionnaires 
 
Oral dryness during the day was largely relieved in 8 (19%), 
moderately relieved in 26 (62%) and not changed in 7 (17%) 
in the active group.  
Thirty-two patients (76%) preferred the mucin lozenges, 4 
patients (14%) preferred placebo. 
Mucin lozenges resulted in a larger reduction in complaints 
(P<0.001)  
and a reduction in the sensation of dry mouth (P<0.01) 
NR 
(da Silva 
Marques et 
al. 2011)  
Portugal 
(not clear) 
80 
(none) 
Not clear Gustatory stimulus 
(malic acid) 
Gustatory stimulus 
(citric acid) 
Objective: 
-Stimulated salivary flow 
Both groups obtained a significant increase in salivary flow. NR 
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Table 15. Qualitative analysis: Saliva sialagogues (NR= not reported, NS=not significant). 
 
Study Country 
(Funding 
source) 
Number of 
participants 
(Males) 
Study 
duration 
Intervention/ 
dose 
Control  Outcome measure Results Adverse events 
Sa
liv
a 
si
al
og
og
ue
s 
(Petrone 
et al. 
2002a)  
USA 
(Industry) 
197 
(10) 
12 weeks Cevimeline 
15 mg tid  
or 30 mg tid 
Placebo Primary efficacy endpoints:  
-Global evaluation of dry 
mouth (1 hour post-dose) 
 
Secondary efficacy endpoint:   
-Salivary flow (90 min post-
dose) 
 
 
-Dry mouth VAS (1 hour post-
dose) 
 
45% in the 15mg group and 66% of the 30mg group, reported a 
better response, compared to 37% in the placebo group. 
 
 
The change from baseline to postdose was statistically significant 
between placebo and 30mg. 
The mean postdose salivary flow at endpoint also was statistically 
significant between placebo and 30mg. 
 
Change between baseline and final  visitvalue: 
15mg:  mean±SD  -17.7±25.5 
30mg:  mean±SD -27.0±30.4 
Placebo:  mean±SD  -15.0±33.4 
Statistically significant difference between placebo and 30 mg group. 
82.2% reported at least one 
adverse event. 
 
25.7% in the placebo group, 
30.8% in the 15-mg group and 
48.4% experienced drug-
related adverse events.  
(Fife et 
al. 
2002) 
USA 
(Industry) 
75 
(10) 
6 weeks Cevimeline 
30 mg tid 
or 60 mg tid 
Placebo Objective measurement: 
-Whole unstimulated salivary 
flow (post-dose) 
 
Subjective measurement: 
-Global patient evaluation 
(1 hour post-dose) 
 
 
-Dry mouth VAS 
(1 hour post-dose) 
 
Change, mean±SD ml/min (predose to postdose) 
30mg 0.194±0.179 / 60gm 0.258±0.310 
Placebo 0.015±0.064 
 
Statistical significance to favor the active treatment. 
19 patient receiving 30 mg (76%)   
18 patients receiving 60 mg (67%)  
8 in the placebo group (35%) had a response of “better” 
 
Change, mean±SD, mm  (predose to postdose),  
30mg:-16.59±22.54/ 60mg:-19.95±22.10 
Placebo: -8.27±14.24 
Patients received 60 mg had at 
least one adverse event. 
 
Significant difference between 
60 mg and placebo were in: 
Sweating 
Nausea 
Rigors  
(Leung 
et al. 
2008)  
China 
(not clear) 
50 
(none) 
10 weeks 
first period 
 
4 washout 
period 
 
10 weeks  
second 
period 
Cevimeline 
30 mg / three 
times 
Placebo 
3 
times/day 
Objective measurement: 
-Whole stimulated saliva: 
ml/min 
 
-Stimulated Parotid flow: 
ml/min 
 
Subjective measurement: 
-Xerostomia inventory (XI) 
 
Pre/ active 0.56 (0.67), placebo 0.59 (0.64) 
Post/ active 0.60 (0.59), placebo 0.55 (0.60) 
Change: active 0.04 (0.3), placebo -0.04 (o.1) 
 
Pre/ active: 0.08 (o.11), placebo:0.08 (0.08) 
Post/ active: 0.11 (0.12), placebo: 0.08 (0.11) 
 
Pre / Active 34.3 (8.7)/ placebo 34.3 (7.7) 
Post/ Active 31.7 (8.4)/ placebo 33.4 (9.2) 
Change: active 0.03(0.1)/ placebo 0(0.1) 
18.2% in the cevimeline group 
developed side effects. 
Including: 
Sweating, gastrointestinal 
disturbance, palpitation and 
heat sensation. 
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Study Country 
(Funding 
source) 
Number of 
participants 
(Males) 
Study 
duration 
Intervention/ 
dose 
Control Outcome measure Results Adverse events 
Sa
liv
a 
si
al
og
og
ue
s (
co
nt
.) 
(Papas 
et al. 
2004)  
USA 
(Industry) 
256 
(14) 
12 weeks Pilocarpine 
5mg or 7.5mg  
Placebo Objective measurement: 
-Whole unstimulated saliva (30,45, 60 minutes post-dose) 
 
Subjective measurement: 
-Subjective 3-point categorical question 
-Dry mouth VAS 
 
 
Significant increase post dose in the 
pilocarpine group.  P≤0.0001 
 
Global Improvement in mouth dryness.  
Proportion of responders, week 12 
Active 61% 
Placebo 31%   
P≤0.0001 
Most frequent 
reported adverse 
experience:  
sweating, 
headache, urinary 
frequency, and 
nausea. 
(Vivino 
et al. 
1999)  
USA 
(Industry) 
373 
(16) 
12 weeks Pilocarpine 
2.5mg or 5mg / 
4times a day  
Placebo Objective measurement: 
-Whole unstimulated saliva (ml/min) (60 min post-dosing) 
 
Subjective measurement: 
-Global improvement in dry mouth 
 
-Dry mouth VAS 
5mg 0.37 (±0.46). vs Placebo 0.17(±0.19).  
 
 
Significant finding favoring  
5mg (61.3%), compared to placebo (31.1%). 
 
Significant findings favoring pilocarpine 
group. 
Most frequent 
reported adverse 
experience: 
Sweating, 
headache, flue 
syndrome and 
nausea 
(Wu et 
al. 
2006)  
Taiwan 
(not clear) 
44 
(5) 
12 weeks Pilocarpine 
5mg / four times  
Placebo Objective measurement: 
-Whole unstimulated saliva (g/min) (60 min post-dosing) 
 
 
 
 
Subjective measurement: 
- Global improvement in dry mouth 
 
-Dry mouth VAS 
Active: 65.2% had a higher response 
Placebo 28.6  had a higher response 
The median increase in saliva production in 
the pilocarpine group was significantly greater 
than placebo group, 0.05g/min vs. -0.02g/min 
respectively. 
 
Active: 69.6% of had improvement  
Placebo: 23.8% of had improvement. 
 
Significant results favoring pilocarpine. 
21.7% in 
pilocarpine group 
experienced 
perspiration 
Palpitation was 
reported in 4.3% 
in the pilocarpine 
group. 
(Sugai 
et al. 
2009)  
 
 
Japan 
(not clear) 
104 
(3) 
8 weeks Rebamipide 
100 mg / three 
times a day 
Placebo Objective measurement: 
-Saxone test, g/2min 
 
 
 
Subjective measurement: 
-Self-assessed overall severity of dry mouth 
 (4-grade scale) 
 
-Dry mouth VAS 
Mean increase in salivary secretion  
Week 8: 
Active:  0.35±0.54  
Control:  0.17±0.58  
NS 
 
Improvement rates favoring rebamipide was 
Week 8 46.9% vs. 39.1%  NS 
 
NS 
Adverse events 
were observed in 
60.4% in 
rebamipide group, 
and 66.7% in the 
placebo group. 
 
The most frequent 
was 
gastrointestinal 
disorders in both 
groups. 
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Table 16. Qualitative analysis: Electrostimulation and acupuncture (NR= not reported, NS=not significant). 
 
Study Country 
(Funding 
source) 
Number of 
participants 
(Male) 
Study 
duration 
Intervention/ dose Control Outcome measurements Results Adverse 
events 
El
ec
tro
st
im
ul
at
io
n 
 
(Steller 
et al. 
1988) 
USA 
(Industry) 
29 
(2) 
4 weeks Electrostimulation 
Three min/ 3times a 
day 
Sham 
device 
Objective measurement: 
-Whole unstimulated saliva  (g/2min) 
 
 
 
 
 
 
 
 
 
 
 
 
Subjective measurement 
-Subjects evaluated the increase in saliva 
Pre stimulation (resting condition) 
                   Week 0           week 4 
Active      0.05±0.06       0.09±0.15 
Placebo    0.08±0.16       0.07±0.19     NS 
 
Post stimulation (acute enhancement) 
                   Week 0            week 4 
Active       0.08±0.08        0.24±0.33 
Placebo     0.11±0.15        0.08±0.18   P=0.04 
 
Net increase (post-pre stimulation) at week 4 
Active: 0.15±0.24 
Placebo 0.02±0.03 
 
Five patients using the active device reported slight increase 
in salivary flow, 8 felt no increase. 
None 
(Talal 
et al. 
1992)  
USA 
(Industry) 
77 
(3) 
4 weeks Electrostimulation 
Three min/ 3times a 
day 
Sham 
device 
Objective measurement: 
-Whole unstimulated saliva  (g/2min) 
 
 
 
 
 
 
 
 
 
 
 
 
-Subjective measurement 
Pre stimulation (resting condition) 
                   Week 0           week 4 
Active           0.060            0.102 
Placebo         0.071             0.094  P≤0.05 
 
Post stimulation (acute enhancement) 
                    Week 0            week 4 
Active            0.330             0.385 
Placebo          0.209             0.196  P≤0.05 
 
Difference between active and placebo post stimulation 
scores 
Week 0 +0.121 
Week 4  +0.190 
 
Significant improvement in difficulty in swallowing and 
burning tongue. 
NR 
A
cu
pu
nc
tu
re
 
 
(List et 
al. 
1998)  
Sweden 
(Govern
mental)  
 
21 10 weeks Acupuncture 
Twice a week 
No 
treatment 
Objective measurement: 
-Whole unstimulated saliva: median (minimum and 
maximum), before and after acupuncture treatment (ml/15 
min) 
-Stimulated salivary flow: median (minimum and maximum), 
before and after acupuncture treatment (ml/5 min) 
 
Subjective measurement: 
-Mouth dryness VAS:  median (minimum and maximum), 
before and after acupuncture treatment 
 
Active: before 0.0(0.0-0.2). after 0.0(0.0-0.6) NS 
Placebo: before:0.0(0.0-0.7). after 0.0(0-0.2) NS 
 
Active: before 0.6(0.0-1.2). after 1.2(0.05-2.6)  P≤0.05 
Placebo: before 0.5(0.0-2.4). after 0.6(0.1-2.5) NS 
 
 
Active: before 7.2(4.5-10.0). after 5.5(3.2-10.0)  P≤0.05 
Placebo: before 6.3(0.0-9.5). after 6.8(0.0-9.5) NS 
NR 
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Table 17. Qualitative analysis:  Biologic agents. (NR= not reported, NS=not significant) 
 
Study Country 
(Funding 
source) 
Number of 
participants 
(Males) 
Study duration Intervention/ 
dose 
Control Outcome measurements  Results Adverse events 
B
io
lo
gi
ca
l a
ge
nt
s 
(Mariette et al. 
2004)  
France and 
Belgium 
(not clear) 
103 
(not clear) 
Infusions on 
week 0, 2 and 6 
 
Assessed on 
week 10 and up 
for 22 weeks 
Infliximab 
Infusions 
5mg/kg 
Placebo Primary endpoint 
-Overall response to treatment  
≥ 30% improvement as measured on 2 of 3 
factors (fatigue VAS, joint pain VAS and 
most disturbing dryness VAS) 
 
Secondary endpoint 
-Salivary flow rate (ml/min) 
 
Week 22 
Fulfilled the overall response: 
Active 16.7% 
Placebo 20.4% 
P=0.62 
 
Week 22  
Active=0.03±0.15 
Placebo= 0.02±0.19 
P=0.24 
Infusion reactions 
(2). 
Isolated cutaneous 
facial eruption (1). 
Autoimmune 
hepatitis (1). 
Pneumococcal  
septicemia (1). 
Breast cancer (1). 
(Sankar et al. 2004)  Netherlands 
(not clear) 
28 
(2) 
12 weeks Etanercept 
25 mg S/Q 
injections 
/twice a week 
Placebo Primary endpoint 
-20% improvement in 2 of the 3 SS disease 
domains: oral, ocular and laboratory tests 
 
 
-Stimulated salivary flow (ml/min) 
 
 
 
 
-Dry mouth VAS 
Improvement in primary outcomes 
Active: 5 patients 
Placebo: 3 patients 
P =0.2 
 
Median (25th, 75th percentiles) 
Active -0.033 (-0.31,0.16) 
Placebo -0.22 (-0.56,0.13) 
P =0.63 
 
Median (25th, 75th percentiles) 
Active -2(-13,2) 
Placebo 3(-11,10) 
P =0.44 
Injection-site 
reactions (2). 
Multiple actinic skin  
lesions (1). 
(Meijer et al. 2010)  Netherlands 
(Industry) 
30 
(1) 
Followed up 
week 5, 12, 24, 
36 and 48. 
Rituximab 
IV infusion 
of 1000mg 
on day 1 and 
15 
Placebo Primary endpoint 
-Stimulated salivary flow: (ml/min)  
 
 
Secondary endpoint 
-Unstimulated salivary flow: (ml/min) 
 
 
-Oral dryness VAS: significant results at 
week 24, 36 and 48. 
 
 
-SF-36: significant results at week 36 
Significant results in week 5 and 12. 
Week 5 Active=0.84±0.71 Placebo=0.41±0.24 
Week 12 Active=0.87±0.87 Placebo=0.28±0.17 
 
Significant results in week 5 and 12. 
Week 5 Active= 0.24±0.22 Placebo=0.09±0.07 
Week 12 Active= 0.23±0.22 Placebo=0.05±0.05 
 
Week 24 Active=34±27 Placebo=64±27 
Week 36 Active=51±28 Placebo=68±26 
Week 48 Active=50±28 Placebo=69±25 
 
Week 36 Active60±17 Placebo 63±16 
Early infusion 
reaction (2). 
Late infusion 
reaction (2). 
Serum sickness (1). 
Infections within two 
weeks after infusion 
(2). 
Infections within 
forty-eight weeks 
after infusion (10). 
(Devauchelle et al. 
2014) 
France 
(Governmental, 
industry) 
120 
(8) 
Infusion at 
week 0 and 2 
 
Follow up week 
6, 16 and 24 
Rituximab 
IV infusion 
of 1g at week 
0 and 2 
 
 
Placebo Primary endpoint at week 24 
-≥30mm improvement in at least 2 of 4 VAS  
 
Secondary endpoint at week 16 
-Change in individual VAS 
 
 
-Unstimulated salivary flow (ml/min)  
Week 24 Active 23% Placebo 22%   P =0.91 
 
 
Fatigue VAS Active 34.7% Placebo 8.2% 
P <0.001 
Dryness VAS Active 21.1%, placebo 13.6%  NS 
 
Active -0.01, placebo -0.03  NS 
Infusion reaction, 
respiratory disorder, 
shortness of breath, 
dry cough, sneezing. 
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Table 18. Qualitative analysis: Immunomodulatory/ immunosuppressive agents. (NR= not reported, NS=not significant). 
 
Study Country 
(Funding 
source) 
Number of 
participants 
(Males) 
Study 
duration 
Intervention/ dose Control Outcome measurements Results Adverse events 
Im
m
un
om
od
ul
at
or
y 
or
 im
m
un
os
up
pr
es
si
ve
 a
ge
nt
s 
(Drosos 
et al. 
1986)  
Greece 
(not reported) 
20 
(1) 
6 months Cyclosporin A 
5mg/kg daily 
Placebo Subjective measurement: 
-Xerostomia improved 
 
Objective measurement: 
-Parotid flow (ml/5min) 
Active= 8 patients 
Placebo= 2 patients 
 
Active Pre: 0.62±0.67     Post: 1.14±1.28 
Placebo Pre: 0.62±0.66   Post:1.06±1.08 
NS 
Hirsutism (6). 
Infections (4). 
Hypertension (1). 
Gingival  
hypertrophy (1). 
Nausea, vomiting (1). 
(Kruize 
et al. 
1993)  
Netherlands 
(Industry) 
19 
(none) 
24 months 
Crossover 
Hydroxychloroquine 
400 mg daily 
Placebo -Questionnaire reporting the presence and 
severity of dry mouth symptoms. 
Participants had no clear preference to test medication 
with respect symptoms of dry mouth. 
Mild deterioration of 
liver function (1). 
(Gotten
berg et 
al. 
2014) 
France 
(Governmental, 
Industry) 
120 
(10) 
 
 
24 weeks Hydroxychloroquine 
400 mg daily 
Placebo Primary endpoint: 
-Proportion of patients with ≥30% reduction 
from baseline in 2 of 3 (dryness, fatigue and 
pain) on a 0 to 10 numeric scale, at week 24 
Secondary endpoint: 
-Each of 3 primary endpoint 
-ESSPRI, ESSDAI, SF-36 
 
-Unstimulated salivary flow (ml/min) 
at week 24 
Week 24 Active=17.9% Placebo=17.2%    
P =0.96 
 
 
 
No difference between both groups in the change 
from week 0 seen in each numerical scale, ESSPRI, 
ESSPRI and SF-36  
 
Mean (SD) 
Active: 0.18 (0.21) Placebo 0.22 (0.21) P =0.45 
Urinary lithiasis (1) 
Breast cancer (1) 
 
(Price et 
al. 
1998)  
UK 
(Non-
governmental) 
 
25 
(2) 
6 months Azathioprine 
1 mg/kg  
Placebo Objective measurement: 
-Unstimulated salivary flow (ml/5min) 
 
 
Subjective measurement: 
-Dry mouth VAS 
 
Active: Pre 0.2(0.1) Post 0.3(0.1) 
Placebo: Pre 0.2 (0.05) Post 0.2 (0.09) 
NS 
 
Active: Pre 76.6 (10.7) Post 72.8 (10.9) 
Placebo: Pre 77.4 (5.10) Post 78 (4.2) 
NS 
Nausea, abnormal liver 
function test, perforated 
large bowel 
(Shioza
wa et al. 
1998)  
Japan 
(Industry) 
60 
(2) 
6 months Interferon-α 
150 IU orally three 
times a day  
Sucralfate 
250mg 
three times 
a day 
Objective measurement: 
-Salivary flow (g/2min) 
 
 
-Mean change from baseline at month 6 
At month 6 
Active 1.17± 0.98   Placebo 0.58±0.48 
P < 0.001 
 
Active 0.50   Placebo -0.10   P<0.001 
Depression (2). 
(Ship et 
al. 
1999)  
USA 
(Industry) 
109 
(8) 
12 weeks Interferon-α 
150 IU once 
150 IU three times 
450 IU once 
450 IU three times 
orally 
 
Placebo Primary endpoint: 
-Complete response  
 
Objective measurement: 
-Unstimulated salivary flow (g/5min) 
 
 
-Stimulated salivary flow (g/5min) 
 
Subjective measurement: 
-Dry mouth VAS 
Non-significant, but a suggestion of benefit in the 150 
IU tid group. 
 
Non-significant, but 150 IU tid and 450 IU tid groups 
had greater percentage of participants with positive 
response. 
 
150IU TID 0.79±0.46    Placebo 0.06±0.11   P=0.04 
 
Non-significant, however there was a trend over time 
for 150 IU tid and 450 IU tid groups. 
None. 
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(Continue table 18) 
	 	
 
Study Country 
(Funding 
source) 
Number of 
participants 
(Males) 
 
Study 
duration 
Intervention/ dose Control Outcome measurements Results Adverse events 
Im
m
un
om
od
ul
at
or
y 
or
 im
m
un
os
up
pr
es
si
ve
 a
ge
nt
s 
(c
on
t.)
 
(Khurshud
ian 2003)  
USA 
(not clear) 
12 
(2) 
24 week Interferon-α 
150IU 3times 
orally 
Placebo Objective measurement: 
-Unstimulated salivary flow (ml/min) 
 
 
-Stimulated salivary flow (ml/min) 
 
 
 
Subjective measurement: 
Dry mouth VAS  
Week 24 , mean±sem(median) 
Active 0.242±0.06 (0.192)   
Placebo 0.176±0.06 (0.181) NS 
 
Week 24,  mean±sem(median) 
Active 0.507±0.14 (0.399)  NS 
Placebo 0.696±0.27 (0.704) NS 
 
Week 24:  mean±sem(median) 
Active 46±11.1 (41)  
Placebo 35.7±11.2 (29.5) NS 
None. 
(Cummins 
et al. 2003)  
USA 
(Industry) 
497 
(37) 
24 week Interferon-α 
150IU 3times 
orally 
Placebo Primary endpoint  
-Stimulated salivary flow (gm/5min) 
 
-Dry mouth VAS 
 
 
Secondary endpoint 
-Unstimulated salivary flow (gm/5min) 
 
 
No significant improvement compared with 
placebo. 
No significant improvement compared with 
placebo. 
 
Week 24 
Test group showed a significant increase 
compared to placebo P=0.01 
Gastrointestinal 
adverse event. 
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Table 19. Qualitative analysis: Other agents (NR= not reported, NS=not significant). 
  
 
Study Country 
(Funding 
source) 
Number of 
participants 
(Males) 
Study 
duration 
Intervention/ dose Control Outcome measurements Results Adverse events 
O
th
er
s 
(Theander 
et al. 2002)  
UK 
(Industry) 
90 
(8) 
6 
months 
Gammalinolenic acid 
800 mg or 1600 mg 
Corn oil Secondary endpoint 
-Unstimulated salivary flow 
(ml/15min) 
 
 
-Dry mouth VAS 
Month 6, (median, interquartile range)  
Active (1600 mg): 0.4 (-0.4;1.1) 
Placebo: 0.1 (-0.1;0.4) 
 
NS 
Mild gastrointestinal 
side effects. 
(Pillemer 
et al. 2004)  
Not clear 
(not clear) 
28 
(none) 
6 
months 
Dehydroepiandrosterone 
200mg  
Placebo 	 Primary outcome  ≥20% improvement in dry mouth VAS or 20% improvement in stimulated 
salivary flow 
-Stimulated salivary flow (ml/min) 
 
 
 
-Dry mouth VAS 
 
 
 
 
Change at week 24 (Mean (SEM) 
Active 0.086(0.09)     Placebo -0.09(0.09)  
P= 0.17 
 
Change at week 24  (ml/min) (Mean (SEM) 
Active 9(5.5)     Placebo -10(5.5)  P = 0.02 
Acne, facial 
hirsutism, post-dose 
chills, disseminated 
streptococcal 
infection. 
(Hartkamp 
et al. 2008)  
Netherlands 
(Non-
governmental) 
60 
(none) 
6 
months 
Dehydroepiandrosterone 
200mg  
Placebo Secondary outcomes 
-Dry mouth VAS 
Both groups showed a significant change. NR 
(Kasama et 
al. 2008)  
Japan 
(not clear) 
27 
(5) 
8 weeks Nizatidine 
150 mg/ twice 
Famotidine 
20mg/twice/ 
day 
Objective measurement 
-Saxone test (g/2min) 
 
Subjective measurement 
-Dry mouth VAS 
Active : 
Pre 0.57±0.39    Post 0.90±0.65    P<0.05 
 
More patients in the test group achieved a 
20% improvement    71.4 vs 15.4    P<0.05 
None. 
(Singh et 
al. 2010)  
USA 
(Governmental) 
61 
(4) 
3 
months 
Omega-3 and Vitamin E 
supplements 
Once daily 
Wheat germ 
oil 
Objective measurement 
-Unstimulated salivary flow (ml/ 5min) 
 
 
-Stimulated salivary flow (ml/ 5min) 
 
Subjective measurement 
-Dry mouth VAS 
Difference from baseline to month3 
(mean(SD)) 
Active 0.064(0.173)    Placebo 0.029(0.09)  
 
Active 0.242(0.64)    Placeb0 0.101 
 
Month 3 (mean(SD)) 
Active 1.69(2.19)    Placebo 1.56(2.16) 
NR 
(Wei et al. 
2014) 
China 
(Governmental) 
240 
(11) 
6 weeks ShengJinRunZao 
YangXue 
Once daily 
Placebo 
Once daily  
Primary endpoint (week 6) 
-Saliva flow rate (ml/15min) 
 
 
Secondary endpoint (week 6) 
-Dry mouth numerical scale 
(NRS-11) 
Improved salivary flow by  
0.04 ml/15 min  
NS difference 
 
Improved difference by 0.83 
P<0.01 between groups 
Liver dysfunction (4) 
Diarrhea (4) 
Upper respiratory 
tract infection (4) 
Leucopenia (4) 
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2.3.3 Results: Quantitative analysis (meta-analysis) 
The meta-analysis compared 9 studies; none of them had any high-risk bias 
item. Statistical analysis of subjective xerostomia symptoms (5 studies) and 
objective assessment of salivary function changes (8 studies) was possible. 
QoL outcome assessment was not possible due to the statistically lack of 
homogeneity.  
In relation to the primary outcome (change measured on a 100-mm visual 
analogue scale (VAS), evaluating degree of mouth dryness), pilocarpine versus 
placebo: Three studies with a pooled total of 638 participants, with no 
heterogeneity among them, indicated that systemic pilocarpine use for 12 
weeks is 3.58 times more likely to have a long-term effectiveness in 
ameliorating dry mouth symptoms than placebo. These studies indicated that 
the magnitude of effect is having more that 25mm change on dry mouth VAS. 
The OR was 3.58 [95% CI 2.55-5.03] (Figure 12). 
Cevimeline versus placebo: Two studies again with no heterogeneity and a total 
of 180 participants indicated that long-term use of 60mg of cevimeline is 
associated with higher reduction in dry mouth symptoms than placebo with a 
MD of 10.11 [95% CI 2.52-17.69]  (Figure 13). 
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Concerning the secondary outcomes we were able to compare the (short and 
long term) effect of electrostimulationvs sham stimulation, pilocarpine vs 
placebo, cevimeline vs placebo and interferon- α vs placebo in improving 
unstimulated salivary flow (ml/min) (Figure 14). Electrostimulation versus 
placebo: Two studies using 1st generation device with no heterogeneity and a 
total of pooled 101 participants showed a moderate evidence that 
electrostimulation leads to an increase in the unstimulated salivary flow with a 
small effect size (0.05mL/min) [95% CI 0.02-0.09]. The clinical relevance 
remains unclear and the effect is likely to be short-lived. The effects of long-
term use where not significant (0.01ml/min) [95% CI-0.14, 0.16]. 
Pilocarpine versus placebo: Two homogeneous studies (I2=21) with a total of 
594 participants indicated that one tablet of pilocarpine is more effective in 
increasing unstimulated salivary flow in a short-term (measured at 60min) (0.22 
ml/min) [95% CI 0.17-0.28]. Long-term effect of pilocarpine is unknown. 
Cevimeline versus placebo: Two studies (I2=61) with a total of 180 participants 
reported an effect in regards to the short term salivary flow enhancement 
(measured at 90 min) of one tablet of cevimeline to increase unstimulated 
salivary flow. The effect size was small (0.08mL/min) [95% CI 0.03- 0.14]. Long-
term benefits remain unknown.  
Interferon-α versus placebo: With two studies (I2=17) comparing interferon- α 
did not show efficacy in increasing unstimulated salivary flow compared to 
placebo (0.01 [95% CI  -0.00 - 0.02].     
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2.4 Discussion 
Treating dry mouth aspects in patients with SS can be challenging especially 
with the absence of an evidence-based guide for clinicians. One systematic 
review on the treatment of salivary gland hypofunction of SS has been 
published in 2010 (Ramos-Casals et al. 2010). This review has a number of 
limitations including linguistic constraints (only papers in English were 
reviewed) and the inclusion of non-randomized studies (Grégoire, Derderian 
and Le Lorier 1995, Higgins et al. 2013).  Hence we have designed this 
systematic review and meta-analysis with the aim of overcoming limitations of 
previous reviews providing accurate estimate of effectiveness of available 
treatments. The objective is to support the development of evidence-based 
practice guidelines for the management of SS-induced hyposalivation and 
xerostomia. We have considered a number of study characteristics that were 
not included in reviews, which we believe are important to assess the efficacy 
of interventions. These include the type of outcomes (dry mouth symptoms, 
salivary function, quality of life), the timing of collecting outcome measurements 
at endpoint (shortly after administration of the intervention or away from 
treatment completion) and timing of outcome changes, e.g. whether they reflect 
long or short term changes in salivation or xerostomia (after weeks/months or 
a few minutes/hours of therapy). Table 20 displays these characteristic for each 
study.  
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The results of 33 RCTs with a total of 3170 randomized patients were 
summarized to estimate the effectiveness of treatment on SS-induced 
xerostomia and hyposalivation where possible. The meta-analysis was possible 
only for 9 studies. Results of this review suggest that the long-term use (12 
weeks) of systemic pilocarpine provides improvement in dry mouth sensation 
of SS.  Individuals using pilocarpine were 3.58 times more likely to perceive a 
reduction in dry mouth symptoms of at least 25mm. Effect size was however 
unclear and clinical significance was unknown. With respect to cevimeline, our 
meta-analysis shows that the short-term use of one tablet of cevimeline is 
associated with a small 10.11 [2.52, 17.69] reduction in dry mouth symptoms. 
Nothing is known regarding its clinical meaningfulness of cevimeline on VAS 
scores. 
This meta-analysis suggests that electrostimulation, pilocarpine and cevimeline 
can increase the salivary flow in pateints with SS.  Short-use of the 
electrostimulation device can lead to a small increase in salivary flow of 
unknown clinical significance. Whereas long-term use does not seam to provide 
a very notable effect. One tablet of cevimeline also improved salivary flow; 
effect size was (0.08 ml/min [0.03, 0.14], yet it did demonstrate high clinical 
significance. The use of 1 tablet of pilocarpine can increase salivary flow with a 
moderate effect size (0.22 ml/mi [0.17, 0.28]) but unknown clinical significance. 
No information is available for cevimeline and pilocarpine effect on salivary 
function in resting conditions. Interferon-α had a small effect size of (MD 0.01 
[-0.00, 0.02]) furthermore the clinical significance was unknown nor the timing 
of outcome assessment.  
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Some practical implications can be withdrawn from these results when 
managing SS induced xerostomia. It is helpful to consider two aspects: 
reducing dry mouth symptoms and increasing salivary flow. Prescribing 
pilocarpine and cevimeline can both provide an improvement in salivary flow 
(larger effect seen using pilocarpine), yet both are likely to be short-lived, as no 
available evidence supports their long-term effect. However in the same time 
both are expected to reduce dry mouth symptoms, which is clinically important 
to patients. Short use of ectrostimulation can provide a small symptomatic 
benefit but failed to provide evidence regarding beneficial effect of longer use 
of the device. Clinical significance also remains unknown. The toxicity of 
pilocarpine and cevimeline seems similar, possibly with a tendency for 
cevimeline to be better tolerated, although evidence is not robust as no direct 
comparison is available. And on the other hand electrostimulation did not give 
rise to any adverse events. 
With respect to interventions that were not included in the meta-analysis, this 
systematic review suggests that there is no evidence that acupuncture, 
infliximab, etanercept, azathioprine, cyclosporine, hydroxychlorquine, 
gammalinolenic acid, dehydroepiandrosterone and omega-3/ vit E can have an 
effect on reducing dry mouth symptoms, improving salivary flow or improving 
quality of life in SS patients with xerostomia. However Salivary substitutes 
(mouth washes) and topical salivary stimulants (lozenge) provided low level of 
evidence suggesting that they might have potentials in relieving in mild dry 
mouth cases without having adverse effects. Furthermore interferon-α, 
rituximab and nizatidine provide low-quality evidience of beneficial effect as 
they were of an unclear/high risk of bias. 
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This systematic review has some limitations. We detected significant 
heterogeneity between the studies. Most heterogeneity could be accounted for 
by variations in doses and application procedures. In addition to the type of 
treatment in the experimental and control groups, there were discrepancies in 
the baseline characteristics of the patients. The studies included were 
conducted between 1981 and 2014. During this time the classification criteria 
of SS has changed, leading to different characteristics of study samples. The 
low number of studies included in the meta-analysis highlights the limited 
evidence available to determine the effectiveness of dry mouth therapy. 
2.4.1 Summary 
• Heterogeneity among studies was high. Data pooling for quantitative meta-
analysis was possible in only 9 studies out of the 33 included in the systematic 
review. The 9 selected studies were of moderate/good quality with low risk of 
bias. 
• Dry mouth symptoms can be effectively reduced with long-term use of 
pilocarpine. Effect seems notable (at least 25 point on 0-100 VAS) but the precise 
effect size and its clinical meaningfulness remain unclear.  
• There is limited evidence regarding the efficacy (long) of cevimeline in lessening 
xerostomia. Effect size seems small (10 points on 0-100 VAS). 
• With respect to salivary gland function, there is robust evidence that short-term 
use (60 minutes after 1 tablet) of pilocarpine can increase unstimulated whole 
salivary flow rate by 0.2ml/min more than placebo. Clinical significance of this 
effect is unknown. Long-term effects of pilocarpine could not be evaluated.  
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• The effects of cevimeline upon salivary flow are similar to those of pilocarpine, 
although the effect size seems to be significantly smaller (0.08 vs 0.2 mL/min). 
• There is some limited evidence that the short-term use of the 1st generation 
electrostimulating device is associated with an increase in salivation. However, 
the effects size seems very small (0.05 mL/min).  
• For most the studies the beneficial effects seem short-lived and longer-term 
effects are unknown.	
• This review did not conclude with much of a good evidence of a suitable therapy 
for the oral aspects of SS – yet some promising evidence that electrostimulation 
may provide a cheap, reliable, safe method of controlling this problem. However 
ultimately the burden of this disease will only fall once the primary cause is 
identified and appropriate therapy developed.  
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Records	identified	through	database	search	(n=694)	 Additional	records	identified	through	other	sources	(n=12)	
Total	records	(n=706)	 Duplicate	records	removed	(n=468)	
Title	screened	(n=238)	 Records	excluded	for	irrelevance	topic	(n=173)	
Full-text	articles	assessed	for	eligibility			(n=65)	 Records	excluded	for	un-eligible	study	design	(n=32)	
Qualitative	analysis	eligible	studies			(n=33)	 Records	excluded,	lacking	uniform	outcomes	to	compare	in	meta-analysis	(n=24)	
Meta-analysis	eligible	studies			(n=9)	
			
 
       Figure 9. Flow diagram of the strategy search. 	
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Figure 10. Risk of bias summary: each bias item for each included study. 			
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 Figure 11. Risk of bias graph: percentages across all included studies 
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Figure 12. Forest plot. Primary outcomes: oral dryness VAS. (pilocarpine vs. placebo)- dichotomous data. 
	 173	
	
 										 	
Figure 13. Forest plot. Primary outcome: oral dryness VAS. (cevimeline vs. placebo)- continues data. 
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Figure 14. Forest plot Secondary outcome: unstimulated salivary flow ml/min. (electrostimulation, pilocarpine, cevimeline, biologic 
agents and Interferone-α vs. placebo)- continues data. 
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Table 20. Individual study characteristics.  
A
uthors 
N
um
ber of 
participants 
Intervention 
D
ry m
outh 
sym
ptom
s 
Salivary 
function 
Q
uality of 
Life 
B
ias risk 
Included in 
the m
eta-
analysis 
SALIVA SUBSTITUTES vs PLACEBO OR ANOTHER SUBSTITUTE  (N=3) 
Klestove 108 
New developed 
salivary substitute 
vs glycerine 
mouthwash 
Significantly more participants on the new 
salivary substitute vs glycerine mouthwash 
had less dry mouth at night. 
Effect size unknown 
Clinical significance unknown. 
Unclear whether results refer to symptoms 
perceived during resting salivation or 
enhanced salivary flow. 
N.A N.A.  
U
nclear  
N
o 
van der 
Reijden 
(part 1) 
43 
Poly acrylic acid 
(PAA),  Xanthan 
gum (XG)  and 
Porcine gastric 
mucin (PM) vs 
placebo 
No Significant difference in reduction of 
patient’s symptoms between groups.  
Effect size unknown. 
No Clinical significance was seen 
between groups. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
sWSF was significantly lower in patients 
that preferred PAA compared to who 
preferred SO. 
Effect size unknown. 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A. 
 
U
nclear 
N
o 
van der 
Reijden 
(part 2) 
33 
High Xanthan 
gum vs Low 
Xanthan gum 
No significant difference in the efficacy of 
High and low XG. 
Effect size unknown. 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
 
Patients with a reduction in symptoms 
using LVXG had significant lower 
stimulated flow rate than patients with 
symptoms reduced using HVXG or 
reduced by both. 
Effect size: mean sWSF using LVXG was 
0.093 ml/min (in general xerostomia) and 
0.069 ml/min (in day time xerostomia). 
Clinical significance unknown. 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A 
U
nclear 
N
o 
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(Continue table 20)  
Johansson 22 
Salinum without 
chlorhexidine 
(SAL) vs  Salinum 
with chlorhexidine 
(SAL/CHX) 
Significant reduction in dry mouth 
symptoms in Sal (P<0.05) and Sal/Chx 
(P<0.001). 
Effect size unknown. 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
-No significant changes in uWSF. 
 
-Friction was reduced to normal in all nine 
patients (with elevated initial values) in the 
SAL group (P<0.01). And in the SAL/CHX 
group mirror friction was also reduced in 8 
out of 10 participants (P<0.05).  
Effect size unknown.  
Clinical significance unknown.  
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A 
U
nclear 
N
o 
TOPICAL	SALIVA	STIMULANT	vs	ANOTHER	STIMULANT	OR	PLACEBO	(N=2)	
Gravenmade 42 Mucin lozenges vs placebo 
Significantly more participants on mucin 
lozenges vs placebo reported a reduction 
in general complaints P<0.001. 
 Effect size:  mean change 1.7 vs 1 (on a 
five point scale) 
Clinical significance : 76% preferred 
mucin lozenges P<0.001 . 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
N.A  N.A. 
H
igh 
N
o 
Da Silva 
Marques 80 
Malic acid 
gustatory 
stimulant vs citric 
acid gustatory 
stimulus 
N.A 
Significant short-term (20 minutes) 
increase in sWSF in both groups. 
Difference between groups was not 
significant. 
Effect size: unknown.  
Clinical significance unknown. 
 Results refer to enhanced salivary flow 
(short-lived). 
N.A. 
Low
 
N
o 
	 177	
(Continue table 20)	 	
CEVIMELINE	vs	PLACEBO	(N=3)	
Petrone 197 Cevimeline vs  placebo 
-Significant difference in patient’s global 
evaluation of dry mouth.  
Effect size unclear (graphs only).  
Clinical significance favouring long-term 
use of cevimeline  (66% responded better 
in the test group). 
  
-Significant difference in dry mouth VAS 
between Long-term use of cevimeline 
30mg vs placebo.  
Effect size: mean -27.0 vs -15.0 
(P=0.038). Results refer to enhanced 
salivary flow (60 min post dose) (short-
lived). 
Significant long-term change in uWSF 
30mg vs placebo.  
Effect size unclear (graphs only).  
Clinical significance unkown. 
Results refer to enhanced salivary flow 
(90 min post dose) (short-lived). 
N.A. 
U
nclear 
Yes 
Fife 75 Cevimeline vs placebo 
-Significant difference in dry mouth 
favouring long-term use of cevimeline.  
Effect size unknown.  
Clinical significance favouring cevimeline  
(76% with cevimeline responded better).  
 
-No statistical significance found at 
endpoint in change in dry mouth VAS 
between 30mg cevimeline and placebo 
(short-term use) 
. Effect size: mean -16,59 vs -8.27. 
 Results refer to enhanced salivary flow 
(60 min post dose) (short lived). 
Significant higher change in mean uWSF 
in short-term use of cevimeline group 
compared to placebo. 
 Effect size: mean 0.194 vs 0.015 ml/min.  
Clinical significance unknown. 
Results refer to enhanced salivary flow 
(short-lived). 
N.A 
U
nclear 
Yes 
Leung 50 Cevimeline vs placebo 
No statistical significance change in XI 
between groups. (long-term use)  
Effect size: mean -2.6 vs -0.9. 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
No statistical difference in sWSF and 
parotid SF (long-term use). 
Effect size: mean change: 
uWSF: 0.04 vs -0.04 ml/min. 
Parotid: 0.03 vs 0 ml/min. 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
-No statistical significance change in 
GOHAI between groups (long-term 
use) Effect size: mean 1.4 vs -0.1. 
 
-SF-36 did not show any significance. 
Effect size unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
Low
 
N
o 
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(Continue table 20) 
PILOCARPINE	vs	PLACEBO	(N=3)	
Papas 256 Pilocarpine vs placebo 
Significant (long-term use) improvement 
in oral dryness symptoms favouring 
pilocarpine. 
Effect size unclear (> 25mm on VAS). 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced (more likely) 
salivary flow. 
Significant improvement in short-term use 
of pilocarpine post does uWSF rates. 
Effect size: unclear (figures only) 
Results represent acutely enhanced 
salivary function (30,60 and 90 min) post 
dosing (short-lived). 
N.A 
U
nclear 
Yes 
Vivino 373 Pilocarpine vs placebo 
Significant (long-term use) improvement 
in mouth dryness favouring pilocarpine. 
Effect size: unclear (> 25mm on VAS). 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced (more likely) 
salivary flow. 
 
Statistical significance uWSF in the 
pilocarpine group (short-term use) in the 
60 min post dose sample at end point. 
Effect size: mean 0.37 vs 0.17 ml/min. 
Results represent acutely enhanced 
salivary function (60 min) post dosing 
(short-lived). 
 
N.A 
U
nclear 
Yes 
Wu 44 Pilocarpine vs placebo 
Significant (long-term use) improvement 
in mouth dryness favouring pilocarpine. 
Effect size: unclear (> 25mm on VAS). 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced (more likely) 
salivary flow. 
Significantly greater increase in uWSF in 
(short-term use) pilocarpine group. 
Effect size: median 0.05 vs -0.02 g/min 
Results represent acutely enhanced 
salivary function (60 min) post dosing 
(short-lived). 
N.A 
Low
 
Yes 
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(Continue table 20) 
	REBAMIPIDE	vs	PLACEBO	(N=1)	
Sugai 104 Rebamipide vs Placebo 
No significant difference seen in dry 
mouth between groups. 
Effect size: unclear (figure only) 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
No statistical difference seen between 
groups in the saxone test. 
Effect size: mean at end point 0.35 vs 
0.17 g/2min. 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A. 
U
nclear 
N
o 
ELECTROSTIMULATION	vs	PLACEBO	(N=2)	
Steller 29 
Active vs sham 
Electrostimulating 
device 
Only five patients using the active device 
reported subjective slight increase in 
salivary flow. 
Effect size unknown. 
Clinical significance unknown. 
-Significant increase in the post-
stimulation uWSF (short-term use). 
 
-No statistical significance difference in 
pre-stimulation uWSF  (long-term use) 
neither in the changes in uWSF. 
Effect size: mean change from week 0 to 
week 4: 0.15 vs 0.02 g/2min 
Clinical significance unknown. 
Results were measured to represent 
resting salivation and enhanced salivary 
flow (short and long lived results). 
N.A. 
U
nclear 
Yes 
Talal 77 
Active vs sham 
Electrostimulating 
device 
No significance found in dry mouth 
symptoms. 
Effect size unknown. 
Clinical significance unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
Significant difference between active and 
placebo in post-stimulation uWSF (long-
term). 
Effect size: mean difference in post-
stimulation at week 4 is +0.190 g/2min. 
Clinical significance unknown. 
Results were measured to represent 
resting salivation and enhanced salivary 
flow (short and long lived results). 
N.A. 
Low
 
Yes 
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(Continue table 20) 
ACUPUNCTURE	vs	NO	TREATMENT	(N=1)	
List 21 Acupuncture vs no treatment 
No significant difference between groups 
on dry mouth VAS. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation or enhanced salivary flow. 
No significant difference between groups 
in uWSF or sWSF. 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A. 
H
igh 
N
o 
BIOLOGICAL	AGENTS	vs	PLACEBO	(N=4)	
Mariette 103 Infliximab vs placebo 
No significant difference in dry mouth 
symptoms. 
Effect size: mean 22.2 vs 22.5. 
Results represent symptoms perceived 
during resting salivary condition. 
No significant difference in WSF. 
Effect size: mean 0.05 vs 0.01 ml/min. 
Results represent resting salivary 
condition. 
No significant difference in SF-36 
between groups. 
Effect size: mean change 
Physical component  
4.3 vs 2.2 
Mental component  
2.1 vs 4.9 
Low
 
N
o 
Sankar 28 Etanercept vs placebo 
No significant difference in dry mouth 
symptoms. 
Effect size: median -2 vs 3. 
Results (more likely) represent symptoms 
perceived during resting salivary 
condition. 
No significant difference in sWSF. 
Effect size: median -0.033 vs -0.22 
ml/min. 
Results (more likely) represent resting 
salivary condition. 
N.A. 
U
nclear 
N
o 
Meijer 30 Rituximab vs placebo 
Significant difference in the mean change 
in VAS dry mouth scores between groups. 
Effect size: mean at week 48:  
50 vs 69 
Clinical significance unknown. 
Results represent symptoms perceived 
during resting salivary condition (long-
term changes). 
Significant difference in the mean change 
of sWSF at week 12 was found in 
between groups. 
Effect size: mean 0.87 vs 0.28 ml/min 
Clinical significance unknown. 
Results represent resting salivary 
condition (long-lived changes). 
 
Significant improvement in SF-36 
score (from baseline to week 36) in 
the test group. 
Effect size: mean at week 36: 60 vs 
63 
Results represent resting salivary 
condition. 
 
Low
 
N
o 
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Devauchelle 120 Rituximab vs placebo 
No significant difference in VAS oral 
dryness. 
Effect size unclear (at least 30 mm 
improvement) 
Results represent symptoms perceived 
during resting salivary condition. 
 
No significant difference in the mean 
change of UWSF. 
Effect size: at week 16: 
 -0.01 vs -.03 ml/min. 
Results represent resting salivary 
condition. 
 
No significant differences in the SF-
36 between groups. 
Effect size: at week 16: 
Physical component  
3.2 vs 2.2 
Mental component  
3.2 vs 0.8 
Results represent resting salivary 
condition. 
Low
 
N
o 
IMMUNOMODULATORY/	IMMUNOSUPPRESIVE	AGENTS	vs	PLACEBO	(N=8)	
Drosos 20 Cyclosporin A vs placebo 
Significant improvement in dry mouth 
symptoms in the test group. 
Effect size unknown. 
Unclear whether results refer to symptoms 
perceived during resting salivation (more 
likely) or enhanced salivary flow. 
No significant change in the parotid 
salivary flow. 
Effect size unknown. 
Unclear whether results refer to collection 
during resting salivation (more likely) or 
enhanced salivary flow. 
N.A. 
U
nclear 
N
o 
Kruize 19 Hydroxychloroquine  vs placebo 
No improvement in dry moth symptoms in 
both groups. 
Effect size unknown. 
Unclear whether results refer to symptoms 
perceived during resting salivation (more 
likely) or enhanced salivary flow. 
N.A N.A 
Low
 
N
o 
Gotten 120 Hydroxychloroquine  vs placebo 
No significant change in dryness 
numerical scale between groups at week 
24. 
Effect size: mean 6.22 vs 5.85. 
Unclear whether results refer to symptoms 
perceived during resting salivation (more 
likely) or enhanced salivary flow. 
No significant change in uWSF between 
groups at week 24. 
Effect size: mean 0.22 vs 0.18 ml/min. 
Unclear whether results refer to collection 
during resting salivation (more likely) or 
enhanced salivary flow. 
No significant change in dryness 
numerical scale between groups at 
week 24. 
Effect size: mean  
Physical component  
54.5 vs 48.1 
Mental component  
63.1 vs 54.4 
Unclear whether results refer to 
symptoms perceived during resting 
salivation (more likely) or enhanced 
salivary flow. 
Low
 
N
o 
(Continue table 20) 
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Price 25 Azathioprine vs placebo 
No significant difference in dry mouth 
VAS. 
Effect size: mean at end point 
72.8 vs 78 
Unclear whether results refer to symptoms 
perceived during resting salivation (more 
likely) or enhanced salivary flow. 
No significant difference in uWSF. 
Effect size: mean at end point 
0.3 vs 0.2 ml/5min 
Unclear whether results refer to collection 
during resting salivation (more likely) or 
enhanced salivary flow. 
N.A. 
Low
 
N
o 
Shioza 60 Interferon-α vs Sucralfate N.A. 
Significant difference in the mean change 
from baseline between groups (long-term 
use). 
Effect size: mean change: 
0.50 vs -0.10 g/2 min 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A. 
H
igh 
N
o 
Ship 109 Interferon-α vs placebo 
No significant difference in dry mouth 
VAS. 
Effect size unknown. 
Unclear whether results refer to symptoms 
perceived during resting salivation or 
enhanced salivary flow. 
-No significant difference in uWSF. 
 
-Significant difference in sWSF at week 
12. 
Effect size: mean 0.79 vs 0.06 g/min 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A. 
U
nclear 
N
o 
Khurshud 12 Interferon-α vs placebo 
Significant improvement in dry mouth VAS 
at week 24 in the test group only (long-
term use). 
Effect size: mean at week 24 
46 vs 35.7 
Clinical significance unknown. 
Unclear whether results refer to symptoms 
perceived during resting salivation or 
enhanced salivary flow. 
Significant improvement in uWSF at week 
24 in the test group only (long-term use). 
Effect size: mean at week 24 
0.242 vs 0.176 ml/min 
Clinical significance unknown. 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A. 
U
nclear 
N
o 
Cummins 497 Interferon-α vs placebo 
No improvement in dry mouth VAS. 
Effect size unknown. 
Unclear whether results refer to symptoms 
perceived during resting salivation or 
enhanced salivary flow. 
-No significant difference in sWSF 
between groups 
 
-Significant difference in uWSF between 
groups(long-term use). 
Effect size: ACNOVA on mean (week 24) 
252.2 vs 244.2 gm/5min 
Unclear whether results refer to collection 
during resting salivation or enhanced 
salivary flow. 
N.A. 
Low
 
N
o 
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(Continue table 20)	
OTHER	AGENTS/COMPOUNDS		(N=6) 
Theander 90 Gammalinolenic acid vs corn oil 
No significant improvement in dry mouth 
VAS. 
Effect size unknown. 
Unclear whether results refer to 
symptoms perceived during resting 
salivation (most likely) or enhanced 
salivary flow. 
No significant improvement in uWSF. 
Effect size: median 
0.4 vs 0.1 ml/15 min 
Unclear whether results refer to collection 
during resting salivation (most likely) or 
enhanced salivary flow. 
N.A. 
U
nclear 
N
o 
Pillemer 28 Dehydroepiandrosterone vs placebo 
Significant improvement in dry mouth VAS 
in test group. 
Effect size: change in mean 
9 vs -10. 
Clinically meaningful unclear (author 
reports improvement was not clinical 
meaningful) 
Unclear whether results refer to 
symptoms perceived during resting 
salivation (most likely) or enhanced 
salivary flow. 
No significant improvement in sWSF. 
Effect size: median 
0.086 vs -0.09 ml/5 min. 
Unclear whether results refer to collection 
during resting salivation (most likely) or 
enhanced salivary flow. 
N.A. 
U
nclear 
N
o 
Hartkamp 60 Dehydroepiandrosterone vs placebo 
Both groups had significant improvement 
in dry mouth. 
Effect size unknown. 
Timing of outcome unclear.  
N.A N.A. 
U
nclear 
N
o 
Kasama 27 Nizatidine vs famotidine 
Significantly more participants in the test 
group had an improvement in global 
assessment of xerostomia at week 8 
(long-term use).. 
Effect size unclear (20% improvement in 
VAS). 
Clinical significance unknown. 
Timing of outcome unclear. 
Significant improvement in Saxon’s test at 
week 8, in the test group only (long-term 
use).. 
Effect size: mean at week 8 
0.90 vs 0.71 g/2min 
Clinical significance unknown. 
Timing of outcome unclear. 
N.A. 
U
nclear 
N
o 
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Singh 61 
Omega-3 and 
Vitamin E 
supplements vs 
wheat germ oil 
No significant difference in dry mouth VAS 
seen between groups. 
Effect size unclear. 
Timing of measurement unclear. 
No significance in difference in uWSF at 
month 3. 
Effect size: mean 0.064 vs 0.029 ml/min. 
 
No significance in difference in sWSF at 
month 3. 
Effect size: mean 0.242 vs 0.101 ml/min. 
 
Timing of measurement unclear. 
N.A. 
U
nclear 
N
o 
Hu 240 
ShengJinRunZao 
YangXue vs 
placebo 
Significant difference in dry mouth NRS 
between groups at week 6. 
Effect size: mean 0.83. 
Clinical significance unknown 
Timing of measurement unclear.  
No significant difference in WSF between 
groups at week 6. 
Effect size: mean 0.04 ml/15min. 
Timing of measurement unclear. 
N.A. 
U
nclear 
N
o 
(Continue table 20) 
	
 
 				
Chapter Three:  
Study Aim, Patients and Methods 
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3.1 Knowledge gap and research need 
 
The use of intra-oral second-generation devices may represent an ideal 
therapeutic strategy for individuals with SS-induced dry mouth. The device sits 
comfortably in the patient’s mouth and can be easily applied and removed; it 
stimulates natural salivation with no notable adverse side effects; and there is 
even some suggestion that electrostimulation may also have cumulative and 
trophic effects on glandular parenchyma (Schneyer et al. 1993). 
As discussed previously the evidence supporting its efficacy is however limited.  
More importantly, the design and overall quality of published clinical trials is 
debatable.  
As a consequence it remains unclear whether the second-generation intraoral 
electrostimulating device is indeed effective in providing (i) long-term reduction 
in dry mouth symptoms and (ii) increase of salivary flow. It is also unknown 
whether it could lead to a significant improvement in quality of life. Finally, the 
magnitude of any potential benefit is also unclear. 
 
3.2 Trial design 
LEONIDAS-1 (Long-term Effectiveness Of a Novel Intra-oral electro-stimulator 
for the treatment of Dry mouth in pAtients with Sjögren’s Syndrome) is a 
feasibility multicentre randomised double-blind trial of 6   months therapy. It 
was followed by a 6 month uncontrolled phase aimed at investigating long-term 
effectiveness. 
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3.2.1 Hypothesis 
The study tested the hypothesis that long-term application of the removable 
intraoral electrostimulation device will:  
1) Reduce dry mouth symptoms (i.e. reduction in dry mouth VAS score) 
2) Improve salivary function (i.e. an increase of resting salivary flow rates) 
3) Improve quality of life in individuals with dry mouth due to SS.  
We also investigated whether adaptation mechanism would reduce its 
beneficial effect over time. 
3.2.2 Study aim 
The main objective of LEONIDAS-1 was to obtain preliminary data regarding 
the effectiveness of this new intra-oral removable device for the long-term relief 
of distressing symptoms of reduced salivation (xerostomia) resulting from SS.  
3.2 3 Primary objective 
That long-term (6 months) application of the removable electro-stimulation 
device will reduce dry mouth symptoms (primary outcome). The hypothesis 
was addressed through comparisons of outcomes between patients 
randomised to an active device (releasing electronic stimuli) and a device that 
is not active (determining mechanical/tactile stimulation only).  
3.2.4 Secondary objectives 
To ascertain whether the device also improved salivary function. The device’s 
frequency of use by patients and their acceptability of the intervention were 
also determined. 
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3.2.5 Randomisation and blinding 
3.2.5.1 Sequence generation 
 
A blocked random list, which allocated the patient identification numbers to the 
specific type of stimulation was prepared by an independent study coordinator 
(central randomisation at Leeds clinical trial unit) see figure 15 and figure 16. 
The method of sequence generation was a random-number generator on a 
computer. The randomisation code was disclosed only at the end of the trial 
after statistical analysis. 
3.2.5.2 Allocation concealment 
 
Allocation concealment, was aimed at keeping clinicians and participants 
unaware of upcoming assignments, this was guaranteed as the computer-
generated list was prepared and maintained by the independent study 
coordinator based at a different study centre. The independent study 
coordinator had no contact with the patients and had undertaken the 
randomisation, allocated the study devices, and held the trial codes which was 
disclosed only after the termination of the study and completion of the statistical 
analysis.  
3.2.5.3 Implementation 
 
The ‘implementation process’, consisting of enrolling participants and 
assigning the next available study number, has been performed by clinical 
researchers at the clinical centres, who had no contact with the individual 
responsible for sequence generation. 
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3.2.5.4 Blinding 
 
The study is a double-blind controlled randomised trial, during which patients 
have been randomly assigned to electrical or sham tactile stimulation (e.g. 
controls used a device that does not release electricity but provides tactile 
stimulation only). Neither clinical investigators nor participants knew which 
devices are active and which are not. The double-blind design was feasible as 
(1) the computer-based randomisation was performed in a centre other than 
the clinical centre and remained blinded to the clinicians, (2) the electronic 
stimulus was completely asymptomatic and the patients could not possibly 
realise whether or not they were using an active or sham device. 	
 
Figure 15. Recruitment Form 
     (Eastman Dental Institute – 
     University College Hospital) 
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3.3 Endpoints 
3.3.1 Primary endpoints 
1. Reduction of dry mouth symptoms as evaluated through a 0-100 mm 
VAS (Appendix 2) between baseline and end of trial.  
2. VAS scores of dry mouth symptoms recorded during treatment. This 
was evaluated at baseline, 1 month, 3 months and 6 months. 
3. Reduction of Xerostomia Inventory (XI) (Appendix 3) and questionnaire 
scores recorded at baseline and end of the trial. 
4. Reduction of EULAR Sjögren’s Syndrome Patient Reported Index 
(ESSPRI) (Appendix 4) recorded at baseline and end of the trial. 
5. XI and ESSPRI questionnaire scores during the treatment (on the basis 
of serial measurement recorded during patients' appointments). 
Figure 16. Recruitment Form 
 (Birmingham Dental Hospital) 
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3.3.2 Secondary endpoints 
1. Changes in salivary flow (recorded via standardized sialometry) at 
baseline and end of the trial. 
2. Salivary flow during the treatment (on the basis of serial measurement 
recorded during patients' appointments).  
3. Intervention compliance and acceptability as recorded in the Patient 
diary. 
3.3.3 Exploratory analysis 
1. Changes between baseline and month 12 on the VAS, XI, ESSPRI 
questionnaire and salivary flow scores was explored. 
3.4 Endpoint analysis 
The effect of treatment over time on the VAS scores, salivary flow, the XI and 
ESSPRI scores was examined graphically using individual patient response 
profiles and overall mean profile plotted against time, estimated using 
regression, to assess the relative patterns of response between active and 
placebo (non-active device) groups.   
Summary statistics for reduction from baseline to 6 months and scores at each 
time point was presented by treatment arm from VAS scores, salivary flow, XI 
and ESSPRI. 
An exploratory analysis of data collected during the open-label phase up to 12 
months was undertaken. This analysis was restricted to patients at UCL for 
which the data were recorded. As this is an exploratory analysis the differences 
and 95% CIs of the changes from baseline are quoted but no formal tests were 
completed. 
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3.5 Patients 
After obtaining a favourable ethical approval on the 13th January 2012 (REC 
reference 11/YH/0423) from the NRES committee Yorkshire and the Humber 
– Sheffield, patients with pSS were invited to a screening visit in the Eastman 
Clinical Investigational Centre (ECIC), they were provided with a patient 
information sheet at the oral medicine clinic at the Eastman Dental Hospital 
(EDH) or at the Rheumatology clinic at the University College London Hospital 
(UCLH).  
Other subjects contacted EDI after the posting of an advert about the trial on 
the British Sjőgren’s Syndrome Society website and including it in its 
newsletter. 
A screening appointment was arranged to answer and clarify any issues that 
patients might have, explain the trial in detail, show patients a model of the 
device and insure that patients are diagnosed with pSS according to the 2001 
EU-USA classification criteria. 
Inclusion criteria (Appendix 5) 
Ø Subjects being ≥ 18 years old. 
Ø Have clinical symptoms of xerostomia (dry mouth) due to primary SS 
syndrome diagnosed on the basis of 2001 EU-USA classification criteria. 
Ø 50 mm minimum degree of dryness on a 100 mm VAS scale. 
Ø Unstimulated salivary flow higher than 0 ml/15min. 
Ø Evidence of residual salivary function by having an increase in salivary flow 
with proper stimulation using a piece of parafilm wax during saliva 
collection for 15min. 
Ø No sialogogue therapy during the study. 
		 193	
Ø Not to be pregnant or trying to have children.  
 
Exclusion criteria 
Ø Severe systemic disease (on the basis of the classification of the American 
Society of Anaesthesiology: ASA 3 or more). 
Ø Known allergy to materials similar to those used in the investigational 
product. 
Ø Wearing of other active implants such as cardiac pacemaker, defibrillator, 
or hearing aids. 
Ø Unstimulated whole salivary flow of 0ml/15min (complete absence of 
unstimulated salivary flow as measured via sialometry for 15 minutes). 
Ø To have evidence of no residual salivary gland function (via citric acid 
stimulation or chewing paraffin wax test). 
Ø Use of pilocarpine as systemic sialogogue therapy. 
Ø Pregnant or trying to become pregnant. 
Subsequently, after subjects fulfilled the inclusion criteria and where happy to 
take part in the study, they were asked to sign three copies of the consent form 
(1 copy to patient, 1 copy to clinical notes, 1 copy added to the case report form 
(CRF)) and sign all pages of patient information sheet with their initials.  
3.6 Intervention 
Electrostimulating devices had been manufactured for each participant using 
impressions taken from the lower dental arch. Participants have been randomly 
assigned to either: 
• Group A (cases): patients who received a fully functioning 
electrostimulating device. or 
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• Group B (controls): patients who received a device that did not release 
electric stimuli (but provided mechanical/tactile stimulation). 
The general structure of experimental procedures consisted of: (Appendix 6) 
A: Screening/Enrolment   
B: Impression   
C: Delivery of individualised device at start of experimental treatment 
D: Follow-up (end of month 1, 3) 
E: Study closure and end of randomised part at month 6 
F: Uncontrolled visit at month 12 
 
3.6.1 Screening/ enrolment  
Potential participants identified during routine clinical sessions were invited to 
attend an initial screening appointment, which included collection of detailed 
information on SS.  A dedicated Case Report Form was used to gather clinical 
data. The forms have been stored at the UCL (EDI), London, UK and 
Birmingham Dental Hospital in locked facilities. 
As the device was designed to stimulate the salivary glands, only patients with 
demonstrated residual salivary gland function capable of a significant response 
to stimuli were included. For this purpose, unstimulated and stimulated (after 
the patient has chewed paraffin wax for 15 minutes) whole saliva was collected 
and measured gravimetrically using pre-weighted tubes (Sterilin, UK, catalog 
n.185CM) and a precision balance (Scout Pro SPU123, Ohaus, NJ). Salivary 
flow rates was measured via standardised sialometry: participants were asked 
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to (i) avoid eating and drinking for 90 minutes before the measurement, and (ii) 
to collect saliva for 15 minutes into pre-weighted tubes (Figure 17). 
 
Figure17. Sialometry steps.  (A) Weigh empty pot. (B) Weigh pot with saliva. 
  
 
 
 
 
 							
 
 
 
 
 
 
    
   
 
 
 
 
 
 
 
 
 
 
 
All assessments were performed at a fixed time of the day to minimise 
fluctuations related to the circadian rhythm of salivary secretion. The grade of 
A 
B 
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dry mouth symptoms was also assessed using the dedicated XI / SSPRI and 
dry mouth VAS score.  
When entry criteria was satisfied, patients were provided with the relevant 
Patient Information Sheet (Appendix 7) and given all the time they needed to 
consider participation, ask further questions and provide written consent 
(Appendix 8). 
3.6.2 Impression and manufacturing  
A dental impression using polyvinylsiloxane material (Figure 18) was taken by 
one of the clinical investigators and shipped to Saliwell Ltd for device 
manufacturing.  
 
Figure 18. Lower arch impression taken																								
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3.6.3 Delivery of individual device  
On the insertion appointment, the device was taken out of its packaging (Figure 
19) and inspected visually and manually for any sharp edges (Figure 20). When 
the safety was insured, the device was inserted by a clinician and seated on 
the lower arch. Participants were asked if they had any issues with comfort or 
if any part of the device gave rise to any pain. If an area of discomfort was 
present due to flanges of the acrylic being too long, an acrylic bur on a low-
speed hand piece was used to trim and smooth flanges until participant was 
happy (Figure 21. A). In cases were the electrodes were impinging on the oral 
mucosa, the electrodes were shorten and smoothed until comfort was insured. 
It was explained to patients that electrodes should touch but not injure the 
mucosa for the device to stimulate the lingual nerve (Figure 21. B). 
After insuring comfort, participant was asked to hold a mirror to observe 
clinician when inserting and taking the device out. Afterwards the participant 
was instructed to insert the device by taking the side with the electrodes in first, 
then seating the rest of the device. Afterwards participant was instructed to 
take it out.  
Participants were asked if they were confident in inserting the device and if 
they needed to practice more or had any questions. Participants were 
instructed to contact the clinician whenever they had any complaints so they 
could be seen in clinic to address any issues.  
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Figure 19. Electrostimulation device + Remote control 
Figure 20. Electrostimulation device to be inspected for any sharp edges 
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Figure 21. Areas of possible adjustments on electrostimulating device 
(A) Too long acrylic flanges. (B) Sharp electrodes impinging the oral mucosa. 
 
A 
B 
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Participants were informed and trained by the clinical investigators regarding 
the modality of use of the device during the study period. Patients were asked 
to use the device with a frequency of 5 minutes/hour, as many times as they 
wanted during the day. Participants received a ‘guide for user’ and were asked 
to complete a diary of the frequency of application of the device per day (Figure 
22) (Appendix 9). 
 
 
 
 
 
 
 	
 
3.6.4 Follow-up 
After the delivery of the individualised device to the patient (baseline), follow 
up visits and relevant study measurements were scheduled at 4 time points: 
end of the 1st, 3rd, 6th, 12th months. Measurements included dry mouth VAS 
score, XI and ESSPRI and sialometry. As safety-related secondary outcome 
measures, vital signs, changes in health condition and oral mucosal status 
were assessed. Any oral mucosal abnormality or oral discomfort caused by the 
electrostimulating device was also recorded. 
Figure 22. Home diary and User guide 
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3.7 Statistical analysis 
Statistical support and supervision of this study was be provided by a dedicated 
statistician at CTRU. Changes in the effect of treatment over time on the VAS 
scores, salivary flow and the XI scores was initially examined graphically using 
individual patient response profiles plotted against to assess the relative 
patterns of response between active and placebo groups. In doing so, the 
optimal timing of the primary outcome was judged. The difference in 
proportions achieving a reduction in xerostomia was estimated and adjusted 
for baseline score, to assess the possible size of difference that was achieved 
with the device and to inform sample size calculations for a larger study. For 
the secondary outcomes of salivary flow as measured by sialometry, data was 
compared between groups at the final visit using an analysis of covariance 
(ANCOVA) to control for any potential baseline differences. Adjusted mean 
differences and associated 95% confidence intervals was calculated. Rates of 
recruitment and compliance will be summarised and used to plan a larger 
study.   
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Chapter four: 
Results 
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4.1 Feasibility and Demographics 
Two study sites (UCLH and Birmingham University) recruited participants. 
Forty-two patients with pSS-induced xerostomia were screened and 30 were 
recruited on the basis of the inclusion and exclusion criteria 
(screening/recruitment ratio: 42:30), 12 patients did not meet entry criteria 
(Table 21) and (Figure 23). The 30 participants were recruited over 11 months 
(recruitment rate: 2.7/month). Acceptability to participate and to be randomised 
was 100%, as no eligible participants decided not to participate. The drop out 
rate was 13.3% (4/30). Reasons for drop out were: perceived no benefit (n=2), 
travelling abroad (n=1), and joined another trial (n=1). Twenty-six participants 
thus completed the study. The majority of participants (93%) were females. 
The mean age was 61.6 years (range 31 to 82 years). No adverse side effects 
were noted. 
Table 21. Study demographics and baseline measurement 
 Active Sham Total 
Number of participants 15 15 30 
Mean age 64.8 56.3 61.6 
Number of males 0 2 2 
Number of withdrawals 2 2 4 
VAS1 (mean, sd) 7.4 (1.8) 7.5 (1.5) 7.5 (1.6) 
Sialometry2 (mean, sd) 0.68 (0.61) 0.69 (0.88) 0.68 (0.74) 
XI3 (mean, sd) 47.3 (6.5) 45.4 (6.1) 46.4 (6.3) 
ESSPRI4 (mean, sd) 8.4 (1.4) 8.3 (1.1) 8.3 (1.2) 
1 Dry mouth visual analogue scale. 2  Sialometyry (ml/15min). 3  Xerostomia inventory questionnaire.  
4   The European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported 
Index. 
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42 patients assessed for eligibility
15 
Randomised 
to recieve 
active 
device 
15 completed 
month 1
follow up
2 withdrawn
(Lack of 
compliance)
13 completed
month 3
follow up
13 completed
month 6
follow up
15 
Randomised 
to recieve 
sham device
13 completed
month 1
follw up
13 completed
month 3 
follow up
13 completed
month 6 
follow up
2 withdrawn
(1 Joined another trial)
(1 traveling)
12 Excluded
(did not meet 
inclusion criteria)
26 completed  
Month 12 (open label visit) 
Using active device 
Figure 23. Study flow chart 
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4.2 Outcome results 
The median use of the device was 3 times/day in both active and sham groups. 
The range was 0-11 times/day in the active group and 0-10 times/day in the 
sham group. Table 22 details the outcome results baseline vs. month 6 visit 
and Table 23 details the outcome results through study visits. 
 
Table 22. Clinical assessments: baseline and at month 6 (controlled part of trial) 
 
 Mean VAS1 
(cm) 
Mean Sialometry 
(g/15min) 
Mean XI2 
 Baseline Month 6 Baseline Month 6 Baseline Month 6 
Sham 7.5 7.3 0.69 0.75 45.4 45.3 
Active 7.4 6.9 0.68 1.9 47.3 43.5 
1 Dry mouth visual analogue scale. 2 Xerostomia inventory questionnaire.  
 
 
 
Table 23. Clinical assessment trends during follow up visits. 
 
 
 Controlled visits results 
Uncontrolled visit 
results 
Baseline Month 1 Month 3 Month 6 Month 12 
VAS1 
(cm) 
Sham  7.5 7.7 7.3 7.3 7.5 
Active  7.4 6.8 6.3 6.9 7.1 
Sialometry 
(g/15min) 
Sham 0.69 0.56 0.56 0.75 0.5 
Active  0.68 1.1 1.4 1.9 2.4 
XI2 Sham  45.4 44.9 45.5 45.3 45.5 
Active  47.3 45.5 43.6 43.5 43.1 
1 Dry mouth visual analogue scale. 2 Xerostomia inventory questionnaire. 
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4.2.1 Visual analogue scale (VAS) 
There was no obvious pattern of response for the (dry mouth) VAS. There was 
an initial reduction in VAS in the active group with a maximum reduction at 3 
months. By 6 months the gap between the groups had almost closed. The 
mean difference between the groups in VAS change at 6 months was -0.3 (95% 
CI -2.8 to 2.1) (Table 24) (Figure 24). VAS had an effect size of 0.24 (P=0.54) 
This gap was further reduced in the open-label period up to 12 months. 
 
Figure 24. Mean VAS by group 
 	
Table 24.  VAS Two –sample t test (month 6). 
Group Mean Std. Err. Std. Dev. 95% Conf. Interval 
Active - 0.7230769 0.4603725 1.659897 -1.726142 0.2799885 
Sham - 0.3615385 0.355459 1.281626 -1.136017 0.4129401 
Difference - 0.3615384 0.5816304  -1.561965 0.8388876 
55.5
66.5
77.5
88.5
99.5
10
Baseline Month	1 Month	3 Month	6
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4.2.2 Sialometry 
There was an increase in salivary flow rate in the active group at 6 months 
being 1g/15 min higher (95% CI -0.5 to 2.4 g/15 min) (Table 25) (Figure 25) 
and effect size 0.54 (P=0.17). The mean difference between the groups in 
sialometry change at 12 months is 1.7 (95% CI -0.5 to 3.9). 	
 
 
 
Figure 25. Mean sialometry by group 				
 
 
 				
  
Table 25.  Sialometry Two –sample t test (month 6). 
Group Mean Std. Err. Std. Dev. 95% Conf. Interval 
Active 1.214385 0.6898906 2.487436 - 0.2887579 2.717527 
Sham 0.2329768 0.1700454 0.6131076 - 0.1384203 0.6025741 
Difference 0.9823077 0.7105382  - 0.484171 2.448786 
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4.2.3 Xerostomia inventory (XI) 
XI score reduced more in the active group than in the sham group at endpoint 
(6 months) by 3.3 points (95% CI -6.2 to -0.4) (Table 26) (Figure 26). XI results 
related to effect size 0.93 (P=0.02). The mean difference between the groups 
in Xerostomia Inventory change at 12 months is -4.2 (95% CI -8.5 to 0.04). 
 
 
Figure 26. Mean XI score by group 
 
 
 		
 
 
 
 	  
Table 26.  XI Two –sample t test (month 6)  
Group Mean Std. Err. Std. Dev. 95% Conf. Interval 
Active - 3.461538 1.124411 4.054121 -5.911419 -1.011658 
Sham - 0.1538462 0.8231129 2.967776 -1.947255 1.639563 
Difference - 3.307692 1.39349  -6.183714 - 0.4316701 
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4.2.4 EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) 
There was no difference between the groups in terms of overall dryness as 
measured by ESSPRI Q1 (dryness). The mean difference between the groups 
in ESSPRI Q1 (dryness) change at month 6 was -0.2 (95% CI -1.6 to 1.1) 
(P=0.73) (Table 27). This persisted in the open label period. 
There appears to be no difference between groups in terms of overall ESSPRI. 
The mean difference between the groups in ESSPRI (overall) change at month 
6 was -0.6 (95% CI -2 to 0.7), effect size 0.36 (P=0.37) (Table 28). The mean 
difference between groups in overall ESSPRI change at 12 months is -1.5 
(95% CI -3.1 to 0.2). Again there is some evidence that the difference between 
the groups increases during the open label phase. 
 
  
Table 27.  ESSPRI Q1 (dryness) Two –sample t test (month 6) 
Group Mean Std. Err. Std. Dev. 95% Conf. Interval 
Active - 1.307692 0.5925241 2.136376 -2.598691 -0.0166932 
Sham - 1.076923 0.3293649 1.187542 -1.794548 -0.3592985 
Difference - 0.2307692 0.677913  -1.629913 1.168374 
Table 28.  ESSPRI (overall) Two –sample t test (month 6) 
Group Mean Std. Err. Std. Dev. 95% Conf. Interval 
Active - 0.358974 0.4810683 1.734516 -1.407132 0.6891834 
Sham - 0.256410 0.479128 1.727521 -0.7875205 1.300341 
Difference - 0.615384 0.6789628  -2.016695 0.7859258 
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Chapter Five: 
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At present there remains no cure for SS and thus regarding the dry mouth 
aspects of the disease, patients rely greatly on frequent sips of water (Cho et 
al. 2010). While this may transiently lessen the symptoms of oral dryness 
patients would be missing a great deal of benefits that saliva provides in 
addition to lubrication such as: repair, antimicrobial, and buffering properties 
which all contribute extensively to the protection of oral hard and soft tissue 
integrity (Mandel 1987). In addition it contains amylase and lipase which aid 
initial digestion of starch and fat (Valdez and Fox 1991). All the benefits that 
saliva can provide, likewise can be absent with salivary substitutes as these 
agents provide mainly moister only. Furthermore the physical properties of 
salivary substitutes can be different from natural saliva and they only provide 
short-term relief (Vissink et al. 1983; Olsson and Axéll 1991). 
For these reasons it would be of advantageous to provide a treatment option 
that can stimulate existing functioning salivary gland tissue to produce saliva, 
thus attaining saliva moister and the other aforementioned functions. Studies 
have shown that salivary sialogogues (pilocarpine and cevimeline) can reduce 
dry mouth symptoms and increase salivary gland function (Vivino et al. 1999a; 
Fife et al. 2002b; Petrone et al. 2002c; Papas et al. 2004a) yet these non-
selective M-agonists can often cause adverse side effects: sweating, 
headache, increased urinary frequency, bronchospasm, bradycardia, 
dizziness and gastrointestinal upset. In qaddition it is estimated that treating 
patients with SS would cost the health service in the UK (in 2004) £2188 per 
patient (annual direct health cost) (Callaghan et al. 2007; Sada, Isenberg and 
Ciurtin 2014). Pilocarpine 5 mg tid would cost around £534.82 / year, while in 
contrast the second-generation electro stimulation intra-oral device costs us 
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$575, where the batteries last for a year or possibly more and did not give rise 
to notable adverse effects. Therefore when considering the therapy for 
xerostomia associated with SS, it is crucial that the treatment can 
stimulate/increase natural saliva, be free of side effects, be self administered 
by patients and not notably expensive. 
 
These criteria might be achieved by electrostimulation. It has been reported 
that electrostimulation increases the salivary flow (Erlichman 1990), and in 
1992 a study demonstrated an improvement in xerostomia symptoms in a 
group of patients with SS who were treated with electrostimulation (Talal, 
Quinn, and Daniels 1992b). Yet there is no available robust evidence of the 
efficacy of the second-generation electrostimulation device in treating 
xerostomia caused by SS. Previous studies included patients with dry mouth 
due to different causes (radiotherapy, medications, etc) they also had an open-
label and uncontrolled design in some of them, additionally these studies 
assessed the short-term effectiveness only of the device (Strietzel et al. 2007; 
Strietzel et al. 2011; Alajbeg et al. 2012). Consequently these studies did not 
provide robust evidence for the use of electrostimulation for xerostomia of SS. 
The present study was advanced due to the promising data in regards to the 
effectiveness of treating SS induced dry mouth with electrostimulation, and to 
provide a high quality study investigating the long-term effectiveness of the 
second-generation electrostimulation device. 
In the present study the use of the second-generation electrostimulation device 
for 5 minutes as needed in LEONIDAS-1 did not result in any side effects or 
any kind of erythematous reaction at the site of stimulation. Any complaints of 
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discomfort were easily solved by adjusting the electrodes and flanges till 
participants were satisfied.  
The unstimulated salivary flow (USF) in the present results favour the active 
group, at month 6 (end of the randomised controlled part of trial). The USF 
difference between baseline and month 6 in the active group was 0.08ml/min 
and in the sham group 0.015ml/min, these results were better than that of 
previous trials on electrostimulation treating xerostomia: active: 0.02 ml/min vs. 
sham: -0.005 ml/min (Steller, Chou, and Daniels 1988c), active: 0.021 ml/min 
vs. Placebo: 0.017 ml/min (Talal, Quinn, and Daniels 1992b), active: 0.033 
ml/min vs. Placebo: -0.033 ml/min (Strietzel et al. 2011). In the present study 
at month 12 the difference from baseline in USF reached 0.11ml/min in the 
active group and -0.0012ml/min in the control group and thus demonstrates 
more improvement in the active group with longer use. 
The VAS of dry mouth symptoms in the active group improved in the initial 3 
months, however by 6 months and with further completing the 12 months, the 
active and sham VAS scores are almost identical, this may suggest that 
participants were more sensitive to changes in the symptoms of oral dryness 
when they were newly enrolled in the trial. In addition SS is considered a 
chronic condition, where patients may live with it for years and adapt to the 
sensation of dry mouth, therefore a larger objective improvement (higher 
increase in salivary function) may be needed in order for symptoms of oral 
dryness to improve. 
Indeed, it is suggested that for XI to be of use the minimally important difference 
should be 6 units.  At 6 months the XI score in the present study has reduced 
by 3.3 points more in the active group than in the sham group. At month 12 
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further widening of the differences between the groups XI score were 
observed. The XI is not only used to assess subjective feelings of dry mouth, 
it also involves the habitual behaviour in reaction to xerostomia (i.e. sipping 
liquids when swallowing, sucking sweet or feeling dry skin, hands and inside 
of nose), hence it is likely that although subjective symptoms have been 
improved using electrostimulation device, the habits may persist. It is also vital 
to consider the small sample size in this study, which might explain the small 
differences seen between the two arms of the trial. 
With regards to the ESSPRI, the overall ESSPRI includes 3 domains covered 
in three questions; (1) general dryness, (2) fatigue and (3) pain. Question one 
in the ESSPRI covers general dryness (eye, cutaneous, vaginal etc.). The 
present results revealed that the ESSPRI did not change in either the active or 
sham groups, this is not unexpected as the present device influenced a local 
reflex loop affecting the salivary gland function, hence it is unlikely to have an 
effect on eye, skin and vaginal dryness or demonstrate a significant change	
particularly as the XI did not. 
 
Using the second-generation intra-oral electrostimulation device is limited with 
few contraindications as wearing active pacemakers, defibrillators, hearing 
aids and mental disease/depression. Yet these are not absolute 
contraindications; built-in safety features are included in pacemakers to protect 
them from other electrical devices that may affect their operation. Also 
professional pre-assessment is necessary for patients with pacemakers or 
defibrillators (by a cardiologist) or hearing aids (by an ear, nose and throat 
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(ENT) specialist) and psychiatric patients (by a psychiatrist) (Strietzel et al. 
2007).  
The present results of the efficacy of the use of an electrostimulation device on 
the salivary gland in patients with SS are promising. However although a 
cumulative improvement in salivary function was found, an improvement in 
subjective symptoms was not definitely detected. Thus a larger study is 
coloured by the present results is now warranted to confirm these results. 
Future study: 
A 12- month multicentre, parallel group, double-blind, randomised sham-
controlled trial (RCT) in patients with primary Sjogren’s Syndrome is now 
anticipated. 
A total of 124 patients are required to have 90% power for detecting an effect 
size of 2.5 units for the change in XI score at 12 months post randomisation 
(informed by the feasibility study and clinical opinion), assuming a between 
patient standard deviation of 4 units, 2-sided 5% significance level and 10% 
dropout. 
The Primary Objective of this study will be: 
• Is salivary electro-stimulating device over 12 months of use superior to the 
sham device in terms of reducing dry mouth symptoms in patients with 
Primary Sjogren’s Syndrome (pSS)? 
While the Secondary Objectives will be:  
• Will 12-month use of the salivary electro-stimulating device result in an 
increase in salivary flow in individuals with pSS? 
• Will 12-month use of the salivary electro-stimulating device result in 
improved oral health-related quality of life in individuals with pSS? 
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• To what extent do patients adhere to the device protocol over a 12-month 
period? 
• What is the safety profile of the salivary electro-stimulating device? 
Cost-effectiveness: To assess whether the use of a salivary electrostimulating 
device is cost effective when compared with the sham device. 
 
To conclude this detailed study successfully demonstrated feasibility of 
recruitment and randomization into a sham-controlled salivary 
electrostimulation trial. The device was safe and well tolerated. Although the 
study was not designed to investigate effectiveness, we looked at changes in 
dry mouth symptoms and salivary flow before and after treatment, so to identify 
a “clinical signal” or “preliminary suggestion” that supported conducting a full 
definitive RCT. The present study will be used to identify the primary outcome 
and estimate the variability, in order to calculate the sample size for the 
definitive RCT. Out of the 4 study outcome measures, XI and uWSFR captured 
changes in dry mouth symptoms and salivation and suggested that the device 
can lessen dry mouth symptoms (3.3 units on XI score) and increase salivation 
(1g/15min). 
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Appendices  
 
Appendix 1. Systematic review search strategy 
 
 
Medline (Ovid): 
 
 
Xerostomia 
Hyposalivation 
Asialia 
Mouth Dryness 
Dryness, Mouth 
xerostomia.mp. 
xerostomi* 
(dry$ adj2 (oral or mouth$)).mp. 
(asialia or “salivary gland hypofunction” or hyposalivat$).mp. 
or/1-9 
salivary gland dysfunction 
Sjogrens Syndrome 
Syndrome, Sjogren's 
Sjogren Syndrome 
Sicca Syndrome 
Syndrome, Sicca 
or/ 11-16 
Therapeutic 
Treatment 
Treatments 
parasympathomimetic* 
cholinergic agonists 
sialogogue$.mp. 
(“anticholinergic drug$” or “anti-cholinergic drug$”).mp. 
“sympathomimetic drug$”.mp. 
pilocarpine 
acetylcholine  
bethanechol  
carbachol  
methacholine chloride  
cholinesterase inhibitors  
ambenonium chloride  
edrophonium  
neostigmine  
paraoxon  
physostigmine  
pyridostigmine bromide  
choline esters  
cholinomimetics  
aceclidine hydrochloride  
choline alfoscerate   
exp mucin/ 
(carboxymethylcellulose or cellolax or cethylose or “croscarmellose sodium” or “carboymethyl cellulose” 
or hydroethylcellulose or polyglycerylmethacrylate or “polyethylene oxide” or 
hydroxypropylmethylcellulose).mp. 
(CMC or HEC or PGM).ti,ab. 
exp Candy/ 
(lozenge$ or candy or candies or “chewing gum” or sweet$).mp. 
“malic acid$”.mp. 
((xylitol adj3 gum$) or (xanthan adj3 gum$)).mp. 
“saliva substitut$”.mp. 
Mouthwashes/ 
(mouthwash$ or mouth-wash$ or “mouth wash$” or mouthrins$ or mouth-rins$ or “mouth rins$”).mp. 
(linseed$ or rape$ or canola$ or aloe$).mp. 
Hyperbaric Oxygenation/ 
“hyperbaric oxygen$”.mp. 
Electrical Stimulation/ 
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((electric$ adj3 stimulat$) or neuroelectrostimulation or “masticatory stimulation”).mp. 
intra-oral device$”.mp. 
Acupuncture/ 
acupuncture.mp. 
Lasers/ 
laser$.mp. 
or/ 18-61 
 9 and 17 and 62 
 
 
The above subject search will be linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for 
identifying randomized trials in MEDLINE:  
#64 randomized controlled trial.pt. 
#65 controlled clinical trial.pt. 
#66 randomized.ab. 
#67 placebo.ab. 
#68 drug therapy.fs. 
#69 randomly.ab. 
#70 trial.ab. 
#71 groups.ab. 
#72 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71  
#73 exp animals/ not humans.sh. 
#74 72 not 73   
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Cochrane Central register for controlled trials: 
 
 
Sjogrens Syndrome 
Syndrome, Sjogren's 
Sjogren Syndrome 
Sicca Syndrome 
Syndrome, Sicca 
or / 1-5 
MeSH descriptor Xerostomia explode all trees  
xerostomia  
(dry* near/2 oral) or (dry near/2 mouth*)  
(asialia or “salivary gland hypofunction” or hyposalivat*)  
or / 7-10 
MeSH descriptor Parasympathomimetics, this term only  
MeSH descriptor Pilocarpine, this term only  
MeSH descriptor Arecoline, this term only  
MeSH descriptor Oxotremorine, this term only  
MeSH descriptor Cholinesterase Inhibitors, this term only  
MeSH descriptor Quaternary Ammonium Compounds explode all trees  
MeSH descriptor Physostigmine, this term only  
MeSH descriptor Pyridostigmine Bromide, this term only  
MeSH descriptor Mucins explode all trees  
cholinergic agonists # 
sialogogue$  
acetylcholine  
bethanechol  
carbachol  
methacholine chloride  
ambenonium chloride  
edrophonium   
neostigmine  
paraoxon  
choline esters  
cholinomimetics   
aceclidine hydrochloride  
bethanechol chloride  
choline alfoscerate  
mesh descriptor carboxymethylcellulose, this term only  
carboxymethylcellulose or cellolax or cethylose or “croscarmellose sodium” or “carboymethyl cellulose” 
or hydroethylcellulose or polyglycerylmethacrylate or “polyethylene oxide” or 
hydroxypropylmethylcellulose 
(cmc or hec or pgm): ti,ab,kw  
mesh descriptor candy explode all trees  
lozenge* or candy or candies or “chewing gum” or sweet*  
“ascorbic acid tablet*”  
“malic acid*”  
((xylitol near/3 gum*) or (xanthan near/3 gum*))  
“saliva substitut*”  
mesh descriptor mouthwashes explode all trees  
mouthwash* or mouth-wash* or “mouth wash*” or mouthrins* or mouth-rins* or “mouth rins*”  
linseed* or rape* or canola* or aloe*  
mesh descriptor hyperbaric oxygenation, this term only  
“hyperbaric oxygen*”  
mesh descriptor electric stimulation explode all trees  
electric* near/3 stimulat*  
neuroelectrostimulation or “masticatory stimulation”  
“intra-oral device*”  
mesh descriptor acupuncture, this term only  
acupuncture  
or/ 12-55 
6 and 11 and 56 
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EMBASE (OVID): 
 
 
Sjogrens Syndrome 
Syndrome, Sjogren's 
Sjogren Syndrome 
Sicca Syndrome 
Syndrome, Sicca 
or/ 1-5 
xerostomia.mp.  
(dry$ adj2 (oral or mouth$)).mp.  
(asialia or “salivary gland hypofunction” or hyposalivat$).mp.  
(radioxerostomia or radio-xerostomia).mp.  
or/7-10 
parasympathomimetics 
cholinergic agonists 
sialogogue$.mp.  
(“anticholinergic drug$” or “anti-cholinergic drug$”).mp.  
“sympathomimetic drug$”.mp.  
acetylcholine  
bethanechol  
carbachol  
methacholine chloride  
pilocarpine  
cholinesterase inhibitors  
ambenonium chloride  
edrophonium   
neostigmine  
paraoxon  
physostigmine  
pyridostigmine bromide  
choline esters  
cholinomimetics   
aceclidine hydrochloride  
choline alfoscerate   
anticholinesterases 
ambenonium  
demecarium bromide 
distigmine 
eseridine salicylate  
galantamine hydrobromide  
cevimeline 
exp Mucin/ 
Carboxymethylcellulose/  
(CMC or HEC or PGM).ti,ab.  
exp Candy/ 
(lozenge$ or candy or candies or “chewing gum” or sweet$).mp.  
“ascorbic acid tablet$”.mp.  
“malic acid”.mp.  
((xylitol adj3 gum$) or (xanthan adj3 gum$)).mp.  
“saliva substitut$”.mp.  
Mouthwashes/ 
(mouthwash$ or mouth-wash$ or “mouth wash$” or mouthrins$ or mouth-rins$ or “mouth rins$”).mp. 
(linseed$ or rape$ or canola$ or aloe$).mp.  
Hyperbaric Oxygenation  
“hyperbaric oxygen$”.mp.  
Electrical Stimulation/ 
((electric$ adj3 stimulat$) or neuroelectrostimulation or “masticatory stimulation”).mp.  
“intra-oral device$”.mp. 
Acupuncture/ 
acupuncture.mp.  
or/12-58 
6 and 11 and 59 
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The above subject search will be linked to the Cochrane Oral Health Group filter for EMBASE via OVID: 
random$.ti,ab. 
factorial$.ti,ab.  
(crossover$ or cross over$ or cross-over$).ti,ab. 
placebo$.ti,ab. 
(doubl$ adj blind$).ti,ab. 
(singl$ adj blind$).ti,ab.  
assign$.ti,ab. 
allocat$.ti,ab. 
volunteer$.ti,ab.  
CROSSOVER PROCEDURE.sh.  
DOUBLE-BLIND PROCEDURE.sh.  
RANDOMIZED CONTROLLED TRIAL.sh.  
SINGLE BLIND PROCEDURE.sh. 
or/61-73 
6 AND 11 AND 60 AND 74 
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AMED (OVID): 
  
 
xerostomia.mp.  
(dry$ adj2 (oral or mouth$)).mp 
(asialia or “salivary gland hypofunction” or hyposalivat$).mp.  
(Sjogrens Syndrome or Syndrome, Sjogren's or  Sjogren Syndrome or Sicca Syndrome or Syndrome, 
Sicca).mp.  
or/1-4  
 
The above subject search will be linked to the Cochrane Oral Health Group filter for AMED via OVID: 
exp randomized controlled trials/  
exp double blind method/  
exp random allocation/  
(random$ or control$ or placebo$ or factorial).mp.  
(double adj blind).mp.  
(single adj blind).mp.  
exp comparative study/  
or/6-12  
5 AND 13 
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Appendix 2.  Dry mouth visual analogue scale 
  
  
 
Please place a mark on the line below representing the degree of dryness in 
your mouth today (as one end indicates no dryness and the other maximum 
dryness) 
How	severe	is	your	dry	mouth	today?	
 
 
   
 
                (no dryness)                                                        (maximum dryness) 
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Appendix 3. Xerostomia Inventory (XI) 
 
 
 
Please score the following statements referring to the preceding 4 weeks 
 
Scoring      Never = 1; Hardly ever = 2; Occasionally = 3; Fairly often = 4; Very often = 5 
  
 Never Hardly 
ever 
Occasionally Fairly 
often 
Very 
often 
Final 
I sip liquids to aid 
in swallowing food 
     
My mouth feels 
dry when eating a 
meal 
     
I get up at night to 
drink  
     
My mouth feels 
dry 
     
I have difficulty in 
eating dry foods 
     
I suck sweets or 
cough lollies to 
relieve dry mouth 
     
I have difficulties 
swallowing certain 
foods 
     
The skin of my 
face feels dry 
     
My eyes feel dry      
My lips feel dry      
The inside of my 
nose feels dry. 
     
Scores 
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Appendix 4. Eular Sjögren’s Syndrome Patient Reported Index 
 
 
 
 
ESSPRI 
EULAR Sjögren’s Syndrome Patient Reported Index 
 
Your physician has asked you to answer several questions relating to your disease. To 
answer to these questions, please take into account how bad your symptoms have been at 
their worst during the last two weeks only. 
Please tick one box only that best reflects your response. Please take care to answer all the 
questions. 
Example:  
 
No pain                      
 0       1       2       3      4       5       6       7      8       9      10 
 Maximal 
imaginable 
pain  
 
 
 
 
1) How severe has your dryness been during the last 2 weeks? 
No dryness                       
  0       1       2       3      4       5       6       7      8       9      
10 
Maximal 
imaginable 
dryness 
 
 
2) How severe has your fatigue been during the last 2 weeks?  
No fatigue                       
0       1       2       3      4       5       6       7      8       9      10 
Maximal 
imaginable 
fatigue 
 
 
3) How severe has your pain (joint or muscular pains in your arms or legs) been during the 
last 2 weeks?  
No pain                         
    0       1       2       3      4       5       6       7      8       9      10 
Maximal 
imaginable pain 
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Appendix 5. Trial inclusion criteria 
 
 
Appendix 6.Study visits 
 
 
 
  
 Yes No 
≥ 18 years old   
Have clinical symptoms of xerostomia (dry mouth) due to primary SS 
syndrome diagnosed on the basis of 2001 EU-USA classification criteria 
  
Degree of dry mouth symptoms: a minimum degree of dryness of 50mm 
(≥50mm) on a 100mm VAS scale (0= no dryness; 100= maximum dryness). 
  
To have unstimulated whole salivary flow higher than 0 ml/15min 
(unstimulated salivary flow as measured via sialometry for 15 minutes) 
  
No systemic sialogogue therapy (e.g. pilocarpine) for the duration of the study   
To have evidence of residual salivary gland function, by demonstrating an 
increase in salivary flow on appropriate stimulation [eg citric acid stimulation or 
chewing paraffin wax] 
  
Not be pregnant or trying to have children for the length of their participation. 
Female participants of child bearing potential would need to take measures to 
avoid pregnancy 
  
 
Procedures 
Study  
visit (n.) 
1 Information (verbal and written) regarding the study 1 
2 Consent 
3 Medical  and drug history 
4 Vital signs 
5 Clinical oro-facial examination and questionnaires: 
Examination of oral and dental tissues 
Dry mouth VAS score 
Measurement of stimulated vs unstimulated salivary flow 
6 Confirmation that inclusion/exclusion criteria are met. Enrolment into the 
study 
7 Generation of study codes (for randomization).  
Dental impression (to build individualized device) 
2 
8 Delivery and fitting of the device, usage instruction and start of 12 month 
trial.  
BASELINE value of Dry mouth VAS score, XI and ESSPRI 
questionnaire, salivary flow. 
3 
9 Hospital appt  month 1:  
- Salivary flow rate + Dry mouth VAS score + XI and ESSPRI 
questionnaires 
4 
10 Hospital appt  month 3: 
- Salivary flow rate + Dry mouth VAS score + XI and ESSPRI 
questionnaires 
5 
11 Hospital appt  month 6 
- Salivary flow rate + Dry mouth VAS score + XI and ESSPRI 
questionnaires. 
Final assessment – discharge from trial 
6 
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Appendix 7. Participant information sheet 
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Appendix 8. Consent form 
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Appendix 9. Home diary 
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